Mild Traumatic Brain Injury with Associated Visual System Dysfunction:  Investigating Histopathology, Functional Correlates, and a Novel Therapeutic Immune Modulator by Guley, Natalie M.
University of Tennessee Health Science Center
UTHSC Digital Commons
Theses and Dissertations (ETD) College of Graduate Health Sciences
5-2016
Mild Traumatic Brain Injury with Associated Visual
System Dysfunction: Investigating Histopathology,
Functional Correlates, and a Novel Therapeutic
Immune Modulator
Natalie M. Guley
University of Tennessee Health Science Center
Follow this and additional works at: https://dc.uthsc.edu/dissertations
Part of the Medical Neurobiology Commons, and the Neurosciences Commons
This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been
accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please
contact jwelch30@uthsc.edu.
Recommended Citation
Guley, Natalie M. (http://orcid.org/0000-0002-4427-1799), "Mild Traumatic Brain Injury with Associated Visual System
Dysfunction: Investigating Histopathology, Functional Correlates, and a Novel Therapeutic Immune Modulator" (2016). Theses and
Dissertations (ETD). Paper 387. http://dx.doi.org/10.21007/etd.cghs.2016.0406.
Mild Traumatic Brain Injury with Associated Visual System Dysfunction:
Investigating Histopathology, Functional Correlates, and a Novel
Therapeutic Immune Modulator
Document Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Program
Biomedical Sciences
Track
Neuroscience
Research Advisor
Anton J. Reiner, Ph.D.
Committee
Scott A. Heldt, Ph.D. Marcia G. Honig, Ph.D. Monica M. Jablonski, Ph.D. Bob M. Moore II, Ph.D.
ORCID
http://orcid.org/0000-0002-4427-1799
DOI
10.21007/etd.cghs.2016.0406
This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/387
 “ 
 
Mild Traumatic Brain Injury with Associated Visual System Dysfunction:  
Investigating Histopathology, Functional Correlates, and a Novel Therapeutic 
Immune Modulator 
 
 
 
 
 
 
 
 
A Dissertation 
Presented for 
The Graduate Studies Council 
The University of Tennessee 
Health Science Center 
 
 
 
 
 
 
In Partial Fulfillment 
Of the Requirements for the Degree 
Doctor of Philosophy 
From The University of Tennessee 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By 
Natalie M. Guley 
August 2016 
 
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Portions of Chapter 3 © 2015 by Mary Ann Liebert, Inc. 
All other material © 2016 by Natalie M. Guley. 
All rights reserved. 
 
  
 iii 
DEDICATION 
 
 
To my Dad, the man who believed I could do anything, and my Mom, the woman who 
showed me how to. 
 
 
  
 iv 
ACKNOWLEDGEMENTS 
 
 
 To begin, I would like to express my profound gratitude and appreciation to my 
mentor Dr. Anton Reiner, without whom this dissertation would not be possible.  As an 
undergraduate, Dr. Reiner brought me into his lab and immediately entrusted me with 
important projects and data, allowing me the freedom to look at things from my own 
perspective.  Later, as a medical and then graduate student, he inspired in me a love of 
discovery, and constantly challenged me to learn more and investigate my own 
hypotheses, while guiding me always back to focus on the task at hand.  Through the 
years, his leadership has taught me to think critically about my data, troubleshoot 
research problems relentlessly, and to always ask questions.  With his help, I have grown 
into a scientist, and for that I will be forever in his debt. 
 
 I would also like to thank Dr. Marcia Honig, who has displayed immense patience 
in discussing countless research issues with me throughout my dissertation work, and in 
assisting me on confocal microscopy.  Her meticulous and thoughtful examination of 
both histology and immunohistochemistry has taught me to never overlook the minute 
details of my work, because in them, you can often find the truth. 
 
 To my committee members Dr. Scott Heldt, Dr. Monica Jablonski, and Dr. Bob 
Moore, I can’t thank you enough for all of the insightful discussion and critiques 
throughout the process of planning and running my dissertation experiments.  A special 
thanks is also due to Dr. Bob Moore for the many long hours he spent synthesizing the 
experimental drug that played such an important role in my research.  I owe my gratitude 
to Dr. Wei Bu, Dr. Nobel Del Mar, Dr. Chunyan Li, and Dr. Malinda Fitzgerald for so 
much help on a day-to-day basis with running experiments, learning new techniques, 
discussing issues, and scholarly debate.  A very special thanks is owed to Marion Joni, 
who hates to be called the lab manager, and so instead I will simply call her the lab rock.  
She has helped me in so many ways, I can not even enumerate them.  Suffice to say, 
much of the work in this dissertation would have been impossible without her.  I have 
rarely seen a more hard-working and steadfast individual. 
 
 Dr. Chaela Presley and Dr. Ammaar Abidi, you graciously set aside your own 
work to prepare for me the experimental drug, often with very little notice, and I truly 
appreciate that.  Additionally, I thank Chaela for the excellent chemokine and cytokine 
assay figures used in Chapter 2.  I am indebted to Josh Rogers, Lauren D’Surney, Ting 
Wong, and Jessica Ferrell for all of their hard work running behavioral and vision tests on 
animals, performing histologic processing and analysis, and generally for their friendship.  
Also to Dr. Jeffery Marchetta at the University of Memphis, whose engineering 
experience and guidance has been integral for the creation and optimization of our blast 
device.  Dr. John Varriano at Christian Brothers University, I appreciate not only your 
excellent physics teaching, but your input on the biomechanics of our model.  A very 
heartfelt thank you to the Gangaraju lab for training on retinal angiography, Dr. T.J. 
Hollingsworth, and Dr. Amanda Preston for their constant help on confocal microscopy 
 v 
and retinal processing, and to the many, many people who have helped me along the way 
and that I am regrettably forgetting. 
 
 A special thanks is in order to Dr. Pat Ryan and Dr. Jay Callaway for helping in 
any way they could to coordinate and facilitate my progress through the MD/PhD 
program.  Many hurdles were removed from my path with their gracious assistance.  I 
would also like to extend my most sincere appreciation the UTHSC College of Graduate 
Health Sciences and the UTHSC Neuroscience Institute for providing the generous 
funding that has allowed me to pursue this degree. 
 
 Arguably the most important recognitions are due to my parents Michael and 
Sally, and my siblings Jessica, Lara, and Michael.  You helped mold me into the person I 
am, and have provided unwavering support and assistance through my entire journey.  No 
words can convey my gratitude.  Also to my beautiful and intelligent daughter Elowyn, 
you are too young to read this now but you have brought me joy and grounded me 
through some of the toughest days.  You have also frustrated me to tears, a feat your 
grandfather would be proud of.  To my best friends, Erin Gooch, Jordan Toler, and Dr. 
Brienne Petcher.  You women are beautiful and amazing, and I am honored that you are a 
part of my life.  All of these people have graced my life with so many blessings, it is truly 
unbelievable to reflect on. 
 
 Lastly, to my husband, Dr. Patrick Guley, the most analytical and thoroughly 
skeptical scientist I have ever met.  Your incessant love of debate has often challenged 
my patience, while simultaneously expanding my mind to explore possibilities and topics 
I would never have previously considered.  I cannot thank you enough for the countless 
hours you’ve spent discussing my research, giving opinions and suggestions, and 
critiquing conclusions at every step of the way.  When we joined our hands in marriage, 
we vowed to always pursue the truth, and I could not have asked for a better partner in 
exploring every inch of this wondrous cosmos.  I love you with all of my being. 
  
 vi 
ABSTRACT 
 
 
Background.  Traumatic brain injury (TBI) is a significant source of morbidity and 
mortality worldwide.  Injuries associated with moderate to severe TBI can be profound, 
and have historically overshadowed the significant impact mild TBI (mTBI) can have on 
the lives of affected individuals.  Mild TBI can manifest in a number of different ways, 
but one of the most significant and often debilitating is its impact on the visual system.  
In order to further investigate the underlying pathology of mTBI and test potential 
therapeutics, we developed a mouse model of mTBI induced by blast overpressure.  In 
this model, a 50-60 psi blast wave from a highly pressurized bolus of air is directed at a 
focal region of the left lateral cranium of a mouse, and produces replicable motor, 
emotional, and visual system deficits with concomitant histopathology.  Importantly, this 
model closely simulates functional visual system damage seen in human cases of mTBI.  
A major component of the brain’s reaction to trauma is an immune response that can 
cause additional long-term damage above and beyond that of the initial injury.  This 
response was observed in our model as regions of microglial cell activation throughout 
areas of the brain important for visual processing.  A novel therapeutic drug acting at 
cannabinoid type 2 receptors (CB2), known as SMM-189, had previously shown promise 
in improving visual outcome after mTBI in our model, but no studies were done to 
elucidate the cause of this improvement.  The purpose of this dissertation was to further 
characterize visual system dysfunction and histopathology in our model, as well as 
investigate how the drug SMM-189 acts to exert its beneficial effects on these areas.  
Mice were blasted with either 50-psi or sham blast, and then injected over the next two 
weeks with either drug or vehicle intraperitoneally.  Functional tests were administered at 
30 days after blast, and perfused tissues were used for subsequent histologic evaluation.  
Tissue used for histologic analysis was collected from mice at 3 and 7 days post-blast, 
and in another cohort at 11 weeks after blast. 
 
Functional results.  Optokinetic testing was administered to obtain visual acuity (VA) 
and contrast sensitivity (CS) thresholds in mice at 30 days after blast.  It was found that 
no group showed any defects in VA, but the 50-psi vehicle-treated group (50V) showed 
significant deficits in the CS function of both eyes, which was completely rescued with 
drug treatment.  Electroretinograms were run both pre- and post-blast on mice to obtain 
an electrophysiological readout of retinal cellular function over the first month after blast.  
The left eye of 50V animals showed a pathologic B-wave elevation, but no change in the 
A-wave, or peak latency times.  Drug treatment corrected this abnormality, returning the 
50-psi SMM-189 treatment group (50SMM) B-wave average back to control levels. 
 
Structural results.  Optical coherence tomography at 30 days post-blast revealed 
pathologic outer retinal thinning in the left eye of 50V animals, with 50SMM animals 
showing no such change.  Immunohistochemistry (IHC) to visualize microglia in the 
retina showed a significant microglial increase in the left eye of 50V animals at 3 days 
post-blast, and a lesser but still pathologic elevation in both left and right eyes at 30 days 
post-blast.  Drug treatment decreased the pathologic microglial elevation at both 3 days 
and 30 days, indicating its efficacy in quelling inflammatory microglial recruitment.  
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Another readout of pathological response in the retina, GFAP immunoreactivity, was 
found to be elevated in the left eye of 50V animals at 30 days as well.  50SMM animals 
did not show any GFAP immunoreactivity at this time point.  Brn3a+ RGCs in the retina 
were visualized using IHC, and no significant changes were seen.  Cross-sections through 
optic nerves (ON) were analyzed from animals 11 weeks after blast.  Left ONs from both 
50V and 50SMM animals were found to be atrophic compared to controls, while the right 
eyes were all equivalent.  Manual axon counts revealed left ONs from 50V animals had a 
decreased axon density, as well as a decrease in total axon count.  Animals in the 50SMM 
group had a decreased axon density in the left eye, but the total axon count returned to 
normal.  The right ON of 50V animals also had a decrease in axon density, but the total 
axon count was not significantly different than controls.  In the mouse brain, the right 
optic tract (ROT) contains predominantly the uncrossed axons originating from the left 
eye and optic nerve.  The ROT of 50V animals at 3 days after blast showed a significant 
number of pathologic axon bulbs, indicating areas of traumatic axonal disruption.  These 
tracts also showed an increased presence of M1 inflammatory-polarized microglia when 
compared to controls, as determined by IHC markers specific to the M1 polarization 
state.  In the ROT of 50V animals at 5 and 7 days, large axon bulbs had decreased in 
number and numerous smaller granular accumulations became apparent, possibly 
indicating axonal degeneration.  Drug treated animals showed a significant decrease in 
the number of axon bulbs at 3 days post-blast, and 20% of the microglia in this same tract 
had been converted from M1 to an M2 anti-inflammatory polarization state. 
 
Conclusion.  The novel drug SMM-189 was shown to significantly improve many 
aspects of visual system damage in our model.  Histologic evidence supports its role in 
positively modulating the immune response in neurotrauma, and acting to alter microglial 
polarization into a more neuroprotective phenotype.  Furthermore, histologic benefits 
were associated with corresponding improvements in visual system function, showing its 
efficacy in treating mTBI visual system damage, a disease with no currently available 
pharmacotherapy.  Future studies into mTBI-associated visual dysfunction should seek to 
investigate long-term outcome in this model, and to determine if drug benefit is sustained 
over an extended period after injury. 
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CHAPTER 1.    INTRODUCTION AND BACKGROUND 
 
 
History and Epidemiology of TBI 
 
 Traumatic brain injury (TBI) is the top cause of neurological dysfunction and 
death in most age groups worldwide 1,2.  In the United States alone, it has been estimated 
that as many as 3.8 million people per year suffer from some sort of traumatic brain 
injury 3.  Recent headlines have brought TBI and its mildest form, the concussion, to the 
attention of people around the country, with professional football players and physicians 
alike labeling the concussion as a new epidemic plaguing America 4.  Despite this being 
thought of as a modern phenomenon, it is a malady that has afflicted humans since the 
beginning of recorded history.  One of the oldest medical texts ever discovered, an 
Egyptian papyrus dating back to the 16th century BC, includes complex descriptions of 
traumatic head wounds, both penetrating and non-penetrating, succinctly describing 
symptoms and outlining rudimentary treatments used by high priests, the medical doctor 
equivalent of the time 5,6.  Indeed, injuries to the head would have been a major concern 
to early humans, as they were well understood to be some of the most resistant to tribal 
medicine and a cause of life-long disability.  Classically, TBI was probably encountered 
as a result of contusive, penetrating, or acceleration-deceleration (A-D) injury.  In the 
modern day, most instances of TBI occur as a result of falls, motor vehicle accidents, and 
assaults 7, with males in general and populations in the military, professional sports, and 
construction work being at the highest risk 8,9.  Those most likely to be affected by TBI 
are some of the most vulnerable patient populations in our society, being the very young 
(0-4 years of age) and the very old (above 75 years of age) 3.  Thus, the focus of research 
aimed at prevention and treatment of TBI rightly continues to be a high priority 
nationally. 
 
 TBI categorization is yet to be standardized, and as such has somewhat broad 
definitions compared to many other diseases 10,11.  At its most general, it can be 
understood as any injury resulting from biomechanical disturbance of the brain and 
surrounding tissue.  The United States Department of Defense (DoD) has implemented a 
categorization scheme for TBI that is widely used in both research and clinic settings, and 
will be adopted for use in the remainder of this dissertation 12.  According to the DoD, 
TBI can be classified as either mild, moderate, or severe based on a number of criteria 
that serve as a readout of neurocognitive function 13.  See Table 1-1 for a complete 
explanation of the DoD’s TBI severity criteria.  Importantly, mild TBI (mTBI) is unique 
from the other more severe forms in that it has structurally normal radiologic findings, a 
normal to near-normal score on the Glasgow coma scale, and does not necessarily 
involve a loss of consciousness or altered mental status 13.  The apparent lack of physical 
findings are in stark contrast to the myriad of symptoms patients experience after mTBI, 
many of which can be debilitating.  Mild TBI is thought to comprise anywhere from 80-
95% of all TBI seen in hospitals 9, and has been estimated by the CDC to account for 
over 16 billion dollars in US healthcare spending over the lifetime of affected individuals 
11.  With a prevalence of over 500 per 100,000 people in the population per year 14,15, it is 
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Table 1-1. Department of Defense traumatic brain injury classification criterion. 
 
Criteria  Mild  Moderate  Severe 
       
Structural imaging  Normal  Normal or 
abnormal 
 Normal or 
abnormal 
       
Loss of consciousness  0- 30 min  > 30 min and 
< 24 hrs 
 > 24 hrs 
       
Alteration of consciousness/ 
mental state* 
 A moment 
up to 24 hrs 
 > 24 hours. Severity based on 
other criteria 
       
Post-traumatic amnesia  0-1 day  > 1 and < 7 
days 
 > 7 days 
       
Glascow Coma Scale (best 
available score in the first 24 
hours) 
 13- 15  9- 12  < 9 
 
 
*Alteration of mental status must be immediately related to the trauma to the head. 
Typical symptoms would be: looking and feeling dazed and uncertain of what is 
happening, confusion, difficulty thinking clearly or responding appropriately to mental 
status questions, and being unable to describe events immediately before or after the 
trauma event.   
 
Reprinted with permission. Defense, D. O. & Affairs, D. O. V. Management of 
Concussion/mild Traumatic Brain Injury. 1–112 (2009). 
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estimated that over 5 million people in the US are currently living with mTBI-related 
disabilities 16. 
 
 Milder cases of TBI, usually associated with sports, are known colloquially as 
concussions and are often brushed off without a doctor or emergency department visit 17.  
This is probably at least partially due to pressures associated with return to play or other 
social stigmas18, but also from a general public misconception that concussions have very 
few long term sequelae 19.  In the early 2000’s, when professional football players began 
to manifest symptoms similar to dementia and other neuropsychiatric conditions at 
increasingly younger ages, attention became focused on the role of concussive, and even 
sub-concussive injuries on the long-term health of athletes in football and other high-
impact sports 20.  Hyper-phosphorylated tau accumulation indicative of neural 
microtubule disruption was found in the brains of even very young, non-professional 
athletes, head-bangers, and wrestlers, many with no prior history of concussion 21.  This 
disease became known as Chronic Traumatic Encephalopathy, and is probably related to 
a precursor found exclusively in boxers called Dementia Pugilistica 22.  It is now widely 
recognized in the medical world that concussion is the mildest of a spectrum of injuries 
involving biomechanical disruption of the soft tissue of the brain, with manifestations 
from very minor to very severe in both clinical outcome and effect on patient quality of 
life22. 
 
 With the advent of modern warfare, a new mechanism of brain injury was 
invented, one caused by exposure to extremely high pressure gradients, known as blast 
waves, that are emitted from explosive detonations.  As early as World War I, the disease 
called “shell shock” was known to be associated with blast exposure, and was described 
as being characterized by specific neurological and psychological sequelae 23.  In the 
medical community, it was widely debated as to whether the disease had any structural 
basis, and veterans did not begin receiving benefits for shell shock until World War II 24.  
The long term psychopathology many of these individuals suffered with after returning 
from combat eventually morphed into what we now call post traumatic stress disorder 
(PTSD) 25.  More modern wars brought a new breed of solider, the so-called “breacher,” - 
the men responsible for improvised explosive device recovery and controlled detonation.  
In doing this, they are exposed to hundreds or thousands of blasts across their military 
career.  It was not immediately understood why, but these individuals began to suffer 
with numerous debilitating side effects as a result of this blast exposure 26.  Eventually it 
became recognized that even in the absence of blood or outward signs of trauma, these 
blast exposures were somehow causing damage to an individual’s brain.  Today, 
overpressure blast-induced TBI, or bTBI, is considered to be a subset of mild traumatic 
brain injury, and still has close associations with PTSD, as well as long term motor, 
auditory, and visual deficits.  Blast TBI will be discussed at length later in this 
dissertation. 
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Consequences of TBI 
 
 The physical effects of mTBI can be quite varied, depending both on the injury 
severity and localization, but can often have a profound impact on the patient’s quality of 
life 27.  Clinical manifestations of mTBI are frequently referred to as post-concussion 
syndrome, although this is somewhat of a misnomer since the symptoms are also seen in 
more severe brain injury as well 28.  They can include a variety of behavioral, 
neurocognitive, and somatosensory symptoms that are traditionally thought of as being 
transient, lasting from weeks to as long as 3 months after the injury 2,29.  However, as 
many as 15% of people with mTBI still experience these symptoms long after the 3 
month time point 30, suggesting a tangible neurobiological etiology.  See Table 1-2 for a 
comprehensive summary of TBI-associated symptoms.  The presence of acute-onset post-
concussive symptoms is correlated with worse neurocognitive function as long as a year 
after the injury, and as such indicate the presence of some underlying neurobiological 
basis that could have potentially permanent effects 30.  Accordingly, studies using 
diffusion tensor imaging (DTI) have found white matter abnormalities that significantly 
correlate with post-concussion symptom severity, even more so than cognitive function 
tests alone 31.  This highlights the importance of seemingly subjective readouts, such as 
quality of life and patient-reported symptoms, in determining the extent of 
neuropathology after mild brain injury. 
 
 Somatic symptoms associated with TBI can include headaches, dizziness, nausea, 
and fatigue 16,29  Of these symptoms, headache is the most common 32, and seems to be 
more closely related to mild brain injury - one study found the daily headache incidence 
in the mildest category of TBI to be nearly 80% 33.  Another common, yet poorly 
understood symptom of mTBI is chronic fatigue.  Research shows that despite it being 
more common in women, it is not directly related to other comorbid conditions, 
suggesting a neurobiological etiology relating directly with the brain injury 34.  The 
mechanism behind this symptom has yet to be elucidated, although newer research shows 
a potential link with post-TBI neuroendocrine dysfunction and hypopituitarism 35,36.  
Dizziness and nausea are most commonly thought to be related to vestibular dysfunction 
37, and are not well researched in the literature. 
 
 Other symptoms associated with mTBI involve problems with memory, 
concentration, focus, and attention 38.  These are the most widely and extensively 
researched of the post-TBI sequelae and are closely linked with white matter damage, or 
diffuse axonal injury (DAI) 39,40.  Diffuse axonal injury is an almost universal finding in 
even mild TBI 41, and acute DAI findings on MRI correlate highly with long-term 
cognitive function performance 42.  The non-focal nature of DAI likely accounts for the 
lack of specificity of many of the cognitive symptoms associated with mTBI 40. 
 
 
Neuropsychiatric symptoms in mTBI 
 
 The link of psychiatric illness with brain injury is a complicated one, since pre-
injury factors (genetic, environment, behavioral), as well as post-injury factors  
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Table 1-2. Health effects associated with TBI. 
 
Category  Description 
   
Cognitive  Deficits in: attention; learning and memory; executive functions 
like planning and decision-making; language and communication; 
reaction time; reasoning and judgment 
   
Behavioral/ 
Emotional 
 Delusions; hallucinations; severe mood disturbance; sustained 
irrational behavior; agitation; aggression; confusion; impulsivity; 
social inappropriateness 
   
Motor  Changes in muscle tone; paralysis; impaired coordination; changes 
in balance, or trouble walking 
   
Sensory  Changes in vision and hearing; sensitivity to light 
   
Somatic signs 
and symptoms 
 Headache; fatigue; sleep disturbance; dizziness; chronic pain 
   
 
This table gives a comprehensive overview of the symptoms associated with TBI. 
 
Reprinted with permission. Centers for Disease Control and Prevention (CDC). Report to 
Congress on Mild Traumatic Brain Injury in the United States:. 1–56 (Centers for 
Disease Control and Prevention, 2003). at 
<http://www.cdc.gov/traumaticbraininjury/pdf/mtbireport-a.pdf> 
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(psychosocial) and injury severity/localization, likely play a critical role in long-term 
neuropsychological outcome after mTBI 43.  As a result, the role of mTBI in 
neuropsychiatric illness has been somewhat controversial in the literature.  One strongly 
worded review written in 2005 pointed to the numerous conflicting studies done on a 
number of neuropsychological end points and concluded that there was no strong 
evidence that mTBI had any long-term effects on behavior 44.  Despite this, a large body 
of literature exists that points to associations of mTBI with numerous neuropsychiatric 
sequelae, including depression, impulse control, anxiety, suicidal thoughts, amnesia, 
aggression, apathy, and impulsivity, among others 28.  One review found the incidence of 
depression to be the highest of these symptoms, occurring in anywhere from 15-61% of 
individuals after mTBI, even when controlling for those with episodes of depression prior 
to injury 45.  Additionally, even in the absence of depression symptoms acutely post-
injury, the risk for developing clinical depression is still elevated for many decades after 
TBI 43.  Studies have found significant deficits in cognitive control in individuals with a 
history of mTBI, which increase with increasing number of mTBI incidents 46.  
Importantly, these deficits are present in the absence of any clinical signs or symptoms, 
hinting at a dysfunction in the brain’s impulse control circuitry in individuals who by all 
account are clinically normal.  Finally, the most robust and well-corroborated evidence 
shows a link between mTBI and PTSD 47, which is said to occur in anywhere from 17 to 
30% of individuals after mTBI 48, and has significant correlations with self-reported post-
concussive symptom severity 49.  However, the literature also shows the difficulty in 
disentangling the role of neurobiological and psychological causes in cases of PTSD and 
concurrent mTBI, since many instances of mTBI occur in times of intense psychological 
distress 48. 
 
 
Mild TBI and vision 
 
 General.  One of the most common complaints associated with mTBI comes in 
the form of vision problems 13, with as many as 75% of patients reporting some sort of 
visual disturbance due to their injury 50.  These visual symptoms often exist in the 
absence of any outward damage to the globe of the eye 51, and as such indicate a 
complicated underlying neuro-ophthalmologic pathology.  With as much as 50% of the 
brain’s mass dedicated either directly or indirectly to visual processing 52, it stands to 
reason that stretching and sheering of axons diffusely throughout the brain, as occurs in 
mTBI, could impact the visual system in a myriad of ways 53.  Indeed, visual performance 
is such a reliable readout of even mild forms of brain injury, that it is routinely used in 
sideline tests for determining return to play in high school and college sports after a head 
injury 54-56 and to longitudinally monitor recovery from mTBI 57,58.  The diffuse nature of 
the mTBI injury likely accounts for the non-specific and often difficult-to-pin-down 
nature of mTBI-associated vision complaints as reported by patients, many of whom 
experience significant difficulties with the activity of daily life, yet have normal or near-
normal visual acuity findings on physical examination 51. 
 
 Specific visual disturbances.  TBI-associated vision symptoms can vary 
depending on injury severity and range from headaches, photophobia, blurred/double 
 7 
vision, and difficulty reading to partial or complete blindness 59,60.  Many of these vision 
symptoms are thought to be primarily related to dysfunction in the oculomotor system, 
with as many as 90% of individuals with acquired brain injury manifesting some sort of 
oculomotor problem 61.  Oculomotor disturbance can manifest as vergence insufficiency, 
difficulties with smooth pursuit, and saccadic dysfunction, all leading to significant 
difficulties with activities of daily life 62,63. 
 
 According to Kapoor and Cuiffreda, vision problems related with mTBI can be 
categorized into five main areas of dysfunction:  accommodation, version, vergence, 
visual field integrity, and photosensitivity 64.  Each of these areas will be briefly 
discussed, with emphasis on how these clinical signs translate into functional problems 
(symptoms) for patients, and their possible pathophysiology, when known. 
 
 Accommodation.  Accommodation is the ability of the eye to change focus when 
moving from near-to-far, or far-to-near vision by altering the shape of the lens 65.  Neural 
implementation of accommodation is a complex system, but is primarily driven by a 
reflex arc through the lateral geniculate nucleus (LGN), visual cortex, cerebellum, 
midbrain, and cranial nerve III 66.  In brain injured patients, this reflex arc can be slowed 
(accommodation infacility), decreased in strength (accommodation insufficiency), or 
hyperactive (accommodation spasm) 67, all of which manifest as either constant or 
intermittent bouts of blurred vision 64.  Occasionally, these deficiencies can be 
ameliorated by use of corrective lenses, but not always 68. 
 
 Vergence.  Vergence is the ability of both eyes to move toward or away from one 
another in order to retain binocular vision of stationary and moving objects within the 
visual field 69.  It, like accommodation, involves a complex reflex arc through the LGN, 
visual cortex, cerebellum, midbrain, and numerous cranial nerves.  Vergence problems 
most commonly manifest as deficiencies in horizontal convergence (convergence 
insufficiency), and can result in diploplia (double vision), difficulty reading, headaches, 
nausea, and general difficulty with near tasks 70,71.  These are the most common, and 
arguably most debilitating of the symptoms experienced by mTBI sufferers with visual 
dysfunction 62.   
 
 Version.  Version refers to coordinated conjugate eye movements, such as 
saccades, which allow binocular vision of stationary and moving objects.  Saccades are 
reflexive eye movements that occur very rapidly, at 200-700 degrees per second, and are 
important for visual inspection and vision integration 72.  In brain injured patients, version 
dysfunction manifests primarily as saccadic dysfunction, abnormal smooth pursuit, and 
fixation difficulties 64.  While version and vergence circuits likely overlap to a significant 
extent, studies have found that focalized injuries can result in selective sparing of one 
over the other 73.  Accordingly, the version circuit has been found to involve additional 
areas of the brain, such as the superior colliculus, cingulate cortex, and regions of the 
prefrontal cortex 74.  Importantly, many of the circuits controlling saccade generation are 
also important in directing visual attention 75, another known area of dysfunction in mTBI 
76.  Overall, the main symptoms associated with version dysfunction manifest as 
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difficulties with reading such as skipping words or lines, having to re-read words, and an 
overall decrease in reading speed and efficiency 64. 
 
 Visual field defects.  Visual field deficits seen in TBI are more well-characterized 
than the other symptoms of TBI-associated visual dysfunction, and can represent direct 
damage to either the proximal or distal retino-geniculo-calcarine pathway 65.  Direct 
injury to the optic nerve and chiasm are possible findings with partial or complete 
blindness 77, and the nature of the visual field defect can often help localize the site of 
injury.  Symptoms of partial visual field defects often manifest as perceptual or spatial 
deficits, for example not noticing one side of a room or words on one side of a page.  
These are generally associated with more severe injuries, and are rare in mild TBI 77.  
Other changes in visual character, such as waviness or graininess, are not well understood 
and may be linked with damage to the visual association areas 64.   
 
 Photoallodynia.  Finally, the last category of injury described by Kapoor and 
Cuiffreda is the painful aversion to light, photoallodynia, or abnormal light sensitivity, 
photophobia 51.  Photosensitivity has been the subject of much research, since it is a 
symptom commonly associated with a number of other diseases 78.  Light sensitivity is 
known to be predominantly, but not exclusively, mediated through intrinsically 
photosensitive retinal ganglion cells within the eye 79, and as such may occur in many 
direct ocular injuries.  However, photosensitivity is also a common symptom in migraine 
headaches.  This suggests other extraocular mediators can give rise to photophobia.  
Recent research indicates the trigeminal nerve, and the cortico-trigeminal pathway likely 
play an important role in neuropathic causes of photosensitivity 80,81.  Whether the 
presence of light sensitivity after mTBI is mediated by ophthalmic or neurologic 
pathways is not currently known, and likely depends on the nature and severity of the 
injury. 
 
 The purpose of this dissertation is to focus on the visual manifestations of mTBI.  
Further discussion of this will follow description of important aspects of TBI 
pathophysiology that require a general overview.  We will then return to the discussion of 
the visual system in the section on treatments for TBI. 
 
 
TBI Pathophysiology 
 
 An important hallmark of mild traumatic brain injury is its apparent lack of 
consistent neurophysiological findings when compared with other forms of brain 
pathology, making it an elusive and somewhat controversial disease to study, until recent 
events brought it to mainstream attention 82.  Nonetheless, focused and persistent 
neuroanatomical and neuropathologic studies have elucidated many of the underlying 
mechanisms to this disease.  For categorical purposes, the field of TBI research has 
identified two phases of the TBI pathophysiology, roughly relating to acute, inevitable 
parenchymal damage, and long-term, possibly preventable damage.  The acute effects of 
the biomechanical insult on the brain are commonly referred to as primary injury, and 
represent the first wave of actions that can result in long-term consequences83.  
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Subsequent immune, cerebrovascular, and metabolic responses to the brain injury are 
called the secondary injury, and are the more feasible targets for potential therapies 83.  
These will be discussed in turn. 
 
 
Primary injury 
 
 The pathophysiology of brain injury begins with a biomechanical disturbance, 
which can stretch and shear axons and cell bodies within the soft tissue of the brain.  
White matter tracts are the neuronal superhighways of the brain, consisting of tightly 
organized and directionally arranged axon bundles that transmit electrical signals from 
one region of the brain to another.  Because of their highly ordered nature, white matter 
tracts are uniquely susceptible to stretch and torsion during head acceleration and trauma, 
even more so than regions of tightly-packed neuronal cell bodies such as grey matter 84.  
As a result, even mild forms of brain injury can result in widespread, diffuse axonal 
damage known as DAI 85,86.  Within individual axons, microtubules act as the structural 
framework to shuttle waste products, organelles, and newly synthesized protein to and 
from the soma.  During brain trauma, microtubules can shear and break, disrupting the 
transport processes that are essential to cell survival 87,88.  Transport products are unable 
to be shuttled to their normal locations in the cell, and instead build up, forming localized 
areas of axon swelling (axon bulbs), which are clearly visible on histological analysis 89.  
Studies have found that forces exerted on the head are directionally important as they 
relate to axonal injury 90.  Rotational head accelerations tend to be more important for 
axonal shear damage than simple linear acceleration91. 
 
 During brain trauma, head movement or brain deformation can result in 
mechanical disturbance of cellular membranes 92.  Studies have shown that there is 
widespread blood brain barrier (BBB) compromise 93, and cellular membrane micropore 
formation, allowing uncontrolled leakage of ions into the extracellular space 94.  This 
mechanical disturbance also releases inflammatory cytokines and chemokines into the 
extracellular milieu and exposes damage associated molecular patterns (DAMPS), both 
of which induce an acute inflammatory response by resident immune cells in the brain 95.  
Additionally and concurrently, mechanical disruption causes the acute release of the 
excitatory neurotransmitter glutamate from intact cells, which induces indiscriminate 
neuronal depolarization 96.  Glucose metabolism in the brain is increased rapidly in 
response to injury as ATP-powered ion channels work to equilibrate this sudden ion flux, 
quickly depleting glucose stores 97.  This results in aerobic metabolism and the buildup of 
lactic acid, thought to be responsible for concomitant cerebral edema, while widespread 
NMDA receptor activation floods cells with Ca2+, resulting in mitochondrial dysfunction 
and a decrease in cytochrome oxidase expression 98. 
 
 
Secondary injury 
 
 In addition to the significant metabolic and mechanical disruption after trauma, 
immune activation likely plays an important role in the sustained pathology of TBI 99.  
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Monocyte-derived microglia are the resident immune effector cells within the CNS.  In 
their resting state, they constantly sample the extracellular milieu and respond to signals 
within the surrounding microenvironment.  Damage during neurotrauma and subsequent 
exposure of specific cellular proteins which are not normally present in the 
microenvironment (known as DAMPS) induce activation of toll-like receptor 4 (TLR4) 
found on microglia 100, inducing reactive polarization to an M1 phenotype101.  M1 
reactive microglia release the inflammatory cytokines IL-1, IL-6, and TNF-α 102, which 
can induce peripheral immune cell extravasation, in addition to chemotactic signals such 
as CCL2 that attract other resident microglia to the area.  They also act as antigen 
presenting cells, phagocytosing cellular breakdown products and processing them for 
expression to peripherally-derived immune cells, or traversing the body themselves to 
present these proteins to dendritic cells in regional lymph nodes 103.  This begins the 
activation of the adaptive immune response, and B cells begin producing antibodies to 
target these self-derived proteins 99.  In this way, the acute immune response gives way to 
a long-term, sustained immune response targeted at self-proteins erroneously identified as 
being a threat.  T-cell mediated destruction of myelin and other structural components 
may give rise to long-lasting cell death and immune over-activation in cases of 
subsequent trauma, in a phenomenon referred to as trauma-induced autoimmunity 104.  
 
 
The Role of the Immune System in TBI Pathology 
 
 
The role of peripheral cells 
 
 Under normal conditions, the expression of pro-inflammatory cytokines, 
chemokines, and complement are low in the healthy brain 105.  However, following brain 
trauma their expression rises precipitously 106,107.  Virtually all cell types within the CNS 
are capable of expressing pro-inflammatory cytokines in response to trauma 108, and as 
such even diffuse injury as is seen in mTBI can cause widespread activation of the 
immune system.  Under physiologic conditions, the BBB keeps the CNS an immune 
privileged region 109, but during brain trauma, this barrier becomes compromised and 
leaky 93, allowing immune cell adhesion and infiltration from the periphery into the CNS 
110, driven by inflammatory chemotactic signals.  Studies show that circulating 
monocytes migrate to regions of BBB compromise, extravasate, and differentiate into 
antigen presenting dendritic cells or macrophages in response to trauma 111.  Additionally, 
tissue-specific dendritic cells probably also reside in the CNS 103.  The fate of either type 
of dendritic cell is the same- both phagocytose proteins from the region of trauma and 
navigate to regional lymph nodes to present these antigens to T lymphocytes, which can 
then go on to activate the adaptive immune response112.  Activation of self-specific, 
antibody-producing B cells, and initiation of cytotoxic T cells are both hypothesized 
mechanisms for continued damage after TBI113. 
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Microglia 
 
 Although dendritic cells play an important role, the predominant cell type that 
mediates the immune response in the CNS after trauma is the resident microglia.  More 
than just tissue-specific macrophages, microglia are also glial cells, which perform 
important support functions and release neurotropic factors under physiologic conditions 
114.  Critically, they also respond to injury, infection, and trauma, acting as myeloid-
derived resident tissue monocytes.  They are integral in debris and necrotic tissue 
removal, while also helping maintain tissue integrity after injury 115.  These two 
seemingly disparate roles speak to the ability of microglia to alter their polarization, or 
phenotypic and gene expression profiles, adapting to environmental signals and temporal 
progression of injury under pathologic conditions.  Microglial polarization states are 
identified by their distinct cytokine expression in response to chemical stimuli 116, as well 
as their unique cell surface receptor makeup 117. 
 
 Polarization.  While microglia are in their resting, or M0 state, they display a 
highly arborized “ramified” morphology that assists in their constant monitoring of the 
extracellular environment 118,119.  Upon activation, their phenotypes can be roughly 
categorized into two major polarization states: either M1 or M2.  M1 is the pro-
inflammatory, or neurotoxic state, whereas M2 is the anti-inflammatory or neuro-
protective state 120.  Although overly simplified, the imposed dichotomy of M1 versus 
M2 is useful when discussing the role microglia play in trauma and subsequent immune 
activation, similar to the nomenclature of Th1 and Th2 lymphocytes 116, and as such is 
widely used in the literature. 
 
 The M1 polarization state is neurotoxic 121 and known to be detrimental to tissue 
repair after injury 122.  Indeed, the number of M1 microglia present is highly correlated 
with white matter injury in TBI 123, and plays a prominent role in a number of other 
neuropathologies 124.  In brain trauma, microglia become activated in a graded manner to 
the M1 phenotype by way of TLR4 activation 100.  In this activation state, they retract 
their processes and morph into amoeboid phagocytic cells, expressing a full gamut of 
MHC and cellular adhesion molecules to assist in immune functions 101.  They also 
release the inflammatory cytokines IL-1, IL-6, and TNF-α 102, which can act to further 
aggravate the injury.  Additionally, chemotactic cytokines CCL2, CXCL9, and CXCL10 
are released, which play an important role in leukocyte recruitment to sites of injury 
124,125.  An unintended consequence of M1 activity is the release of additional substances 
that can be directly neurotoxic, such as nitric oxide, glutamate, and reactive oxygen 
species created by unchecked NADPH oxidase activity 120,126. 
 
 An alternative and equally important fate of microglia in response to injury is a 
concurrent or sometimes late-phase predominant polarization to an M2 phenotype, in 
which anti-inflammatory cytokines such as IL-4 and TGF-β are released instead 127.  M2 
polarized microglia are known to be neuroprotective in many CNS pathologies 128, and 
their presence correlates with better prognosis after spinal cord trauma 121, as well as the 
initiation of re-myelination after traumatic axonal injury 129.  The ability of extracellular 
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signals to alter microglial polarization and thus disease progression is clearly fertile 
ground for potential therapies, and will be addressed at length later. 
 
 Timeline.  The timeline of microglial activation and polarization is somewhat 
disputed in the literature, since both M1 and M2 microglia likely exist at all times after 
traumatic insult 120.  However, most studies agree that microglial activation begins within 
hours of injury, peaking within a week, and then tapering off at two weeks 123.  
Microglial polarization is driven by signals released from cells and other events in the 
immediate microenvironment, and is thought to be graded based upon the concentration 
of inflammatory signaling molecules they are exposed to 130.  M1 polarization is induced 
by exposure to IFN-, TNF-, and LPS131, while M2 polarization is driven primarily by 
IL-3, IL-4 , and IL-10 131,132.  Some studies show a sub-acute preponderance of M2 
microglia within the first few days of injury 127, with a quick induction of M1 polarization 
soon after, as injured neurons begin releasing pro-inflammatory signaling molecules such 
as ATP and glutamate 126,133.  Numbers of highly reactive microglia begin to drop off at 
the two week time point, but low levels of reactive microglia can exist for sometimes 
months to years after an acute injury 120,134.   
 
 
Animal Models Used in TBI Research 
 
 A number of different animal models have been developed to both investigate the 
underlying pathology of TBI, and test potential therapies for translation to human 
populations.  In order to understand the model used for the purposes of this dissertation, 
and how it fits into the larger picture of the TBI research field, a brief overview of other 
animal models of acquired brain injury is warranted. 
 
 Roughly five main approaches for creating acquired brain injury in animal models 
exist and are in current use:  Static crush, Overpressure blast, Non-impact head 
acceleration, Non-penetrating impact-driven head acceleration, and Penetrating impact-
driven head acceleration 135.  To better understand these and how they relate to one 
another, please refer to an excellent graphic borrowed from Cernak’s comprehensive 
review of the subject (Figure 1-1).  Briefly, Cernak has divided injuries into two broad 
categories:  dynamic- where the acceleration, velocity, amplitude, and duration are 
variable; and static- where acceleration and velocity are not applicable, because the injury 
consists of only a known force amplitude for a fixed period of time.  Only one model fits 
into the static category, that of crush, and is used predominantly to study secondary injury 
due to the highly artificial nature of the primary injury 135.  For understandable reasons, 
static crush models are not able to replicate the complicated brain deformation seen in 
most TBI injuries, and for this reason we will not delve into them further.  It is important 
to note, however, that crush injuries are common in investigation of traumatic optic nerve 
axon pathology, and as such have a place of importance in the field of vision research 
136,137.  The second, dynamic category is further subdivided into either direct or indirect 
methods, which will now be discussed in greater detail. 
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Figure 1-1. In vivo models of traumatic brain injury. 
 
This figure shows the main categories of animal models used to study TBI.  The model 
used in this dissertation work falls under the dynamic, indirect category.   
Reprinted with permission.  Cernak, I. Animal models of head trauma. Neurotherapeutics 
2, 410–422 (2005). 
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Direct methods 
 
 Direct methods of TBI use direct application of a force to the brain, in either an 
open-skull or closed-skull application.  Many open-skull models require surgical removal 
of skin, muscle, and bone to expose the animal’s dura mater and underlying brain tissue 
for injury.  A fluid pressure pulse, or sometimes pressure-powered piston, is then used to 
inflict a controlled, replicable force to the brain.  While these models are desirable for the 
highly replicable nature of the injury they produce 138, the extensive surgery required 
makes it nearly impossible to study secondary effects of brain injury, since the significant 
inflammation caused by the open-skull procedure must invariably complicate the injury 
caused by the primary brain damage.  At least one study has documented a replicable 
effect on the visual system using a direct fluid percussion model of TBI 139.  Other open-
skull models use penetrating mechanisms, in the form of missile or stab wounds, to inflict 
brain injury 140.  These result in a more severe TBI that is highly related to real world 
penetrating injuries, such as a gun shot, but are not able to replicate less severe, mild to 
moderate forms of closed-skull injury, and as such are inappropriate for research on 
mTBI or concussion. 
 
 Closed-skull direct methods include controlled concussion, impact-driven head 
acceleration, and non-impact head acceleration models 141,142.  Generally, these models 
are excellent replicas of real world injury, yielding diffuse axonal injury in regions seen 
in human cases of mTBI and concussion 143.  However, only after repeated mTBI have 
any of these models given definitive readouts of visual injury similar to that which is so 
prevalent in human cases of mTBI 144, and are thus not helpful for investigating TBI-
associated vision dysfunction after only a single incident. 
 
 
Indirect methods 
 
 Indirect methods use large traveling pressure gradients known as blast waves as 
the mechanism of injury; they are done with a closed skull, and can be directed at either a 
focalized region of the skull, or the whole body.  These are primarily used to replicate 
injuries seen in individuals who have been exposed to explosive detonations, such as 
military personnel.  When an explosive detonates, it creates an ultra-high velocity 
pressure differential that travels in the form of a shock wave through the air radially.  
Upon encountering a fixed object, the energy from the shockwave is transferred in the 
form of kinetic energy, heat, and shear stress.  The pressure wave interaction with the 
skull and brain is considered the primary effect of the blast wave 145, and causes a 
rippling deformative force on the elastic tissue of the brain 146 that can result in diffuse 
axonal injury 147, axonal degeneration, and possibly eventual neuronal degeneration.  The 
tissue distention can also lead to an increase in intracranial pressure, which may give rise 
to further neuroinflammation and neurodegeneration 148.  Secondary injury mechanisms 
then proceed as previously described with non-blast forms of TBI. Much evidence exists 
to support the idea that blast-associated mTBI is a unique form of injury 149, which is 
confirmed by the high association of blast injury with particular neurological sequelae 
which are not as highly correlated with other forms of acquired brain injury 150.  
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However, some studies purport that, while being a unique injury mechanism, blast-related 
mTBI is probably not a unique pathology 151.  At face value, this seems reasonable at 
least as it applies to secondary injuries.  To date, indirect blast overpressure models have 
been the most successful in replicating the specific effect on the visual system that is seen 
in human cases of mTBI 152-155.  For this reason, they represent the ideal model for 
investigating potential treatments for mTBI-associated visual dysfunction. 
 
 
Treatments for TBI 
 
 
General 
 
 Given the significant number of individuals affected by TBI every year, it would 
be assumed that much time and research money should have paved the way for many 
novel therapies to treat TBI and its associated sequelae.  In fact, very few promising 
interventions or current treatments exist for both TBI in general, and TBI-associated 
visual symptoms more specifically.  Overall, symptoms are treated on a case-by-case 
basis by specialists within a related field.  Psycho-emotional symptoms are generally 
treated by a psychiatrist or psychotherapist, vision symptoms are treated by an 
optometrist, and neurological symptoms are treated by a neurologist, etc.  These multi-
disciplinary intervention schemes have been relatively successful in improving patients’ 
quality of life 156, but also involve a significant monetary and time burden on patients 
who choose these methods of rehabilitation.  Historically, and even up until the present 
day, physical and cognitive rest have been considered the cornerstone of concussion 
treatment and other mild forms of TBI157.  This advice, however, seems to contradict 
much evidence that physical inactivity can actually exacerbate many disease conditions 
158, and seems based more in tradition than evidence.  One review on the subject 
concluded that rest lasting more than three days after the injury probably yields no 
benefits on long term outcome 158, while other studies have actually provided evidence 
for the benefit of a controlled physical exercise regime after mTBI, as long as other 
activities that could yield a second mTBI are avoided 159. 
 
 Pharmacologic interventions for mTBI consist primarily of therapies targeted at 
alleviating symptoms, rather than the underlying pathology, but a few more broadly 
acting drugs have been investigated.  Some have shown promise in animal models, others 
have made it all the way through to a full clinical trial, but none have shown efficacy at 
the control clinical trial phase.  Included in these are steroids, progesterone 160, and 
ketamine 161, to name a few.  A recently published comprehensive review summarized 
the bleak landscape of TBI pharmaco-interventions by simply concluding that no single 
pharmaceutical intervention is proven to be efficacious for treatment of TBI and its 
associated symptoms 162. 
 
 Other therapies proposed for TBI are less conventional.  One such therapy, used 
primarily for treating more severe forms of TBI, is known as therapeutic hypothermia and 
involves a controlled decrease of a patient’s body temperature by 2o C 163.  Hypothermia 
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has been shown to be neuroprotective in preliminary studies involving severe TBI, and 
likely works by decreasing activation of the immune system and creation of ROS after 
injury, as enzymatic activity is slowed by decreasing temperature 164.  It is currently 
recommended for a number of other diseases, including stroke and heart attack, although 
its efficacy in mTBI remains unclear 163.  Transcranial magnetic stimulation is another 
novel treatment being investigated for use in mTBI sufferers who experience long-term 
negative effects.  It involves exposing focal regions of the outer skull to large magnetic 
fields, which induce a change in current of the underlying brain region.  Although this 
treatment has shown benefit for headaches, it has yet to pass the rigors of a placebo 
controlled trial 165.  The variety of unconventional treatments being investigated for TBI 
sequelae serve to highlight the unsatisfactory means with which medicine can currently 
treat these patients. 
 
 
Vision treatments 
 
 Treatment for mTBI-associated visual symptoms are primarily aimed at 
addressing oculomotor dysfunction and double vision in an effort to improve the 
functional outcome and improve patient quality of life.  Oculomotor training is done to 
strengthen the muscles of the eye in a similar way that physical therapy works after 
surgery of a joint 166.  It has been shown to significantly improve symptoms in patients 
with oculomotor-based difficulties, such as vergence and accommodation problems 166, 
but, like physical therapy, requires a large input of time for the patient and can be costly.  
Another commonly used treatment, called binasal occlusion, involves the patient wearing 
glasses which obscure the nasal aspect of both left and right visual field through the 
placement of a light-blocking lens 60.  Binasal occlusion blocks diploplia in the central 
visual field (the region of vision seen by both eyes), thus alleviating some of the 
discomfort associated with diploplia, while leaving peripheral vision intact in its 
binocular form.  It is not meant to be used as permanent treatment, but may help to re-
train the visual system when used in conjunction with other vision rehabilitation 167.  
Binasal occluders are often combined with optic prisms, and can bring a patient’s vision 
up to 20/20 or better in some cases 168.  The neural mechanisms underlying these 
treatments are not well understood, but result in tangible changes in the visual evoked 
potential as recorded from the primary visual cortex169.  One case study used high density 
visual evoked potential (VEP) to image brain regions activated in a patient with 
significant vision problems secondary to TBI, both with and without corrective lenses 168.  
Without correction, the VEPs were slowed significantly, and indicated widespread 
activation of many vision and non-vision areas, whereas lens-corrected VEPs 
demonstrated more efficient activation in the primary visual areas, as would be expected.  
This inefficiency in visual processing reflects the brain’s attempt at integrating memory, 
sensory, and language information in an effort to complete missing visual input due to the 
injury.  
 
 Overall, no pharmacologic treatment is available to address the complex array of 
symptoms that occur after mTBI, and even with the system-specific treatments that are 
efficacious, there remain significant pitfalls.  A need exists to develop alternative 
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treatment options aimed at dealing with the underlying pathology of TBI that is 
independent of the initial trauma, namely, the pathology associated with immune 
activation. 
 
 
Blast-Associated TBI and the Military 
 
 It is pertinent to briefly discuss the controversy that surrounds blast-associated 
mTBI, both publicly and in the literature.  Blast-induced traumatic brain injury has 
become an increasingly common occurrence, with the use of improvised explosive 
devices in modern warfare, and has lead to the labeling of mTBI as the “signature” injury 
of the Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) wars 170.  
However, it remains unclear whether the pathophysiology underlying blast-associated 
mTBI differs from that of concussion, or other more common mechanisms of acquiring 
mTBI.  There is some evidence that blast-related mTBI is uniquely associated with vision 
symptoms, which makes it an important concern for the military both now and in the 
future 171-173.  This is made apparent by the military’s commissioning of a special report 
in 2012 to outline the scope of the mTBI vision problem within the non-civilian military 
population.  In this report, it was estimated that over 5,000 new service members will 
present each year with with mTBI-associated vision dysfunction 174, costing an estimated 
2.2 billion dollars in annual healthcare cost for treatment and rehabilitation services 
related to those vision problems 174.  The report also goes on to predict another 24 billion 
dollars in future healthcare expenditures over the lifetime of affected service members.  
These numbers highlight the significant need to both understand the complex pathology 
underlying mTBI vision symptoms, and to find adequate treatment for the thousands of 
individuals living with this burden. 
 
 While the purpose of this dissertation is not to delve in to the differences that may 
or may not exist in the pathophysiology of mTBI resulting from blast injury and mTBI 
from other sources, it is important to note the unique association of blast-related mTBI 
with visual dysfunction.  The debate underlying these potential differences is unlikely to 
be settled any time in the near future, as many political and social institutions would 
probably frown on the conclusion that a cornerstone of modern warfare, the explosive 
device, is leaving indelible and seemingly invisible wounds on many U.S. veterans.  It is 
with this in mind that we will go on to discuss the specifics of the model used in this 
dissertation, the pathology it presents, as well as a potential therapeutic intervention using 
the body’s own immune system to curtail secondary damage of TBI. 
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CHAPTER 2.    PRIOR PUBLISHED STUDIES ON A MOUSE MODEL OF MTBI 
AND THE DRUG SMM-189 
 
 
Mouse Model Overview and Justification 
 
 For this dissertation, we used a mouse model of closed-skull overpressure blast-
induced mild traumatic brain injury that causes distinctive, replicable pathology in the 
whole brain and visual system.  The histopathologic and functional endpoints replicate 
features of mild traumatic brain injury and associated visual dysfunction seen in humans, 
and are positively correlated with blast pressure amplitude.  This chapter will give an 
overview of previously published data using this model, and the experimental drug 
SMM-189. 
 
 In this model, C57BL/6 mice were exposed to a controlled pulse of air at 
pressures ranging from 20-60 pounds per square inch (psi) to the left temporal aspect of 
the cranium.  The eye, ear, and body were shielded from the pressure wave, and the 
mouse’s body and head were cushioned.  In this way, the injury is focalized, replicable, 
and prevents any confounding effects of whole-body blast exposure 175.  Furthermore, 
head movement is severely restricted, in an effort to negate effects from lateral 
acceleration-deceleration injury.  This model was adapted from a published ocular blast 
model using the same apparatus to administer direct ocular injury in mice 176-178, and has 
been extensively described and validated in previous publications 179-181.  The following 
sections will give brief descriptions of the extensive characterization that has been done 
of the model, as well as the main histopathologic and functional findings that have 
previously been described in the literature.  Further information on the blast device, blast 
wave characterization, and blast administration will be found in the Methods section. 
 
 
General health and survival 
 
 Survival studies in this model have found relatively low mortality rate at psi 
exposures producing mild injury (>98% below 50-psi), which is consistent with human 
cases of mild brain injury16, while 70-psi exposure results in almost invariable death.  A 
60-psi exposure gives indications of mild-moderate brain injury, and survival rate is 
slightly lower at 91.5%.  Animals who die as a result of pressures ranging from 50-70 psi 
show widespread intracranial and subdural bleeding, indicating that at these pressures, 
death most likely results from acute intracranial bleed due to blood vessel compromise.  
For the purposes of this dissertation, it was deemed important to have a higher survival 
rate, and so a blast psi of 50 was chosen. 
 
 Blood oxygenation, respiratory rate, and heart rate were measured acutely after 
blast in and did not differ between sham and 50-psi blasted mice.  Importantly, 
intraocular pressure measurements between 0- and 50-psi animals also did not differ 
acutely after blast.  Subsequent gross examination also found no signs of corneal edema.  
These two findings confirm that there was no direct damage to the globe of the eye, as 
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direct ocular injury is known to result in an increase in intraocular pressures and edema 
acutely after blast 176.  Weight was also measured both acutely and long-term after blast, 
with no significant effects between 0- and 50-psi blasted animals.  All of these findings 
speak to the relatively mild form of brain injury occurring in this model. 
 
 
Behavioral endpoints 
 
 Mild TBI and concussion are known to result in subtle, albeit evident deficits in 
gross motor function acutely after injury 54.  To investigate motor function in this model, 
mice subjected to varying pressure levels were tested on rotarod, open field, and digigait 
at multiple time points after blast.  See Figure 2-1 for a summary of all of these findings.  
Animals were grouped according to blast level, with 0-20 psi in one group, 25-40 psi in 
another group, and 50-60 psi in the final group.  Two weeks after blast, the 0-20 psi 
group showed no significant differences on rotarod performance from the 25-40 psi 
group.  Early on, the 50-60 psi group showed large deficits in rotarod performance when 
compared to the other two groups, however this difference subsided at two weeks after 
blast.  Open field assessment found a similar pattern, with the 25-40 psi group only 
showing marginal differences from the 0-20 psi group at all time points after blast, but 
the 50-60 psi group showed persistent deficits compared with the other two groups.  
Unlike with rotarod, these effects were present even at 2 weeks after blast.  Finally, a 
small defect in gait symmetry was found in the 50-60 psi animals compared with 0-20 psi 
animals at 3 weeks after blast, showing persistent motor deficits at a sub-chronic 
timepoint.  These motor effects may be related to histopathology of the corticospinal tract 
that was subsequently identified in these animals, detailed later in the histopathology 
section. 
 
 
Functional vision endpoints 
 
 Visual acuity (VA) is a measurement of the eye’s resolving power- the ability to 
distinguish two points as being separate from one another, and is given as a measurement 
of cycles per degree (c/d), or spatial frequency.  Contrast sensitivity (CS), on the other 
hand, is the contrast required to achieve a certain resolving power, that is the amount of 
contrast required to distinguish two points as separate from one another.  This is usually 
given as a percent of contrast required to resolve the two points, with 100% meaning full 
contrast (black and white) and 1% meaning very little contrast (white and light grey).  
These two fundamental measurements can serve as a basic readout of visual function in 
many retinal diseases 182.  In mice, VA and CS thresholds can be acquired behaviorally in 
awake animals by observing gaze-evoked horizontal nystagmus in response to visual 
stimuli using a device known as an Optomotry system (see Methods section for a greater 
discussion of this device) 183.  In our model, mice were subjected to varying blast 
pressures and then tested for VA and CS at 3 weeks after blast to obtain a readout of 
visual function.  Using the previously described groupings of 0-20 psi, 25-40 psi, and 50-
60 psi, left and right eye measurements of visual acuity were compared.  Neither eye of 
the 25-40 psi group differed significantly from the 0-20 psi group.  However, there was a  
 20 
Figure 2-1. The effect of blast on motor performance. 
 
This figure compares the effects of 0–20 psi blasts, 25–40 psi blasts, and 50–60 blasts on 
Rotarod motor performance (A), and a series of motor end-points in open field (B–H).  
Note that motor performance is impaired for 50–60 psi mice on most parameters (other 
than acceleration), but for very few parameters in the case of 25–40 psi blast (notably 
distance in open field).  Red asterisks at each time point indicate a significant difference 
between 50–60 psi mice and 0–20 psi mice, while a red asterisk to the right indicates a 
significant overall difference between 50–60 psi mice and 0–20 psi mice.  Red pound 
signs at each time point indicate a significant difference between 50– 60 psi mice and 25–
40 psi mice.  Green asterisks at each time point indicate a significant difference between 
25–40 psi mice and 0–20 psi mice, while a green asterisk to the right indicates a 
significant overall difference between 25–40 psi mice and 0–20 psi mice.   
Reprinted with permission.  Guley, N. H. et al. A Novel Closed-Head Model of Mild 
Traumatic Brain Injury Using Focal Primary Overpressure Blast to the Cranium in Mice. 
J Neurotrauma 33, 403–422 (2016). 
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large decrease in both the left eye (25.3%) and right eye (43%) visual acuity in the 50-60 
psi group when compared to the 0-20 psi group.  Contrast sensitivity measurements were 
then acquired for both the 0-20 psi and the 50-60 psi groups at a spatial frequency of 
0.042 c/d.  In the left eye of 50-60 psi mice, there was a significant increase in the 
contrast required to detect 0.042 c/d when compared with 0-20 psi animals, 86.6% versus 
44%, respectively.  The right eye of 50-60 psi animals was similarly, but less severely, 
affected, with a CS threshold of 68.3%.  See Figure 2-2 for a summary of these findings. 
 
 
Histopathologic findings 
 
 General.  On gross inspection, brains from blasted and non-blasted animals 
showed no overt signs of pathology, but were subsequently weighed, then dehydrated and 
re-weighed.  Using this procedure, it was found that a small, but statistically significant, 
amount of brain edema was present in 50-psi animals 1 day after blast.  Brain edema is 
also a common finding in human neurotrauma 102.  This finding was confirmed by 
volumetric measurements of histology sections from the forebrain of 50-60 psi animals 2 
weeks after blast, showing a bilateral enlargement of 11.6% over control animals.  This 
edema was slightly lessened at 3-6 weeks after blast, with a still significant increase in 
size of 7.7% over control animals was found.  SMI-32 immunohistochemistry revealed 
no overt or microscopic histopathology, as indicated by blinded densitometry of the area 
occupied by immunoreactive neurons in the somatosensory and cingulate cortex.  
However, stereological NeuN+ neuron counts revealed a bilateral decrease in total neuron 
number in the cerebral cortex of 60-psi animals 45 days after blast.  Neurosilver stain for 
degenerating axons and terminals also revealed diffuse silver-impregnated fibers 
throughout many white matter tracts, including the medial and lateral lemniscus, 
pyramidal tract, and cerebellar peduncles.  This pattern of axonal injury is 
pathognomonic for DAI found in human forms of mTBI 85.   
 
 In the spinal cord, the corticospinal tract was visualized using an antibody against 
PKC-, and then measured at the level of the mid thorax.  The right dorsal component of 
the corticospinal tract was found to be atrophic, 10% smaller than the left side, in 60-psi 
animals 1-2 months out from blast.  This is consistent with left sided upper motor neuron 
damage, since the corticospinal tract decussates at the more rostral spinomedullary 
junction, and continues caudally on the contralateral side. 
 
 Visual areas.  The most prominent histopathology in this model is found in both 
the central and peripheral visual areas, which makes it an excellent model in which to 
study TBI-associated visual dysfunction.  In this section, we will discuss all of the 
findings relating to the visual system from proximal to distal, starting in the brain and 
ending in the eye.  These histopathologic end points include evidence of significant white 
matter damage, inflammation, and subsequent axonal degeneration within areas central to 
vision and visual processing.  It is believed that these injuries directly translate into the 
functional vision deficits described in a previous section. 
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Figure 2-2. The effect of blast on the visual system. 
 
This figure shows the effect of blast on visual acuity (A) and contrast sensitivity (B).  (A) 
Optomotor visual testing in mice with 20–40psi blast revealed normal visual acuity 
measured at 100% contrast in both eyes compared with sham blasted or normal mice.  
Visual acuity in both eyes of 50–60 psi blast mice was diminished (B).  Contrast 
sensitivity was also significantly reduced in 50–60psi mice compared with 0-psi mice—
that is, the 50–60psi mice needed more contrast to discriminate 0.042c/d than did sham 
mice.  Asterisks indicate significant differences between 50–60 psi and sham (0-psi) 
mice.  TBI, traumatic brain injury.   
Reprinted with permission.  Guley, N. H. et al. A Novel Closed-Head Model of Mild 
Traumatic Brain Injury Using Focal Primary Overpressure Blast to the Cranium in Mice. 
J Neurotrauma 33, 403–422 (2016). 
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 Within the brain, evidence of significant axonal disruption was found beginning 3 
days after blast and lasting until 7 days after blast in 60-psi animals.  EYFP reporter mice 
were used to visualize axonal morphology in a subset of retinal ganglion cell axons 
running through the optic chiasm and tract, while C57BL/6 mice were examined in the 
same areas using SMI-32 immunohistochemistry.  Both EFYP and SMI-32 showed 
regions of bulbous axolemmal swelling, indicative of microtubule breakage and 
subsequent disruption in axonal transport.  These were evident in the right OT, and to a 
lesser extent in the left OT.  Axons in the right OT are predominantly from RGCs in the 
left eye, since nearly all of the axons in the optic nerve decussate at the optic chiasm to 
continue on the contralateral side as the optic tract in the brain.  Axon bulbs were 
quantified and found to peak at 3 days, then decrease by nearly half at 7 days, before 
returning to control levels two weeks out from blast.  This time course is similar to that 
described in the literature for axon damage and subsequent axonal degeneration by 
autophagy 184,185. 
 
 Microglia were visualized using antibodies to Iba-1, a protein expressed 
exclusively in monocytes, and an antibody called OX6 against MHC II.  Note that M1 
reactive microglia upregulate MHC II expression in order to begin antigen presentation.  
On both readouts, highly reactive microglia were found in the right optic tract, right 
dorsolateral geniculate nucleus, and right superior colliculus (Figure 2-3), with temporal 
progression mirroring axon bulb pathology previously discussed.  Accordingly, numbers 
of reactive microglia in both optic tracts returned to control levels by 2 weeks after blast.  
At a month out from blast, numerous silver-impregnated axons were revealed by 
NeuroSilver staining, indicating the active degeneration of axons even after other signs of 
damage had subsided.  Again, the quantity of degenerating axons was higher in the right 
OT than the left, mimicking other pathology seen in the OT.  
 
 Plastic embedded cross sections of optic nerves were analyzed and quantified for 
degenerating axons and total axon number at various levels of blast exposure 2-9 weeks 
after blast 179.  While animals exposed to lower blast levels (25-40 psi) showed some 
degenerating axons in the left ON, the right ON in all blast intensity groups showed very 
few degenerating axons.  However, in animals exposed to 50-60 psi blast, many 
degenerating axons were seen in the left ON early on.  This number diminished by the 
later time point and indicated a decrease in active degeneration processes.  Optic nerves 
from 60-psi animals at 10-11 weeks after blast show a slight decrease in total axons (5%) 
of the left ON, but not significantly so. 
 
 Finally, retinas were analyzed histologically for signs of pathology using toluidine 
blue and immunohistochemistry on animals 10 weeks after blast 179.  Retina thickness 
was measured and found to be significantly decreased compared with controls (11.6%) in 
the left eye of blasted animals exposed to 50-60 psi, with a majority of the thinning being 
in the inner nuclear layer and photoreceptor layer.  Additionally, right eyes of 50-60 psi 
blasted animals showed significant thickening, perhaps indicative of edema or sclerosis.  
Iba-1 immunohistochemistry and EFYP reporter mice 3 days after a 60-psi blast 
exhibited large numbers of axon bulbs at the optic nerve head as the RGC axons exited 
the globe of the eye, with accompanying reactive microglia.  
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Figure 2-3. Iba-1 immunostaining in the brain of blasted animals. 
 
This figure shows transverse sections immunostained for the microglial marker IBA1, 
demonstrating microglial activation in the right optic tract (B), right superior colliculus 
(C), and left pyramidal (E) tract 3 days after a left cranial 60-psi blast, compared with the 
right optic tract (A), right superior colliculus (C), and left pyramidal tract (D) 3 days after 
sham blast.  Images A and B are at the same magnification as one another, and images D 
and E are at the same magnification as one another.   
Reprinted with permission.  Guley, N. H. et al. A Novel Closed-Head Model of Mild 
Traumatic Brain Injury Using Focal Primary Overpressure Blast to the Cranium in Mice. 
J Neurotrauma 33, 403–422 (2016). 
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 The extensive characterization of this model has demonstrated a reliable 
pathology with corresponding functional readouts, and replicates pathology that is seen in 
human cases of TBI-associated visual dysfunction.  Much of the histologic evidence just 
described points to the role of extensive immune cell activation, which may go on to 
exacerbate the injury and lead to long term disability in individuals with TBI.  Thus, this 
model represents an excellent medium in which to examine potential therapeutic agents, 
specifically those aimed at modulating or decreasing the secondary injury associated with 
TBI.  The purpose of this dissertation work was to investigate such a drug, one that acts 
on cannabinoid receptors in the brain and periphery, but before discussing the specific 
drug, it is pertinent to briefly review cannabinoid receptors and their role in the immune 
system. 
 
 
Cannabinoids and the Immune System 
 
 
Cannabinoid receptors and their ligands 
 
 Cannabinoid receptors (CB receptors) are ubiquitous throughout the body and 
central nervous system 186, with at least 2 different types being known and well-
characterized - type 1 and type 2.  Although these are the most commonly discussed, it is 
known that many more are likely to exist 187.  Both types of cannabinoid receptors are 
Gi/o-coupled, and thus inversely coupled to adenylyl cyclase activity, meaning 
functionally that their activation by an agonist decreases cAMP production within the cell 
188.  Additionally, their stimulation can activate other protein kinases that are involved in 
cell survival, differentiation, and proliferation pathways 189.  Importantly, cannabinoid 
receptors have been shown to exhibit constant low level signaling even in the absence of 
ligand, a phenomenon known as constitutive activity 190-192.  Others have hypothesized 
the seeming base level of activation to be a product of tonic endocannabinoid production 
and subsequent receptor activation 193.  Either reality demonstrates the innate importance 
of the cannabinoid receptor system in the human body, even under basal physiologic 
conditions. 
 
 Cannabinoid type 1 (CB1) receptors mediate the well-known psychotropic effects 
of cannabinoids 188 via agonist activation.  They are found predominantly on neurons 
within the brain and more sparingly in other tissues peripherally 192, and thus mediate a 
primarily neurologic function in the body.  Cannabinoid type 2 (CB2) receptors share 
about 44% homology with CB1 receptors, but are found throughout the body on immune 
cells and in the CNS primarily on microglia 194.  As their presence on immune cells 
would imply, CB2 receptors are thought to play a key role in modulating the immune 
system via the endocannabinoid system 192,195.  Naturally occurring cannabinoids 2-AG 
and anandamide (also called AEA) display complex pharmacology, acting on both CB1 
and CB2 receptors, and interact with every cell type involved in the innate and the 
adaptive immune response 196.  Indeed, cannabinoid receptors and their endogenous 
ligands may be critical players in the body’s ability to regulate the immune response and 
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prevent over-activation when inflammation is no longer necessary 196, making this system 
a prime target for therapeutic development. 
 
 
Cannabinoids as immune modulators 
 
 Phytocannabinoids, such as cannabidiol, have long been recognized for their 
neuroprotective effects 197, making them attractive targets for treatment in 
neurodegenerative diseases that have an underlying immune etiology.  Unfortunately, 
non-selective agonism acting at CB1 receptors, and the subsequent psychotropic effects, 
represent an unpleasant and usually intolerable side effect when cannabinoids are used 
for non-recreational purposes 198.  For this reason, modern therapeutic research has aimed 
at creating synthetic CB2-selective compounds for use in neurologic disease states.  
Under physiologic conditions, expression of CB2 mRNA in the brain is very low 199.  
However, during microglial activation, the expression of CB2 receptors is increased 
significantly 200.  This receptor expression increase may allow the body to mediate 
alterations in polarization state in response to the cellular environment by production of 
endogenous cannabinoid ligands 131.  Other research has pointed to the CB2-mediated 
modulation of inducible nitric oxide synthase and mitogen-activated protein kinases as an 
additional source of the neuroprotective effects 201. 
 
 Endogenous and herbal cannabinoids display complex pharmacologic action at 
CB2 receptors, acting as both agonists and inverse agonists depending on the 
environmental conditions 188,202.  Agonists directly activate the receptors, inhibiting 
cAMP production and decreasing cAMP levels intracellularly.  Conversely, inverse 
agonists act to decrease the constitutive activity of the CB2 receptor, and thus have the 
opposite effect of an agonist - that is, inverse agonists yield an increase in intracellular 
cAMP.  Simple CB2 receptor agonists have been found to increase microglial 
proliferation, decrease inflammatory cytokine release 203, and have proven to act as 
neuroprotectives in some disease models 204.  Paradoxically, CB2 inverse agonists display 
robust anti-inflammatory actions as well, decreasing leukocyte recruitment in vivo 205, 
NO-associated tissue injury 206, and inflammatory cytokine release from immune cells 181.  
These seemingly contradictory findings highlight the true pharmacologic complexity 
present in the cannabinoid system - with it’s dependence on both receptor and ligand 
concentrations, and the cell types involved 195.  Despite this, it remains clear that CB2 
plays an important, albeit poorly understood role, in the regulation of microglial 
polarization, and that action on CB2 can powerfully modulate immune-mediated damage 
in injury or neurodegeneration.  With this in mind, we will discuss the specific 
cannabinoid ligand used in this dissertation research. 
 
 
Investigative drug SMM-189, an Inverse Agonist at CB2 Receptors:  Evidence for 
Its Efficacy 
 
 In this dissertation, we used an investigational drug treatment aimed at 
modulating the immune response after TBI by action at CB2 receptors, and sought 
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functional and morphological endpoints to corroborate its therapeutic potential.  This 
drug, SMM-189, was designed and synthesized by the Bob Moore Group at UTHSC and 
was generously provided for all of the animal studies described herein.  Before detailing 
the goal and objectives of this dissertation, it is important to describe basic pharmacology 
of the drug that was used, as well as the preliminary benefits seen in this mouse model 
that prompted further investigation into its therapeutic potential. 
 
 SMM-189 is a novel cannabinoid ligand with a non-classical tri-aryl core that 
exhibits characteristics of a potent and selective CB2 inverse agonist in vitro 207.  Being 
highly lipophilic compounds, tri-aryl cannabinoids similar to SMM-189 have 
demonstrated excellent BBB penetration, and thus characterize a viable drug therapy for 
targeting to the brain 208.  As described previously, inverse agonists involve a novel 
pharmacologic mechanism that has demonstrated promise as a potential 
immunomodulator when selective for CB2 receptors 205.  Accordingly, in vitro studies 
were done using immortalized human microglia, and SMM-189 was shown to decrease a 
multitude of inflammatory cytokines and chemokines in response to LPS stimulation 
181,209 (Figures 2-4 and 2-5).  Further, experiments in these cells demonstrated that SMM-
189 also increased expression of cell surface markers associated with M2 microglia, 
while decreasing M1-associated surface markers (Figures 2-6 and 2-7).  These two 
groups of in vitro experiments taken together indicate a potentially functionally 
significant shift in microglial polarization from M1, pro-inflammatory microglia, to the 
more neuroprotective M2 phenotype by the drug SMM-189. 
 
 In previously published studies with our TBI model, mice were blasted with either 
0 (sham) or 50-60 psi overpressure blast, then treated with drug or vehicle 181.  SMM-189 
was administered intraparitoneally (ip) at 6 mg/kg beginning 2 hours after blast, and once 
every day thereafter for 14 days in total.  The mice were then subjected to a number of 
functional tests that were previously described in this dissertation, and a number of 
notable significant improvements were seen in drug-treated mice, when compared with 
vehicle-treated mice.  Motor, emotional, and histologic end-points not relating to the 
visual system are summarized in totality in Table 2-1.  In addition to motor and 
emotional improvements seen with SMM-189, significant improvement in the areas 
pertaining to the visual system were also seen.  Optomotry revealed a significant increase 
in both the left and right eye on visual acuity threshold, as well as an improvement of 
contrast sensitivity threshold in drug-treated animals when compared to vehicle-treated 
animals.  Histologic analysis of retinas also revealed structural improvements.  The total 
retinal thickness, as well as the inner nuclear layer thickness of left eyes were both 
increased toward normal in drug-treated animals.  In right eyes, the total retinal thickness 
was not significantly improved toward normal, but the inner nuclear layer was with drug 
treatment.  These results are summarized in Figure 2-8. 
 
 
Goal and Planned Experiments 
 
 The goal of this research was to investigate visual dysfunction in our mouse 
model of overpressure blast-induced TBI, and to test the hypothesis that a major pathway  
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Figure 2-4. Cytokine assay profiles of human microglia in vitro. 
 
This figure shows the effect of SMM-189 on cytokines secreted from primary human 
microglial cells in vitro 17 hours after treatment with lipopolysaccharide (LPS) or 
vehicle, and an hour later with SMM-189 or vehicle.  SMM-189 by itself significantly 
elevated interferon-gamma (IFN-γ) and interleukin-12p70 (IL-12p70), but to a lesser 
extent than LPS.  SMM-189 decreased the effect of LPS on cytokine secretion, 
significantly reducing IFN-γ, interleukin-6 (IL-6) and interleukin-10 (IL-10) below LPS-
only levels and restoring IFN-γ and IL-12p70 to SMM-189-alone levels.  SMM-189 also 
trended toward reducing TNFα. Asterisks above bars spanning the LPS-alone and LPS + 
SMM-189 columns, or the SMM-189-alone and LPS + SMM-189 columns indicate 
significance levels for the comparison between these two conditions.  Asterisks on a 
column indicate a significant difference from the control condition.  NS—Not significant, 
* p < 0.05, ** p < 0.005, *** p < 0.0005.   
 
Reprinted with permission.  Reiner, A. et al. Motor, visual and emotional deficits in mice 
after closed-head mild traumatic brain injury are alleviated by the novel CB2 inverse 
agonist SMM-189. Int J Mol Sci 16, 758–787 (2015). 
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Figure 2-5. Chemokine assay profiles of human microglia in vitro. 
 
This figure shows the effect of SMM-189 on chemokines secreted from primary human 
microglial cells in vitro 17 hours after treatment with lipopolysaccharide (LPS) or 
vehicle, and an hour later with SMM-189 or vehicle.  LPS significantly increased 
chemokine levels above those of controls for all chemokines shown.  SMM-189 
treatment alone had no significant effect on chemokine secretion, other than a slight 
reducing effect on MCP-1 (monocyte chemoattractant protein-1).  SMM-189 
significantly reduced the LPS-induced increase in the levels of IL-8 (interleukin-8), 
MCP-1, TARC (thymus and activation-regulated chemokine, also called chemokine 
ligand 17, or CCL17), MDC (macrophage-derived chemokine, also called C–C motif 
chemokine 22, or CCL22), and eotaxin-3 (also called C–C motif chemokine 11, or 
CCL11), and trended toward doing so for MIP-1β (macrophage inflammatory protein-1-
beta, also called chemokine C–C motif ligand 3, or CCL3).  Asterisks above bars 
spanning the LPS-alone and LPS + SMM-189 columns, or the SMM-189-alone and LPS 
+ SMM-189 columns indicate significance levels for the comparison between these two 
conditions.  Asterisks on a column indicate a significant difference from the control 
condition. * p < 0.05, ** p < 0.005, *** p < 0.0005.   
Reprinted with permission.  Reiner, A. et al. Motor, visual and emotional deficits in mice 
after closed-head mild traumatic brain injury are alleviated by the novel CB2 inverse 
agonist SMM-189. Int J Mol Sci 16, 758–787 (2015). 
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Figure 2-6. Cell surface expression of M1 markers on human microglia in vitro. 
 
This figure shows cell surface receptor expression of M1 microglia phenotype-associated 
markers CD11b, CD45, and CD80 of human microglia 24 h after treatment with LPS, or 
LPS + SMM-189.  Levels are expressed as the percent change from control levels (M0).  
LPS significantly increased expression of CD11b, CD45, and CD80, and SMM-189 
significantly reversed expression of M1 markers induced by LPS.  Asterisks above the 
LPS-alone or below the LPS + SMM-189 columns indicate significant differences from 
the M0 condition.  Asterisks above bars spanning the LPS-alone and LPS + SMM-189 
columns indicate significance levels for the comparison between these two conditions. * 
p < 0.05, ** p < 0.005, *** p < 0.0005.   
Reprinted with permission.  Reiner, A. et al. Motor, visual and emotional deficits in mice 
after closed-head mild traumatic brain injury are alleviated by the novel CB2 inverse 
agonist SMM-189. Int J Mol Sci 16, 758–787 (2015). 
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Figure 2-7. Cell surface expression of M2 markers on human microglia in vitro. 
 
This figure shows cell surface receptor expression of M2 microglia phenotype-associated 
markers CD206 and CD209 of human microglia 24 h after treatment with interleukin-4 
(IL-4), or IL-4 + SMM-189.  Note that IL-4 significantly increased expression of both 
CD206 and CD209, and that SMM-189 significantly increased expression of CD206 
beyond that seen with IL-4 alone.  Asterisks above bars spanning the LPS-alone and LPS 
+ SMM-189 columns indicate significance levels for the comparison between these two 
conditions.  Asterisks above a column indicate a significant difference from the control 
condition. * p < 0.05, **** p < 0.0005.   
 
Reprinted with permission.  Reiner, A. et al. Motor, visual and emotional deficits in mice 
after closed-head mild traumatic brain injury are alleviated by the novel CB2 inverse 
agonist SMM-189. Int J Mol Sci 16, 758–787 (2015). 
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Table 2-1. Summary of previous SMM-189 findings in our mouse model of TBI. 
 
 Endpoint examined  Without drug 
50 psi versus sham 
 With drug 
50 psi + SMM-189 
versus sham 
      
Motor     
      
 Rotarod performance  Decreased*  Decreased+ 
      
 Open field- Max speed  Decreased*         - + 
      
 Open field- Turn radius  Decreased*         - + 
      
Emotional     
      
 Tail suspension  Increased*         - + 
      
 Contextual fear  Increased*         - + 
      
 Fear extinction  Decreased*  Decreased+ 
      
Histologic     
      
 Amgydala  Decreased*         - + 
      
 Right corticospinal tract  Decreased*         - + 
      
 
* denotes a significant difference between 50-psi and sham group. 
+ denotes drug treated group and sham group are statistically equivalent. 
- means no change from sham group. 
Italics indicate an evident trend. 
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Figure 2-8. The effect of SMM-189 treatment on visual end points. 
 
This figure shows the effect of blast on visual acuity and contrast sensitivity four weeks 
after blast and retinal thickness 11 weeks after blast in the left eye (A) and right eye (B) 
of vehicle-treated sham mice, vehicle-treated 50-psi mice, and SMM-189 treated 50-psi 
mice. Optomotor testing in vehicle-treated mice with 50-psi blast revealed reduced visual 
acuity and contrast sensitivity in the left eye and retinal thinning (A), compared to 
vehicle-treated sham mice, which was prevented by SMM-189. Optomotor visual testing 
in vehicle-treated mice with 50-psi blast also revealed reduced visual acuity and contrast 
sensitivity in the right eye and retinal thickening, compared to vehicle-treated sham mice 
(B), which were attenuated by SMM-189. Asterisks indicate significant differences 
between vehicle-treated 50-psi and sham mice, and bars indicate significance (S) or non-
significant differences (NS) between the groups spanned by the bar. * p < 0.05.   
 
Reprinted with permission.  Reiner, A. et al. Motor, visual and emotional deficits in mice 
after closed-head mild traumatic brain injury are alleviated by the novel CB2 inverse 
agonist SMM-189. Int J Mol Sci 16, 758–787 (2015). 
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of the disease is immune-mediated secondary injury that can be remedied with the use of 
a targeted immune modulating drug.  Specifically, we sought to: A) further characterize 
the visual histopathology in this mouse model with additional structural and functional 
end points, and B) explore and characterize the improvements in visual function after 
SMM-189 administration.  To achieve these two goals, experiments were planned which 
will be further outlined in the following section.  The discussion of these experiments is 
organized by designation as a structural or functional investigation. 
 
 
Structural endpoints 
 
 In order to test the hypothesis that microglial activation plays a significant role in 
the visual injury after the initial mechanical insult, and that this mechanical injury itself 
was unlikely to be amenable to amelioration by the drug, it was necessary to quantify 
both microglia and axon bulbs in blast-vehicle, and blast-drug treated animals.  Axon 
bulbs in the optic tract were quantified in EYFP reporter mice with and without blast 
injury, to compare drug treated with non-drug treated animals.  Using an antibody to Iba-
1 as described previously, microglia in the same areas in treated and untreated blasted 
and sham mice were also counted and categorized as either reactive or resting based on 
morphologic characteristics, such as retracted processes, intense staining, and amoeboid 
appearance.  The number of axon bulbs was then correlated with the number of 
morphologically reactive microglia. 
 
 In the retina, it was predicted that more extensive pathology should be present 
beyond retinal thickness changes, in the form of an inflammatory response, and that this 
inflammatory response should be diminished by SMM-189 administration.  Microglia 
were again identified using an antibody to Iba-1, and then quantified by counting.  Glial 
fibrillary acidic protein (GFAP), a marker of Müller glia in the retina, was used to 
identify additional signs of inflammation by other resident glia.  This was quantified by 
counting Müller cell processes that penetrated past the RGC layer in the retina 210.  Since 
this model is known to demonstrate signs of axonal degeneration originating from the 
RGCs in the retina, we proposed that there should be a decrease in the number of RGCs, 
since RGC loss is a potential 211, but not invariant 155, feature of RGC axonal injury.  To 
visualize RGCs, retinal cross sections through the horizontal meridian were taken and 
stained with an antibody to Brn-3a, a protein found in a large subpopulation of RGCs 
212,213.  Additionally, a possible localization of injury could be extrapolated by looking at 
early time points, and examining the retina, optic nerve, and optic tract in each animal.  In 
this way, one might be able to determine if the injury of axons in this model is primarily 
focal or diffuse, and if focal, whether the injury occurs proximal or distal in the visual 
pathway.  Retinal sections of EYFP mice were examined at two early time points, 3 and 7 
days, in order to investigate a potential time course.  
 
 Signs of axonal degeneration and eventual loss were described in this model 
previously.  If SMM-189 acts on the immune system to curtail subsequent immune 
damage to these injured axons, one would expect to see an increase in the total axon 
counts of drug treated animals compared with vehicle treated animals.  To determine if 
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there is axonal rescue due to drug, optic nerve cross sections were counted manually, and 
measured for total axonal cross sectional area. 
 
 If SMM-189 is indeed acting to alter microglial polarization, switching it from a 
neurotoxic to a neuroprotective phenotype, this should be reflected in specific surface 
protein expression by microglia in affected tissue.  To examine whether M1/M2 
polarization ratios were altered in optic tract of injured animals, immunohistochemistry 
using antibodies to M1 (CD16/32) versus M2 (CD206) markers were used 131.  Cells 
were imaged on CLSM, and then quantified according to polarization state. 
 
 Finally, non-histologic structural investigations in live animals were performed to 
obtain pre-blast and post-blast comparisons of individual subjects.  Preliminary studies 
indicated that retinal thinning of the left eye occurs histologically at eleven weeks post-
blast in these animals, with a corresponding thickening of the right retina.  Retinal 
thickening can be acute, due to an inflammatory process causing edema, or can manifest 
as a chronic sclerotic lesion, whereas loss of RGCs or support cells might manifest as 
thinning of one or more cell layers in the retina.  Optical coherence tomography (OCT), a 
minimally invasive imaging method that uses optical scattering to visualize the cornea, 
lens, and retina in vivo, was used to perform retinal measurements on live animals.  This 
was done once pre-blast, and then again at a month out from blast.  Measurements of the 
outer retina, inner retina, total retinal thickness, and nerve fiber layer thickness were 
performed, with special attention paid to signs of retinal pathology (such as detachment, 
etc.).  In a small subset of animals, post-blast fluorescence-assisted angiograms were 
obtained, to look for additional signs of retinal pathology at two weeks after blast. 
 
 
Functional endpoints 
 
 To assess the functional visual parameters, and how they are affected by SMM-
189 administration, both optokinetics and electroretinograms were performed.  Visual 
acuity measurements were again performed using the Optomotry device, as previously 
described, on animals treated with drug and with vehicle.  These were done pre- and post-
blast, in order to gauge individual subjects’ visual effects after blast more accurately.  
Contrast sensitivity thresholds were obtained at 6 spatial frequencies, instead of the 1 
frequency used previously, in an effort to gain sensitivity to both CS deficits and 
improvements due to the drug.  The electroretinogram (ERG), a measurement of the 
electrical conductance across the cornea, was used to assess the function of cells within 
the retina in animals both pre-and post-blast.  Based on the hypothesis that the thinning of 
the INL and photoreceptor layer of blasted animals should yield some 
electrophysiological defect in those cell populations as well, ERG waves were analyzed 
with special attention paid to A- and B-wave amplitudes and latency time.  ERG waves 
are well characterized, and highly correlated with the function of specific cell populations 
under both normal and pathologic conditions 214.  A-waves correspond to photoreceptor 
function, while B-waves correspond to functioning of cells in the INL and RGCs 215.  
These waves are variably affected in a number of visual system diseases that display 
retinal pathology, including TBI 216,217, and were hypothesized to show a decrease in 
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amplitude or latency time, or both, due to the injury.  This defect was further expected to 
be ameliorated by drug treatment, with corresponding improvement in retinal 
histopathology. 
 
 A small group of 4x multiple blast animals not receiving drug or vehicle treatment 
were examined at 1 year after blast on optokinetics.  Both VA and CS thresholds at 1 
spatial frequency were obtained, to determine the effect of multiple blast exposure in this 
model. 
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CHAPTER 3.    GENERAL METHODOLOGY* 
 
 
Animals 
 
 Most experiments in this dissertation were done using C57BL/6 mice from 
Jackson Laboratories (Bar Harbor, ME), with an age of 11 weeks at the time of blast 
administration.  Occasionally, mice were also used from a colony kept by our lab at the 
University of Tennessee Health Science Center (UTHSC) bred from C57BL/6 founders 
also from Jackson Laboratories.  These mice were involved in the functional vision tests 
(Chapter 4), as well as the structural analysis performed at one month after blast (Chapter 
5).  Only males were studied to simplify the experimental design and to maximize 
numbers of animals in each time point.  Additionally, this model has only been 
extensively characterized in male mice. 
 
 Where noted, EYFP-reporter mice were used at shorter time points - 3 and 7 days 
after blast administration - and were used primarily for structural studies (Chapter 5).  
These mice were obtained from a cross between a floxed Thy1-EYFP reporter mouse and 
an emx1-Cre driver mouse, whose offspring express EYFP in all Thy1+ cells of the emx1 
lineage.  Although emx1 has not been reported to be expressed in the retina, we found 
prior to these experiments that about 5% of retinal ganglion cells also express EYFP, in 
this way we were able to use these mice to directly image morphology in a subset of 
retinal ganglion cell axons.  The floxed Thy1-EYFP reporter mice (purchased from JAX) 
and emx1-Cre driver mice (purchased from the Mutant Mouse Regional Resource 
Consortium, or MMRRC) were maintained as colonies at UTHSC.  A group of C57BL/6 
mice were used to quantify axon numbers in the optic nerve, and they ranged in survival 
time from 2 to 11 weeks after blast. 
 
 
Blast device description and characterization 
 
 The blast device described in this model and used for the experiments described 
in this dissertation is composed of a modified, horizontally mounted paintball gun which 
administers a controlled bolus of high pressure air to the left lateral side of the mouse’s 
head, at a defined region halfway between the ear and the eye of the mouse.  It was 
designed in corroboration with a fluid dynamics engineer at University of Memphis 
(Jeffery Marchetta, Ph.D; please see acknowledgements).  Extensive characterization has 
been done of both the blast device, the blast wave emitted from the gun, as well as the 
biophysics of mouse head movement during blast administration 179. 
 
-------------------- 
*Adapted with permission.  Guley, N. H., Rogers, J. T., Del Mar, N. A., Deng, Y., Islam, 
R. M., D’Surney, L., Ferrell, J., Deng, B., Hines-Beard, J., Bu, W., Ren, H., Elberger, A. 
J., Marchetta, J. G., Rex, T. S., Honig, M. G., & Reiner, A. (2015). A Novel Closed-Head 
Model of Mild Traumatic Brain Injury Using Focal Primary Overpressure Blast to the 
Cranium in Mice. J Neurotrauma, 2015 Dec 17;:neu.2015.3886. 
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Blast cannon 
 
 The blast device is composed of a paintball gun (Invert Mini, Empire Paintball, 
Sewell, NJ) modified with a custom-machined converging-diverging nozzle which 
chokes the air flow to achieve higher velocity and higher pressure output than is normally 
delivered by a paintball gun.  The paintball chamber is removed, and the gun emits only a 
high pressure, high velocity bolus of normal air provided by the pressurized air canister 
attached to the gun, delivered through a 6.5-mm nozzle opening.  The gun itself is 
attached horizontally to a fixed stage and is aimed at an outer PVC© tube which is 
affixed perpendicular to the gun nozzle on a moveable x-y stage.  The outer tube has two 
7.5-mm holes, one that faces the gun nozzle, and another exactly opposing it that allows 
for insertion of the pressure sensor (used for calibration purposes, described below).  A 
smaller diameter inner tube is used to contain the mouse, and has a larger 11-mm window 
used to expose the entire left side of the mouse’s head.  The large inner window is 
aligned with the smaller outer window, so only a 7.5 mm diameter head region is exposed 
to the blast. 
 
 
Mouse sling 
 
 A flat piece of plastic lined with a thin layer of foam was used to secure the 
mouse for insertion into the inner tube for blast administration.  At the end of the sling 
where the mouse’s head rests, thicker foam pieces were placed on the bottom and top, as 
well as the front, to further cushion and limit the mouse’s head from moving.  A tab 
affixed to the head end of the sling assists with its insertion into the inner tube.  During 
blast administration, the mouse was placed on the sling with the right side of its body 
fully contacting the foam, and was then taped around the mid-abdomen directly to the 
sling to prevent movement during insertion and blast administration. 
 
 
Calibration of blast device 
 
 Just prior to each blast session, the blast device was calibrated for the desired 
pressure output.  A model STJE Sensotec high pressure transducer (Honeywell, 
Morristown, NJ) was inserted into both the inner and outer tube through holes directly 
opposing the nozzle of the gun, and was brought to the same location that the mouse’s 
head occupies during blast administration (about 4-5 mm from the gun nozzle tip).  A 
custom-written program for Labview software (National Instruments, Austin, TX) runs 
the transducer at a sampling rate of 1000 samples/second and allows real-time 
visualization and plotting of the peak pressure during a blast.  By repeatedly firing the 
gun, visualizing the peak pressure, and adjusting the pressure nozzle on the back of the 
gun, the pressure was precisely dialed in to within 0.1 psi of the desired peak pressure.  
Once the desired peak pressure was achieved, a copy of the pressure versus time graph 
was exported and saved for documentary record.  To see a characteristic blast profile 
from this apparatus, please see Figures 2 and 5 from our previously published paper 179. 
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Administration of Single Overpressure Blast and Post-Blast Recovery 
 
 Mice were first weighed, then given an intra-peritoneal (ip) injection of Avertin 
(400 mg/kg body weight).  Anesthesia depth was gauged by suppression of tail pinch 
response.  Electric clippers were then used to completely shave the left temporal area of 
the skull, between the eye and the ear.  A white marker was used to place a dot directly 
on the skin at exactly half-way between the eye and the outer auditory meatus.  Mice 
were then secured in the foam sling using a piece of tape wrapped tightly around the 
abdomen and sling.  The sling was then inserted into the inner tube, with the mouse’s eye 
pinched shut prior to insertion of the head (to prevent corneal abrasion during insertion 
into the tube).  The sling was pulled through the inner tube until the shaved region of the 
mouse’s temporal area was fully visible in the large viewing window, but the left eye was 
still shielded by the tube.  This outer tube was then inserted into the inner tube, with the 
white dot lined up exactly centered in the smaller window in the outer tube.  The blast 
gun was purged no more than 10 seconds before the administration of the blast, by 
covering the gun aperture with a piece of heavy wood, and then discharging it.  This was 
done to clear the valve of any accumulated fluid volume that would cause variability in 
the blast pressure being administered.  After the purge was completed, the stage and 
attached tubes were positioned with the gun nozzle inserted into the aperture of the outer 
tube viewing window completely, such that the end of the gun nozzle was located at 4-5 
mm from the side of the mouse’s skull to be blasted.  The gun was then discharged, and 
the inner tube was then immediately withdrawn from the outer tube, and the sling 
removed.  The tape securing the mouse to the sling was cut, and the mouse was placed 
onto a heating pad for recovery from anesthesia.    
 
 After blast administration, mice were placed onto a heating pad to maintain body 
temperature from anesthesia-induced hypothermia.  Once mice began ambulation, they 
were placed into the common cage with their litter mates.  Most mice were recovered and 
ambulating by 15 minutes after blast.  Tylenol was dosed at 35 mg/mL in the drinking 
water of all mice for at least 3 but as many as 5 days after blast. 
 
 
SMM-189 and Vehicle Administration 
 
 SMM-189 is a highly lipophilic (cLogP= 5.26) tri-aryl cannabinoid with good 
aqueous solubility (~185 μg/mL at pH 7.4), and a terminal half-life of 3.03 ± 0.49 hours 
218.  See reference 217, Figure 1 for the molecular structure of SMM-189.  The drug 
SMM-189 was prepared in accordance with previously described methods 181.  Briefly, 
powdered SMM-189 (purity >98%) was mixed into a vehicle solution which consisted of 
a 90:5:5 ratio of 0.9% sterile saline, 5% Cremophor EL®, and 100% ethanol.  It was 
mixed on a vortex and filtered through a syringe-driven filter unit at 0.22 µm.  Mice were 
given an ip injection of either SMM-189 or vehicle at a dose of 6mg/kg of body weight 
beginning at 2 hours after blast.  This time point was chosen to begin treatment as it 
represented a realistic, clinically-relevant scenario for implementation of treatment after 
mTBI.  This was repeated at approximately the same time every day (± 1 hour) for the 
next 13 days after blast (14 doses in total).  Mice were weighed one week after blast to 
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adjust doses for changes in weight, which were minimal 179.  SMM-189 dosing was 
calculated based off a study using a structurally-similar tri-aryl CB2 receptor ligand 219, 
and is estimated to deliver 4.6 µM of SMM-189 to the brain within hours of the ip 
injection at this concentration.  With the known CB2 affinity 207, this was deemed high 
enough to achieve appropriate receptor activation in the brain 181. 
 
 
Administration of 4x Multiple Overpressure Blast and Post-Blast Recovery 
 
 For multiple blast studies, animals were administered with blast overpressure 
exactly as previously described for animals receiving only a single blast.  The blast was 
administered once every 7 days, for 4 times total.  The time after blast began after the 4th 
blast administration. 
 
 
Animal Sacrifice and Tissue Removal 
 
 
Whole body perfusion 
 
 Mice were deeply anesthetized (Avertin; 0.2 mL/g body weight), the chest 
opened, and 0.1mL of heparinized saline (800 U.S.P. units/mL) was injected into the 
heart.  They were then perfused trans-cardially with 30 mL of 0.9% NaCl in 0.1 M 
sodium phosphate buffer at pH 7.4 (PB), followed by 180 mL of 4% paraformaldehyde, 
0.1 M lysine-0.1 M sodium periodate in 0.1 M PB at pH 7.4 (PLP). 
 
 
Brain collection 
 
 Brains were removed by first decapitating perfused mice, and then removing the 
entire superior portion of the skull.  Great care was paid to preserve the optic nerve and 
chiasm from damage.  The optic nerves were clipped just distal to the optic chiasm, 
leaving the optic nerves and eyes in situ for subsequent removal.  The brain was then 
placed in PLP overnight to post-fix.  The following day, brains were moved into a 20% 
sucrose/10% glycerol solution and were stored at 4°C.  A pin was also inserted 
longitudinally into the right side of the brains, in order to distinguish left from right, and 
was left there until the time of sectioning (a minimum of 3 days). 
 
 
Eye and optic nerve collection 
 
 Eyes were first cauterized at one small site on the temporal side of the cornea to 
mark orientation, then injected with PLP using a small syringe.  They were then removed 
from the socket antero-superiorly, by first reflecting back the tissue of the eyelid, 
removing the orbital part of the frontal bone, and clipping away the ocular muscles to 
release the eye.  The optic nerve was left attached to the eye, and they were both placed 
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into PLP for 2 hours of post-fixation at 4°C.  After two hours had elapsed, the lens was 
carefully removed from each eye by making a corneal flap, leaving the cautery mark 
intact, and then placed in a 20% sucrose and 0.1 M PB solution.  A micro-suture was 
subsequently placed through the cautery mark to enable identification of temporal and 
nasal sides during embedding.  A separate set of optic nerves used for axon counts were 
removed from the eye by excision at the optic nerve head, then fixed in 4% 
paraformaldehyde/0.5% glutaraldehyde in 0.1 M PB, to be embedded in plastic. 
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CHAPTER 4.    FUNCTIONAL VISION OUTCOMES IN MTBI 
 
 
Methods 
 
 
Optokinetics 
 
 Optokinetic data were obtained from all C57BL/6 mice at 30 days after blast.  In 
one small cohort of these animals (n=14), pre-blast VA data were also obtained, to allow 
inter-subject comparison with post-blast test results.  For this subset of animals, their 
post-blast data was compared with their pre-blast data, and this number (a post-test 
percent of pre-test) was used for statistical comparison.  Another cohort of animals was 
analyzed from a long-term multi-blast study that did not include drug treatment.  These 
animals had been blasted 4 times in total - once a week for 4 weeks – and were tested at a 
year after blast.  Their blast intensities were either 0-psi (sham) or 50-psi. 
 
 General information.  Optokinetic nystagmus was used to determine  both visual 
acuity and contrast sensitivity thresholds on live mice pre- and post-blast at one month.  
A Cerebral mechanics OptoMotry system (CerebralMechanics Inc.: 
www.cerebralmechanics.com) was used for this purpose 183.  This apparatus consists of 
four LCD computer screens arranged in a box around a central platform.  A camera is 
suspended above the platform on a ceiling that blocks out all external light.  The camera 
relays a top-down view of the subject and the platform to a computer program  and 
monitor being used by the experimenter during testing.  The system is designed such that 
once the mouse is enclosed in the apparatus, the experimenter cannot see the stimulus 
being presented, and the mouse cannot see external stimuli.  The computer program is 
used to create a virtual barrel displayed on the LCD screens around the platform and 
subject, with evenly spaced vertical bars of either black or white that rotate about the 
center of the arena.  Spacing and width of the vertical bars dictate the spatial frequency 
(c/d) being tested.  Clockwise bar rotation tests the left eye and counter-clockwise 
rotation tests the right eye, since the optokinetic response is driven exclusively by 
temporal to nasal motion.  Within the computer program display for the experimenter, the 
center of the arena is delineated by a crosshair that is moved around by the experimenter 
as the mouse shifts head positions. 
 
 The test was administered in a double-blinded manner, with the experimenter 
unaware of either the spatial frequency/contrast level or the eye being tested at any given 
time.  Mice were placed onto the mouse platform in the optomotry device and allowed to 
acclimate for 1-2 minutes, or until the mouse was calm and still.  During the 
acclimatization period, the screens all displayed a solid grey background, a color that was 
identified by the system vendor as being the most calming for C57BL/6 mice. 
 
 The CerebralMechanics computer program uses a staircase method for achieving 
a stimulus threshold, where it first presents the lowest possible stimulus (.003 c/d in this 
case), waiting for a positive response (a “yes”), and then moves to successively higher 
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stimuli until a negative response is reached, at which time it returns to a lower threshold 
and repeats the process again.  This is done for both counter-clockwise grating movement 
and clockwise grating movement at the same time, randomly switching which direction is 
tested to keep the experimenter unaware of which eye was being tested at each stimulus 
round.  A threshold is achieved at which point the step higher is not visible, but the step 
lower is consistently visible to the test subject.  If at any point during testing the subject 
responded negatively to 7 consecutive stimuli to which it previously responded 
positively, the test was ended automatically by the computer program.  This would occur 
when the test subject became bored or tired of the stimuli, and ceased to respond 
regardless of whether the stimuli was actually visible to it or not.  If at any point the test 
subject became unresponsive or hyper-responsive and it was obvious that the subject was 
under distress or inattentive, it was removed by the experimenter and placed back with its 
litter mates to be tested at another time.  Occasionally it was necessary to flash either a 
black or a white screen at the test subject to keep it awake and attentive; occasionally 
knocking and/or whistling was also used for this purpose at the experimenter’s discretion.  
 
 Visual acuity test administration.  For achieving the visual acuity threshold at 
100% contrast, the system was set to the “visual acuity” program, and after the 
acclimatization period, the experimenter began the test by positioning the crosshair of the 
computer mouse directly over the area where the subject’s eyes were located.  In this 
way, the computer program is able to create a virtual barrel using the crosshairs as the 
center location for the virtual barrel to turn about.  As soon as the experimenter released 
hold of the computer mouse, the stimulus was presented to the subject, and the 
experimenter watched the subject for any head movement.  If head movement was not 
detected for 5 consecutive seconds during which the subject’s body was completely still, 
the experimenter chose “no” as a response to the stimulus.  If at any time the subject 
moved and the crosshair was no longer over the eyes of the subject, the experimenter 
clicked on the crosshairs and repositioned them at the new location over the subject’s 
eyes, and then released it to once again expose the stimulus.  If the subject’s head panned 
in a slow arc, scanning in a clockwise or counterclockwise manner indicative of stimulus 
tracking, the experimenter chose “yes” as a response to the stimulus.  This was repeated 
continually until a visual acuity threshold was reached, above which the subject no longer 
responded to any stimulus presented and the computer program automatically terminated 
the test and indicated the individual threshold for each eye. 
 
 Contrast sensitivity test administration.  Contrast sensitivity thresholds were 
obtained by using the “contrast sensitivity” program and testing each of 5 spatial 
frequencies (0.031, 0.064, 0.092, 0.103, 0.192, and 0.272) independently, as described 
above.  At a given test spatial frequency, the black bars are decreased in intensity until 
they are indistinguishable as separate from the white bars.  The point at which the mouse 
can no longer see the gradient bars is the contrast sensitivity threshold for that spatial 
frequency.  CS thresholds at each spatial frequency yield a contrast sensitivity function. 
 
 Test analysis.  All VA data were analyzed in the Minitab express software 
(Minitab, Inc. State College, PA) by one-way ANOVA using the Fisher’s post-hoc 
analysis.  CS functions were compared by two-way ANOVA on the entire CS curve, 
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across groups.  In the small cohort with pre-blast and post-blast VA data, a pre-post 
difference was achieved and used for comparison as well 
 
 
Electroretinogram 
 
 ERGs were performed on anesthetized mice using a Diagnosys Ganzfeld ERG 
system (Diagnosys, LLC, Lowell, MA).  Prior to the test, mice were dark adapted 
overnight in a light-proof box with attachment to a ventilation hood.  On the day of the 
ERG, they were only exposed to low intensity red lights for the short periods of time 
required to administer anesthesia and place electrodes. 
 
 Test administration.  Mice were first weighed, then given an ip injection of 
ketamine/xylazine (80/10 dilution) at a dose of 0.1 mL/10 g of body weight.  Anesthesia 
depth was gauged by suppression of tail pinch response.  One drop per eye of 1% 
cyclopentolate hydrochloride ophthalmic solution USP (Bausch & Lomb, Tampa, FL) 
was given to induce pupil dilation, and the mouse was moved to the ERG platform for 
positioning.  The ERG platform had a microwavable heating pad under it to keep the 
mouse’s body temperature from dropping during the test.  The mouse’s tail and forehead 
were sanitized with a sterile ethanol swab prior to the insertion of a sub-cutaneous ground 
and reference electrode, respectively.  A drop of methylcellulose gel (Methocel® 2%, 
OmniVision, Neuhausen, Swizerland) was placed onto each eye to assist in signal 
transduction, then left and right gold ring electrodes (Goldring Electrode 2.5 mm, Roland 
Consult, Havel, Germany) were positioned such that they aligned parallel to the surface 
of the cornea, and moved closer until they gently touched the surface of the mouse’s 
cornea without exerting undue pressure.  Impedance was then measured and corneal 
electrodes were adjusted to give the lowest possible impedance readings.  After this, the 
ERG flash hood was lowered into place above the mouse such that the mouse was 
centered in the flash zone (video image guided).  At this point, all red lights were turned 
off, and the test was started.  If at any point during the test, an electrode began to flat line, 
the test was paused, and resumed once the electrode background noise became visible 
again.  This occurred when large transient impedance spikes forced the electrode to go 
offline, and happened variously throughout the test, likely because of body movement 
from the mouse breathing.  At the end of the test, all electrodes were removed and 
sanitized, and the mouse was placed on a heating pad for recovery.  Their eyes were 
rinsed with sterile saline to prevent irritation, and they were placed back in their cages 
with their littermates once they began ambulation.  
 
 Test analysis.  Espion software (Version 5.0.52 , Diagnosys, LLC) was used to 
analyze ERG data.  At each light intensity tested (step), anywhere from 10-20 waveforms 
were captured during ERG administration.  The number captured was determined by the 
intensity of light, with lower intensities having more captures, and higher intensities 
having fewer captures (to prevent photo bleaching).  Anomalous or flat-line waveforms 
were removed prior to averaging of the waveforms at each intensity.  Anomalous 
waveforms were defined as having an opposite direction from the normal trend of the 
ERG wave, and/or having large, regular spike and wave patterns indicative of 
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electromagnetic interference (for example, 60 Hz waveform seen with nearby electronics 
plugged into a wall outlet).  Measurements of peak A- and B-wave amplitude, as well as 
latency time, were taken from the averaged waveform at each light intensity.  This 
analysis was performed on every pre- and post-blast test for each subject. 
 
 To analyze the ERG results, pre-blast test results were compared with post-blast 
test results within the same animal to achieve a ∆-value that was then used for statistical 
purposes.  Subsequently, control pre-test averages were used at each step and were added 
to each individual ∆-value to achieve a scaled ERG peak value that was easier to 
conceptualize for graphing purposes. 
 
 
Results 
 
 For the purpose of discussing the three groups of animals used in these 
experiments, the sham-blasted, vehicle treated group will be referred to as 0V, the 50 psi-
blasted, vehicle-treated group will be referred to as 50V, and the 50 psi-blasted, drug 
treated group will be referred to as 50SMM for the remainder of this dissertation. 
 
 
OKN 
 
 Visual acuity.  Visual acuity thresholds from all groups were compared using 
one-way ANOVA and Fisher’s individual tests for differences in means.  Left eye 
thresholds were not significantly different between any group by either metric (ANOVA 
p=0.8275).  Similarly, right eye VA thresholds were not significantly different between 
any group by either metric (ANOVA p=0.4654).  Furthermore, the post-blast VA data for 
a small group of animals was compared to their available pre-blast VA data, and the pre-
blast versus post-blast difference was found to be insignificant for both left and right eye 
(p=0.3591 and p=0.5024, respectively) (Figure 4-1).   
 
 VA analysis in long term multi-blast animals at a year from blast found 
significant differences in both eyes between the 0- and 50-psi groups.  0-psi LE VA was 
significantly different than the 50-psi group by one-way ANOVA (p=0.0001).  In the RE, 
the 50-psi group was also significantly different from the 0-psi group by one-way 
ANOVA (p=0.0463) (Figure 4-2). 
 
 Contrast sensitivity.  Contrast sensitivity functions were compared using a two-
way ANOVA across all spatial frequencies and groups.  In the left eye, significant 
differences were found between both the sham group and the 50V group (p=0.0041), and 
the drug treated 50-psi group and the 50V group (p=0.0202), while the the sham and drug 
treated blast group had no significant difference between them (p=0.4696) (Figure 4-3).  
In the right eye, even more robust differences were seen between the sham group and 
50V group (p<0.0001) and the drug treated blast group and the 50V group (p<0.0001).  
No difference existed in the right eye between the sham and the drug treated blast group 
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Figure 4-1. Visual acuity thresholds for both eyes at 30 days after blast. 
 
There were no significant changes in the VA thresholds of either eye for any group.  Bars 
are one standard error from the mean. 
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Figure 4-2. Visual acuity thresholds for 4x multi-blast animals a year after blast. 
 
Visual acuity in 50-psi animals is significantly reduced in both eyes compared with 
controls.  Asterisk denotes significance at p=0.0001.  Triangle denotes significance at 
p=0.0463.  Bars are one standard error from the mean. 
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Figure 4-3. Contrast sensitivity functions of the left eye at 30 days after blast. 
 
In the left eye, there was a significant increase in the contrast sensitivity function of 50V 
animals (red), indicating a need for higher levels of contrast across all spatial frequencies 
in order to perceive a given stimulus.  This was significantly, but not completely, 
remedied by SMM-189 treatment (green).  Bars are one standard error from the mean. 
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(p=0.2938) (Figure 4-4).  These results show that contrast sensitivity was reduced after 
50-psi blast, and the deficit was rescued with SMM-189.   
 
 In the long-term multi-blast animals, CS was measured at only one spatial 
frequency, 0.272 c/d.  The 50-psi animals were found to have a significant CS increase in 
the left eye over 0-psi animals by one-way ANOVA (p=0.0277).  In the right eye, 50-psi 
animals were also significantly increased over 0-psi animals (p=0.0345) (Figure 4-5). 
 
 
ERG 
 
 Left eye.  A-wave peak amplitudes and latency time were unchanged across all 
three groups by two-way ANOVA (p=0.3233 for peak amplitude and p=0.8177 for 
latency time) (Figure 4-6C).  Pre-blast and post-blast B-wave peak amplitude 
measurements were unchanged in 0V and 50SMM groups by a paired t-test (p=0.3243, 
and p=0.4250, respectively), however, the 50V group did significantly differ from their 
pre-blast measurements (p=0.0455) (Figure 4-7).  Furthermore, two-way ANOVA 
showed the B-wave peak amplitudes to be significantly increased in 50V animals when 
compared to controls (p=0.0379), while 50-psi SMM-treated animals were not 
significantly different from either vehicle-treated blast animals (p=0.2222) or vehicle-
treated control animals (p=0.5128) (Figure 4-6A).  B-wave latency time was statistically 
unchanged across all groups (p=0.2637) (data not shown).  These results show that the B-
wave was abnormally elevated after 50-psi blast, and the abnormality was rescued with 
SMM-189. 
 
 Right eye.  A-wave peak amplitude and latency time were unchanged across all 
groups by two-way ANOVA (p=0.2660 and p=0.7036, respectively) (Figure 4-6D).  B-
wave peak amplitude and latency time were unchanged across all groups by two-way 
ANOVA (p=0.2203 and p=0.8192, respectively) (Figure 4-6B). 
 
 
Summary 
 
 Functionally, blasted, vehicle-treated mice show mild vision impairment that is 
slightly different in each eye.  The left eye of blasted animals shows a defective ERG 
response specifically in the part of the ERG wave that corresponds to cells in the inner 
nuclear layer, a retinal layer where previous studies have shown thinning in these 
animals.  Oddly, the ERG defect is an increase in peak amplitude, rather than the 
expected decrease under pathologic conditions.  The drug-treated animals had a decrease 
toward normal, with an ERG that was statistically unchanged from control animals.  The 
visual acuity of blasted, vehicle-treated mice was normal in both eyes, and statistically 
unchanged from both pre-blast/post-blast comparisons in the same individual, and when 
compared to control animals.  However, the contrast sensitivity function showed 
significant defects in both eyes.  Surprisingly, the right eye CS deficit was more robust 
than that of the left eye, even when the right eye ERG wave was apparently normal.  This 
hints that there may be some different mechanism underlying the pathology of the right  
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Figure 4-4. Contrast sensitivity functions of the right eye at 30 days after blast. 
 
The right eye of 50V animals showed a very significant deficit in contrast discrimination 
across all spatial frequencies compared to 0V animals (red and blue, respectively).  This 
was almost completely remedied with SMM-189 treatment (green).  Bars are one 
standard error from the mean. 
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Figure 4-5. Contrast sensitivity in 4x multi-blast animals a year from blast. 
 
Contrast sensitivity at 0.272 c/d was pathologically increased in 50-psi animals compared 
to 0-psi animals in both left and right eyes.  Asterisk denotes significance at p=0.0277.  
Triangle denotes significance at p=0.0345.  Bars are one standard error from the mean. 
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Figure 4-6. The effect of blast and SMM-189 treatment on ERG A- and B-wave 
functions at 30 days after blast. 
 
This figure shows the average scotopic ERG peak amplitudes at 6 light intensities for all 
groups.  In the left eye of 50V animals, the B-wave is significantly increased across all 
intensity levels (A), while the right eye is nearly so (B).  Drug treatment slightly rescues 
this anomalous increase in both eyes, being statistically equivalent with controls.  The A-
waves of the 50V left eyes are nearly different from that of controls (C), while the right 
eyes of all groups are statistically equivalent (D). 
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Figure 4-7. Left eye pre-blast and 30 days post-blast scotopic ERG B-wave 
functions for all groups. 
 
Left eye post-blast ERG functions were significantly elevated in the 50V group from 
their pre-blast values (B), but not in the 0V (A) or 50SMM groups (C). 
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eye than the left eye.  Visual acuity in multi-blast animals at a year from blast showed 
significant deficits in the left eye of 50-psi animals.  The right eye visual acuity was only 
significantly compromised in 50-psi animals, indicating again that there seems to be a 
difference in the mechanism of LE and RE damage.  Contrast sensitivity was also 
pathologically elevated in the 50-psi animals a year after 4x blast in both eyes.  These 
multi-blast findings confirm the persistence of visual function pathology at an extended 
time point after blast. 
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CHAPTER 5.    STRUCTURAL VISION OUTCOMES IN MTBI 
 
 
Methods 
 
 
Optical coherence tomography (OCT) 
 
 Test administration.  A Bioptigen 840nm SDOCT system (Bioptigen Inc., 
Morrisville, NC) with Superlum Broadlighter at a 150 nm bandwidth was used for 
obtaining a < 3.5 μm resolution image of the retina in live, anesthetized mice.  Mice were 
first weighed and injected with ketamine/xylazine (80/10 dilution) dosed at 0.1 mL/10 g 
of body weight, then placed on a heating pad to maintain body heat.  Anesthesia depth 
was gauged by suppression of tail pinch response.  Once fully anesthetized, one drop of 
1% cyclopentolate hydrochloride ophthalmic solution USP (Bausch & Lomb, Tampa, 
FL) was placed into each eye to attain pupil dilation.  Mice were then placed into the 
mouse alignment holder and maneuvered into position.  One drop of Systane™ (Alcon, 
Fort Worth, TX) eye drops were placed into the eye directly before imaging began, to 
assist in achieving good image resolution as well as to keep the eye from drying out.  
Mouse eyes were positioned such that the central retinal artery was fully visible on 
fundoscopic view and approximately mid-center, and one to three images were obtained 
from each eye, depending on image quality achieved.  Mice were then removed, and a 
sterile .9% saline solution was used to wash the eyes and prevent irritation.  Mice 
recovered on a heating pad and were placed with littermates upon recovery of 
ambulation.  
 
 Test analysis.  OCT images were loaded into the InVivoVue software (Bioptigen 
Inc., Morrisville, NC), which was used to perform measurements of retinal layers.  The 
following measurements were made:  total retina, inner plexiform layer, inner nuclear 
layer, outer nuclear layer, and photoreceptor segments (inner and outer segments 
measured together).  These measurements were made at the horizontal meridian in 
sections where the optic nerve head and/or central retinal artery were clearly visible.  The 
measurements were performed 50 µm from the optic nerve head on both the nasal and 
temporal sides of each eye, and then averaged.  Post-blast measurements were subtracted 
from pre-blast measurements for each animal in both eyes and at each layer.  This yielded 
a ∆-value that was then used for statistical purposes. 
 
 
Histologic processing 
 
 Sectioning.  Fixed brains were first frozen with dry ice, then sectioned on a 
sliding microtome in the transverse plane at 35 µm.  Each brain was collected as 12 
separate series in 0.1 M PB with 0.02% sodium azide. 
 
 Prior to sectioning, eyes were placed into a 50/50 Optimum Cutting Temperature 
compound (O.C.T.) (Tissue-Tek®, Sakura Finetek USA, Inc.)/ 20% sucrose and 0.1 M 
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PB solution for 10 minutes in a vacuum chamber at 16 psi.  Then they were moved into 
100% O.C.T. and left to equilibrate at ambient pressure for 30 minutes.  Afterward, they 
were once again placed in the vacuum chamber at 16 psi for 10 minutes.  This was to 
enable the O.C.T. medium to completely penetrate the tissue, and to remove any air 
bubbles prior to freezing.  The eyes were then oriented in the mold to allow sectioning of 
the eyes through the horizontal meridian and optic nerve/optic nerve head.  The micro-
sutures were used to maintain nasal-temporal orientation throughout the embedding 
procedure, and the eyes were finally frozen on dry ice inside the molds.  When fully 
frozen, the embedded eye block was removed from the mold, and eyes were sectioned on 
the cryostat (Bright Instrument Company, Ltd., Huntingdon, England) at -16 ºC at 
thickness of 20 µm.  Sections were discarded until the full retina was visible in the 
section, approximately 100 µm into the eye, and then each section was collected onto a 
Superfrost®/Plus slide (Fisher Scientific, Pittsburg, PA), then placed onto a slide warmer 
at 32 ºC for 5 minutes, before being transferred to the freezer (-80 ºC) for storage prior to 
immunohistochemistry (IHC) processing. 
 
 Staining and immunohistochemistry.  All immunohistochemistry was 
performed on free-floating sections (brain), or slide-mounted sections (eyes) in a 
standardized manner that involved the following general steps: (1) 3 5-minute washes in 
PB (pH=7.4), then (2) incubation in primary antibody solution at room temperature for 24 
hours, then (3) 3 5-minute washes in PB, then (4) incubation in secondary antibody 
solution at room temperature for 2 hours, and finally (5) 3 5-minute washes in PB before 
mounting (brains), drying, and cover-slipping.  See Table 5-1 for a list of all primary 
antibodies and dilutions used for these experiments. 
 
 The primary antibody solution always consisted of the primary 
antibody/antibodies diluted into a solution of 5% normal horse serum (NHS) and 0.8% 
Triton X-100/0.01% sodium azide/0.1M PB (PBX).  Free-floating sections were 
incubated in micro-centrifuge tubes with 500 µL of primary antibody solution on a 
countertop rotator, while slide-mounted tissue (eyes) were first outlined with 
hydrophobic pen (ImmEdge, Vector Labs: Burlingame, CA), then incubated with 250 µL 
of primary antibody solution per slide and kept stationary.  Secondary antibody solutions 
always consisted of the secondary antibody/antibodies diluted into PBX without sodium 
azide, and were shielded from light during the 2-hour incubation period, since 
fluorescently-labeled secondary antibodies were used in all IHC studies.  All slides used 
for IHC were cover-slipped with Vectashield Antifade mounting medium with DAPI 
(Vector Labs:  Burlingame, CA).  The edges of coverslipped slides were painted with nail 
polish (Sally Hansen, NYC) to prevent leakage of the mounting medium during imaging.  
 
 Optic nerves used for axon quantifications were embedded in plastic, sectioned 
transversely at 1 µm, and then stained with 1% p-phenylenediamine in 50% methanol 
(PPD) as described in Bricker-Anthony et al 177. 
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Table 5-1. Primary antibodies used for immunohistochemistry. 
 
Antibody target  Host  Dilution  Source 
       
GFAP  Rabbit  1:100  Immunostar 
       
Brn3a  Goat  1:100  Santa Cruz 
biotechnology®, Inc. 
       
Iba-1  Rabbit  1:500  Wako Chemicals 
USA, Inc. 
       
CD16/32  Rat  1:50  Abcam® 
       
CD206  Goat  1:200  R&D Systems®, Inc. 
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Imaging 
 
 Light microscopy.  For optic nerve axon quantification, images were captured 
using an Olympus BH2 series light microscope with S Plan Apochromat objectives, an 
achromatic condenser (Olympus Corporation, Tokyo, Japan) and SPOT idea ™ camera 
(Diagnostic instruments, Inc., Sterling Heights, MI) running on SPOT Advanced software 
(Version 4.6).  Lens magnification of 20x was used to capture images for axon cross 
section measurements.  Axon counts were done on sections at 100x oil immersion.  A 
scale bar was also imaged at each photo session to standardize size comparisons across 
magnifications. 
 
 Confocal laser scanning microscopy.  A Zeiss 710 CLSM microscope (LSM 
800, Carl Zeiss AG, Oberkochen, Germany) was used to image tissue in IHC studies for 
this dissertation.  Laser power, gain, and wavelength were adjusted to optimize image 
quality, and were standardized across all images for a given marker (or combination of 
markers).  Retinal images were always obtained on the horizontal meridian at the level of 
the optic nerve head when possible, and from the nasal and temporal side of the eye.  
Images were always obtained at 20x power, with multiple images stitched together using 
the tile capture feature of the Zen software (Zen Black Version 2.1, Carl Zeiss AG, 
Oberkochen, Germany) in order to quantify large lengths of retina in a single image. 
 
 
Quantification and analysis of structural end points 
 
 For all images of a given marker, contrast, brightness, and color values were 
adjusted in a standard way across every image, in order to optimize viewing for 
quantification.  All analysis was done in a blinded manner.  Unless otherwise noted, 
ImageJ software (Version 1.50c4, National Institutes of Health, USA) and the 
Analyze>Cell counter plugin were utilized for quantification of histology endpoints, from 
images obtained by either LM or CLSM.  Measurements of histology endpoints were 
scaled to the correct image magnification using scale bars either obtained directly (LM) 
from scale bar photographs at a known magnification, or indirectly (CLSM) from the 
image software itself. 
 
 Axons in the optic nerve (LM).  Whole optic nerves were measured for cross-
sectional area using the ImageJ freehand selection tool and Analyze>Measure command.  
Then, high power images were examined from each of 4 quadrants (north, south, east, 
west) of the optic nerve cross section for each eye.  For axon quantification, an image 
from a single quadrant was overlaid with a 10 x 10 µm grid using the Analyze>Grid tool.  
Starting from the top row, a random number generator was used to determine which box 
in each row would be quantified.  As an example, in a row of 10 grid boxes, the random 
number generator was set to populate a number between 1 and 10.  If the number 
generated was 8, then the box 8th from the left side of the image would be the box in 
which axons were counted using the cell counter tool.  At each quantification box, axons 
falling on the north and east line of the grid were counted, whereas axons falling on the 
south and west line of the grid were not counted.  Axons were only counted if a well-
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defined dark ring surrounding a lighter center area could be seen.  Thus, axons too small 
to have an apparent central clearing (axoplasm) were likely missed, due to the 
resolution/magnification restrictions of light microscopy. 
 
 Once an entire image was counted, the total number of axons was divided by the 
total box area counted (each box was a known size, 10 x 10 µm, and the number of boxes 
quantified was the total number of rows, since one box was counted per row, thus the 
total area in which axons were counted was 100 µm2 x number of rows) in order to give 
an axon density for that quadrant.  Finally, the 4 quadrants for that ON were averaged, 
and total ON axon number was extrapolated using the axon cross sectional area and the 
axon density for that ON (axon density x axon area).  For statistics purposes, total axon 
number, ON cross sectional area, and axon density were all compared for each optic 
nerve and each group. 
 
 Brn3a+ cells in the retina (CLSM).  Retinal images from the nasal and temporal 
side of each eye were used to quantify RGCs using an antibody to Brn3a.  Brn3a is 
visible in the cell body of cells, and cells were only counted if they were clearly visible in 
the section, with a nucleus visible on the overlaid DAPI channel.  Brn3a-positive cells 
were counted, and the total length of the retina over which they were counted was 
measured.  This then yielded a number of cells per µm length of retina for each side of 
the eye, which were then averaged together.  The average number of cells per µm length 
of retina for each eye were used for comparison and statistics purposes. 
 
 Iba-1+ cells in the retina (CLSM).  Iba-1+ cells (microglia) were quantified in a 
manner similar to Brn3a+ cells previously described.  The exception is that Iba-1 is also 
visible in the processes of microglia, so many more processes were visible than cell 
bodies.  Cells were only counted if the cell body was clearly visible in the section, and 
the DAPI channel showed a clear nucleus.  Microglial processes were not quantified.  
Average number of cells per µm length of retina for each eye were used for comparison 
and statistics purposes. 
 
 GFAP reactive processes in the retina (CLSM).  As previously, retinas were 
quantified on the nasal and temporal side for each eye.  GFAP+ processes normally exist 
on the deep surface of the retina, in the nerve fiber layer.  Only processes that extended 
past the RGC layer and were clearly visible were quantified.  The total length of the 
retina over which GFAP processes were counted was measured, and this was used to 
yield a number of processes per µm length of retina.  As before, the nasal and temporal 
sides were averaged together, and this number of processes per µm length was used for 
comparison and statistics purposes. 
 
 M1/M2 cells in the right optic tract (CLSM).  Recall that the major damage in 
the white matter seen in this model originates from the left eye, where the axons in the 
left optic nerve almost completely decussate in the optic chiasm to continue in the brain 
as the right optic tract.  To simplify the experimental design and focus solely on a region 
of known injury, images of the right optic tract were captured using a 4 µm thick z-stack, 
capturing separate channels for CD16/32, CD206, and Iba-1.  The maximum intensity 
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projection of the z-stack was used for analysis purposes.  In order to quantify cellular 
staining for both M1 and M2 markers, we used a method described by McCloy and 
colleagues that involves calculating a corrected cellular fluorescence level for individual 
cells of interest 220.  Using ImageJ, individual microglial cells in the optic tract were 
circumscribed using the free-form drawing tool on the Iba-1 channel.  With this outline in 
place, the channel was switched to visualize CD16/32 and CD206 independently, where 
measurements of the staining intensity of each channel were collected using the 
integrated density values.  This was repeated for every visible cell in the optic tract.  
Afterward, 5 measurements were taken randomly throughout the optic tract over areas 
where no Iba-1 staining was visible, and the previously described process was repeated.  
These values were averaged together to represent the background staining intensity for 
each channel. 
 
 In order to determine the corrected cellular fluorescence, the background staining 
was multiplied by the area of the cell, and this was subtracted from the integrated density 
value of that cell.  This value, the corrected cellular fluorescence, was then used for direct 
comparison.  For each cell, a ratio of M1 (CD16/32) and M2 (CD206) markers were 
obtained, and from this number a cell was then categorized as M1-biased (an M1/M2 
ratio equal to or above 1.10), M2-biased (M1/M2 ratio equal to or below 0.90), or non-
differentiated (M1/M2 ratio between 1.09 and 0.91).  The categorical distinction of M1, 
M2, or M0 for each cell was used for statistical analysis. 
 
 Axon bulbs in the optic tract (CLSM and LM).  Axon bulbs are clearly visible 
in the optic tract at 3 days post-blast, as described previously.  However, at 7 days, the 
bulbs become smaller and more granular in appearance, at this point they are likely 
indicative of axon degeneration fragments.  Axon bulbs were visualized by either SMI-32 
immunolabeling or direct EYFP immunofluorescence in reporter mice (described 
previously), and were counted in tissue from animals 3, 5, and 7 days after blast.  Some 
of the tissue used for axon bulb quantification at 5 and 7 days after blast was in animals 
exposed to 60 psi blast, and for the purposes of this analysis, was grouped together with 
animals who received 50 psi blasts.  Images were captured by either CLSM or LM.  
Within ImageJ, the freehand tool was used to outline the entire ROT region, and the area 
measurement was acquired.  Then, axon bulbs whose longest dimension was greater than 
6.5 µm were counted.  The axon bulb areal density was calculated by dividing the 
number of bulbs by the area of the ROT section.  These axon bulb densities were used for 
direct statistical comparison. 
 
 
Results 
 
 
OCT 
 
 Pre-blast and post-blast measurements for each animal were compared using a 
paired t-test.  In 50V animals, the left eye showed significant thinning in the outer retina 
(ONL + photoreceptor segments) from their pre-blast measurements (p=0.0076).  The 
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inner retina (IPL+INL) showed no significant changes in the 50V animals (p=0.6238), 
but did show significant thinning in the 50SMM animals (p=0.0427) (Figure 5-1).  In the 
right eye, no significant changes from pre to post-blast measurements were seen in any 
group (Figure 5-2). 
 
 
Optic nerve 
 
 Left eye.  The ON cross sectional area was significantly lessened in both the 50V 
and 50SMM animals when compared with 0V animals by one-way ANOVA (p=0.0393 
and p=0.028, respectively) (Figure 5-3).  In 50V animals, the axon density (count per 
µm2) was significantly less than in the 0V group by one-way ANOVA (p=0.0198), but 
not significantly different than the 50SMM group (p=0.1512) (Figure 5-4).  The 0V and 
50SMM groups were not significantly different in axon density.  The extrapolated total 
ON axon count was significantly decreased in 50V animals compared to 0V animals 
(p=0.0014), as well as in 50SMM animals when compared to 0V animals (p=0.0136), and 
the 50V and 50SMM groups were not significantly different from one another in 
extrapolated total ON axon count (Figure 5-5).  A Pearson correlation revealed a strong 
negative relationship between the axon density and ON area in control animals that was 
significant (r=-0.7138, p=0.0136).  50V animals a weak positive relationship that was not 
significant (r=0.1331, p=0.7140), and 50SMM animals showed a weak positive 
correlation that was also not significant (r=0.2453, p=0.4946). 
 
 Right eye.  The ON cross sectional area was not significantly changed between 
any group, however the axon density was significantly decreased in 50V animals when 
compared with both 0V and 50SMM animals by one-way ANOVA (p=0.0002 and 
p=0.0438, respectively) (Figures 5-3 and 5-4).  The 0V and 50SMM animals were 
nearly, but not statistically different in axon density (p=0.0571).  The extrapolated total 
ON axon count was not significantly different between any group, although the 50V were 
nearly significantly different from 0V group at p=0.0639 (Figure 5-5).  A Pearson 
correlation revealed a moderate negative correlation in controls that was not significant 
(r=-0.2977, p=0.3909), 50V animals showed a strong negative relationship that was 
nearly significant (r=-0.5554, p=0.0761), and 50SMM animals showed a weak negative 
relationship that was not significant (r=-0.2415, p=0.5015). 
 
 
Brn3a counts 
 
 At 30 days after blast, the left eye Brn3a cell counts were not significantly 
different between any group using one-way ANOVA.  The difference between the sham 
and 50V group was, however, nearly significant (p=0.0507).  In the right eye, all groups 
were not significantly different from one another (Figure 5-6). 
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Figure 5-1. Left eye pre-blast and post-blast OCT measurements.  
 
The pre-blast and post-blast OCT measurements for all groups are shown in this figure, 
grouped by inner and outer retinal layers.  Inner retinal layers (IPL+INL) were not 
significantly changed in 0V or 50V animals, however drug treatment caused an odd 
decrease in the inner retinal thickness (denoted by +, p=0.0427).  The 50V animals 
showed a significant decrease in the outer retina (ONL+photoreceptor layers) after blast 
(denoted by *, p=0.0076), while the 0V and 50SMM animals showed no significant 
changes.  The total retinal thickness was not changed from pre-blast to post-blast in any 
group (data not shown).  Bars are one standard error from the mean. 
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Figure 5-2. Right eye pre-blast and post-blast OCT measurements.  
 
The right eye OCT measurements were not significantly altered in any group after blast.  
Bars are one standard error from the mean. 
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Figure 5-3. Optic nerve cross-sectional area at 11 weeks after blast. 
 
Cross-sections of optic nerves were measured circumferentially for area.  In the left eye, 
50V animals showed a significant atrophy that was not remedied by SMM-189.  The 
right eye showed no such atrophy, and all groups were statistically equivalent in right eye 
cross-sectional area.  ** denotes significant difference between 0V LE cross sectional 
area and both 50V (p=0.0393), and 50SMM (p=0.028).  Bars are one standard error from 
the mean. 
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Figure 5-4. Axon density in the optic nerve at 11 weeks after blast. 
 
The axon density was determined from manual counts of axons from four regions of the 
optic nerve in cross-sections.  The counts from these four quadrants were averaged for 
the axon density measurements shown in this figure.  Both the left and right eyes of 50V 
animals had a significant decrease in axon density, which the graph suggests was 
remedied with SMM-189 treatment.  The SMM-189 rescue was not significant in the left 
eye, but showed a clear trend, and was significant in the right eye.  Asterisk denotes 
significant difference between 0V and 50V LE axon density (p=0.0198).  Circle denotes 
significant difference between 0V and 50V RE axon density (p=0.0002).  Triangle 
denotes significant difference between 50V and 50SMM RE axon density (p=0.0438).  
Bars are one standard error from the mean. 
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Figure 5-5. Total axons in the optic nerve 11 weeks after blast. 
 
This figure shows the extrapolated axon counts in the optic nerve for each group.  The 
total number of axons was calculated from the area and the axon density for each animal, 
and these numbers were averaged for all groups.  The number of axons in the left ON of 
50V animals was significantly lower than controls, and this was partially rescued by drug 
treatment.  In the right eye, the 50V animals showed a decrease in axon number that was 
nearly significant compared to controls.  The drug treated animals were undistinguishable 
from controls.  Circle denotes significant difference between 0V and 50V LE total axon 
number (p=0.0014).  Asterisk denotes significant difference between 0V and 50SMM LE 
total axon number (p=0.0136).  Bars are one standard error from the mean. 
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Figure 5-6. Brn3a+ retinal ganglion cell counts in the retina at 30 days after blast. 
 
Brn3a immunohistochemistry was used to quantify RGCs in the retina (A-F).  
Representative sections of double-labeled retinas showing Brn3a+ cells (red) and DAPI+ 
nuclei (blue) are provided for 0V left and right eyes (A, B), 50V left and right eyes (C, 
D), and 50SMM left and right eyes (E, F).  The scalebar is 50 µm.  The graph shows 
Brn3a+ cell quantification from all sections, with the left eye of 50V animals having a 
near significant decrease in the number of RGCs compared to 0V animals.  Drug treated 
animals were indistinguishable from 50V animals in the left eye.  The right eye showed 
no changes across all groups, although the 50V group showed a trend toward fewer 
RGCs than the 0V and 50SMM animals.  Bars are one standard error from the mean. 
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Iba-1 counts 
 
 3 days after blast.  The left eye of 50V animals showed a significant increase in 
number of Iba-1+ cells compared to both 0V and 50SMM animals, by one-way ANOVA 
(p=0.0004 and p=0.0014, respectively).  The 50SMM animals had a decrease in number 
toward controls, but were still significantly different than control (p=0.0079).  The right 
eyes were statistically equivalent for all groups by one-way ANOVA (p=0.9995), 
although it is important to note that the 50SMM group had only an n=1 (Figure 5-7). 
 
 30 days after blast.  At 30 days out from blast, in the left eye, the number of Iba-
1+ cells was significantly greater in 50V animals than in both 0V and 50SMM animals by 
one-way ANOVA (p=0.0001, and p<0.0001, respectively), although not as numerous as 
at the 3 day time point.  No significant difference was found between the 0V and the 
50SMM groups for the left eye.  The right eye showed a similar result, with the number 
of IBa-1+ cells in 50V being significantly greater than both 0V and 50SMM (p<0.0001 
and p=0.0112, respectively).  The 50SMM and 0V groups were nearly significantly 
different at p=0.0779 (Figure 5-8). 
 
 Qualitative observations.  In 50V animals 3 days after blast, microglia in the left 
eye appeared to penetrate further into the outer layers of the retina when compared to 
control eyes, and their processes seemed more numerous throughout the whole of the 
retina.  Drug-treated left eyes had fewer microglia and fewer processes visible, but they 
still penetrated into the outer layers of the retina like the 50V animals.  Both 50V and 
50SMM animals had a large number of vertically oriented microglia, which appeared to 
reach across retinal layers.  These vertically oriented microglia were not evident in 0V 
animals. 
 
 In control retinas 30 days after blast, both eyes showed distinctive stellate 
microglia present in the IPL.  A majority of the cells visible in control retinas were 
horizontally oriented and for the most part were confined to the inner layers of the retina 
in both eyes.  Conversely, 50V animals showed many vertically oriented cells in both 
eyes, with some penetrating into the outer retinal layers.  The more horizontally oriented 
cells in the left eyes of 50V animals had a characteristic lightning bolt appearance, and 
were unlike those seen in control retinas.  Drug treated animals also had many vertically 
oriented cells in both eyes, with fewer cells penetrating into the outer retinal layers than 
the 50V animals.  The horizontally oriented cells in the left eyes of 50SMM animals 
generally had a lightning bolt appearance similar to those of the 50V animals.  However, 
the right eyes of 50SMM animals contained cells with thicker processes that did not have 
the characteristic lightening bolt appearance, and instead had thicker processes that 
tended to branch in all directions. 
 
 
GFAP quantification 
 
 7 days after blast.  Neither the left nor the right eyes were significantly different 
for any group at 7 days by one-way ANOVA analysis (Figure 5-9).  
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Figure 5-7. Microglial cell counts in the retina at 3 days after blast. 
 
Iba-1 immunostaining was used to visualize and quantify microglia in the retina at 3 days 
after blast.  The left eye of 50V animals showed a large increase over control animals, 
which was highly significant.  SMM-189 treatment remedied this significantly, with a 
return toward control numbers.  The right eyes of all groups were indistinguishable from 
one another at this time point.  Circle denotes significant difference between 0V and 50V 
LE microglial counts (p=0.0004).  Asterisk denotes significant difference between 50V 
and 50SMM LE microglial counts (p=0.0014).  Bars are one standard error from the 
mean. 
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Figure 5-8. Microglial cell counts in the retina at 30 days after blast. 
 
At 30 days after blast, microglia in the left eye of blasted animals were decreased from 
their 3 day numbers, but were still significantly elevated when compared to controls.  
Again, the SMM-189 treatment rescued this, with the 50SMM and 0V animals being 
indistinguishable from one another.  Surprisingly, the right eye of 50V animals at this 
time point had an elevation of microglia that were significantly greater than in controls 
and drug-treated animals.  The number of microglia in the two eyes of 50V animals were 
similar, with slightly more in the left eye.  Asterisk denotes significant difference 
between 0V and 50V LE microglial counts (p=0.0001).  Circle denotes significant 
difference between 50V and 50SMM LE microglial counts (p<0.0001).  Square denotes 
significant difference between 0V and 50V RE microglial counts (p<0.0001).  Triangle 
denotes significant difference between 50V and 50SMM RE microglial counts 
(p=0.0112).  Bars are one standard error from the mean. 
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Figure 5-9. Müller cell glial reactivity in the retina at 7 days after blast. 
 
Müller cell glial reactivity was visualized and quantified using GFAP immunostaining.  
Processes penetrating the inner retina past the IPL were counted and averaged to yield the 
numbers in this figure.  At this time point, there was a trend in both left and right eyes of 
50V animals showing more GFAP reactivity than controls, but this was not significant.  
Interestingly, the left eye of drug treated animals was slightly increased over 50V 
animals, but again, not significantly so.  Bars are one standard error from the mean. 
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 30 days after blast.  Left eyes of 50V animals had significantly more GFAP 
processes that extended sclerad from the RGC layer than either 0V or 50SMM animals by 
one-way ANOVA (p=0.0101 and p=0.024, respectively), while 0V and 50SMM were not 
significantly different from one another.  The right eye showed no significant differences 
between any group (Figure 5-10).  A Pearson correlation revealed a slight negative 
correlation (r=-0.196) between the number of reactive GFAP processes in the retina at 30 
days and the number of Brn3a immunopositive cells in the same eye at this time, but it 
was not significant (p=0.5613). 
 
 Qualitative observations.  The control animals showed a thin region of GFAP 
staining in the NFL of the retina in both eyes, and occasional NFL regions with little or 
no staining at all.  In the left eye of 50V animals, there were numerous GFAP positive 
processes that penetrated into the IPL and sometimes into the outer retina.  The NFL in 
the 50V left eyes showed variable regions of thicker GFAP reactivity.  The right eye of 
50V animals had many fewer GFAP processes that penetrated into the IPL than the left 
eye, but still had a variable presence of thickened GFAP staining in the NFL.  The 
50SMM animals looked similar to control animals in both eyes, with little or no 
penetration of Müller cell processes past the NFL, and no evident thickening of the 
GFAP staining in the NFL. 
 
 
M1/M2 markers in the right OT 
 
 The 50V and 50SMM groups were both significantly different from 0V in the 
number of M1 and M2-biased cells using Chi square goodness-of-fit testing (p<0.0001 
for both).  They were also significantly different from one another (p<0.0001).  The 
abundance of M1-biased cells was highest in the 50V animals, at nearly 90% of the cells 
quantified.  In 50SMM animals, this number dropped to just below 70%.  Accordingly, 
the M2-biased cell abundance in 50V animals was very low, with only 6.5% of cells 
being M2-biased, contrasted with 50SMM animals who had about 25.5% of cells being 
M2-biased.  In control 0V animals, half of the cells quantified were M1-biased, with 
almost 28% being M2-biased.  The frequencies of M1 and M2-biased microglial cells in 
the different experimental groups are shown in Figure 5-11. 
 
 
Axon bulbs 
 
 Axon bulbs were present in significantly higher numbers at 3 days after blast in 
50V animals when compared to controls (one-way ANOVA, p=0.0059), and were 
lessened in 50SMM animals (Figure 5-12).  This decrease was nearly significant by one-
way ANOVA (p=0.0540).  The 50SMM and 0V animals were not statistically different 
from one another at 3 days.  No SMM treated animals were available at 5 or 7 days, so 
only 0V and 50V animals were compared at these time points.  A two-way ANOVA 
showed a significant difference between the 0V and 50V animals across all 3 time points 
after blast (p=0.0341) (Figure 5-13).  A Pearson correlation revealed a strong negative 
correlation (r=-0.8414) between the number of axon bulbs in the ROT of 50SMM  
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Figure 5-10. Müller cell glial reactivity in the retina at 30 days after blast. 
 
At 30 days after blast, the left eye of 50V animals showed a clear and significant increase 
in the number of reactive Müller cell processes, which was also significantly remedied by 
drug treatment.  The right eye levels were nearly identical for all three groups.  Asterisk 
denotes significant difference between 0V and 50V LE GFAP+ processes (p=0.0101).  
Plus sign denotes significant difference between 50V and 50SMM LE GFAP+ processes 
(p=0.024).  Bars are one standard error from the mean. 
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Figure 5-11. Microglial polarization in the right optic tract at 3 days after blast. 
 
At 3 days after blast, immunostaining for CD16/32 (M1 marker) and CD206 (M2 marker) 
was used to categorize microglial polarization in the right optic tract.  Individual cells 
were categorized based on their predominant marker, with cells expressing equal amounts 
of both placed into the no predominance category.  The control animals had the highest 
number of cells with no predominant surface marker, where the 50V and 50SMM 
animals had very few.  The 50V animals had a large increase in M1 pro-inflammatory 
microglia over the controls, with much fewer M2 anti-inflammatory than 0V animals.  
Drug treatment decreased the number of M1-predominant microglia, but increased the 
number of M2-predominant, suggesting the drug may indeed act to alter polarization of 
microglia into a more anti-inflammatory phenotype.  The slight increase in the number of 
non-predominant cells in SMM-189 treated animals may signify a group of cells who are 
shifting polarization from M1 to M2. 
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Figure 5-12. Axon bulbs in the right optic tract at 3 days after blast. 
 
EYFP reporter mice were used to quantify axon bulbs at 3 days after blast in the right 
optic tract.  The right optic tract contains fibers that originate mostly from the left optic 
nerve and retina.  In 50V animals, there was a very large number of pathologic axon 
bulbs present, where 0V animals had almost none.  Drug treatment decreased the number 
of bulbs drastically, although they were not significantly different than 50V animals.  The 
50SMM animals were statistically equivalent to 0V animals.  Asterisk denotes significant 
difference between 0V and 50V axon bulbs in the ROT (p=0.0059).  Bars are one 
standard error from the mean. 
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Figure 5-13. The number of axon bulbs in the right optic tract over the first week 
after blast. 
 
The number of axon bulbs was quantified in EYFP reporter mice and using SMI-32 IHC 
at 3, 5, and 7 days after blast in 50-psi and control animals.  These counts showed the 
number of bulbs in the ROT of 50-psi animals is highest at 3 days after blast, then 
decreases at 5 days, and 7 days.  The sham blasted animals had nearly zero bulbs at all 
three time points.  The number of bulbs over these three days was significantly different 
from the sham-blasted animals.  Asterisk denotes significant difference between 0V and 
50V axon bulbs in the ROT at all three time points after blast (p=0.0341).  Bars are one 
standard error from the mean.  Data not available for 50SMM animals after 3 days post-
blast. 
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animals at 3 days and the number of M2-biased microglia in the ROT at this time, but it 
was not significant (p=0.3635). 
 
 
Summary 
 
 The retinas of blasted animals show signs of both acute, and sustained 
inflammation.  At 3 days post-blast, the number of microglia is increased significantly 
when compared to controls.  This is remedied by drug treatment, with a decrease in the 
number of microglia in the 50SMM animals when compared to 50V animals.  At 7 days, 
retinal Müller glia show no obvious signs of reactivity, however at 30 days, left eyes of 
50V animals show a significant GFAP response over controls.  This response is quelled 
by drug treatment, such that there was no statistical difference between 50SMM and 0V 
animals.  In addition, both eyes of 50V animals show an increased number of microglia, 
with a drug rescue returning the numbers toward that of controls.  There are some hints 
that RGCs may be lost due to the injury, with Brn3a+ cell counts in the RGC layer 
showing a near-significant decrease in the left eye of 50V animals; however this trend 
does not appear to be remedied by drug treatment.  Pre-blast and post-blast OCT 
measurements show significant thinning in the LE outer retina of blasted animals.  Drug-
treated animals show no such change, but have a significant decrease in the inner retina 
of the left eye.  Control animals have statistically unchanged pre-blast and post-blast 
measurements for both eyes. 
 
 In the optic tract of 50V animals at 3 days, axon bulbs are visible in large 
quantities, and to a lesser extent are still present in 50SMM animals.  Quantification in 
50V animals shows that at 5 and 7 days, the number of bulbs in the ROT dissipate, and 
the character of the bulbs appears more granular.  The number of axon bulbs in the ROT 
is consistently higher in 50V animals than 0V animals at all 3 time points examined 
during the first week after blast.  Also in the ROT, at 3 days post-blast, the number of 
microglia displaying predominantly inflammatory (M1) markers is significantly higher in 
50V animals than both controls and drug treated animals.  Conversely, SMM-treated 
animals show an increase in the number of cells displaying a bias toward anti-
inflammatory (M2) markers, with an apparent shift of about 20% of cells from M1 to 
M2-biased markers. 
 
 Finally, at 2 months after blast, optic nerves of the left eye were atrophic in 50V 
and 50SMM animals, with a concurrent loss in total axon number for both groups in this 
eye.  Interestingly, the LE axon density in the 50SMM animals was unchanged from 
controls, while the 50V animals had a significant decrease in axon density.  The right ON 
of 50V animals showed a significant decrease in axon density, but the decrease in total 
axon number was not significantly different from controls.  See Table 5-2 for a 
comprehensive summary of all structural and functional results. 
 
 79 
Table 5-2. Summary of findings. 
 
 Endpoint examined  Without drug  With drug  Comments    
   50-psi + vehicle 
versus 
sham + vehicle 
50-psi + SMM-189 
versus 
sham + vehicle 
    
        
Functional endpoints        
           
 ERG A-wave  LE increased         -  No change at one month 
       
 ERG B-wave  LE increased* RE 
increased 
        -  B-wave amplitude increased in 50V LE, RE 
nearly significant 
       
 Optical coherence 
tomography 
 LE outer retina 
decreased* 
 LE inner retina 
decreased* 
 Drug treatment improved LE photoreceptor 
damage 
       
 Visual acuity threshold         -         -  No change at one month 
       
 Contrast sensitivity 
threshold 
 Decreased*         -  RE more severely affected than LE one 
month after blast 
       
Histology        
           
 Optic nerve axon 
density 
 Decreased*  Decreased  Near significant difference in RE of 50SMM 
compared to 0V 
           
 Brn-3a+ cell counts in 
the retina 
 Decreased  Decreased  Near significant difference in LE of both 50V 
and 50SMM 
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Table 5-2. Continued. 
 
 Endpoint examined  Without drug  With drug  Comments    
   50-psi + vehicle 
versus 
sham + vehicle 
50-psi + SMM-189 
versus 
sham + vehicle 
    
        
 GFAP reaction in the 
retina 
 Increased*         -  Significant difference between 50V and 
50SMM in LE 
           
 Iba-1+ cell counts in 
the retina 
 Increased*         -  Significant increase in 50V LE at 3 and 30 
days, RE increased at 30 days 
           
 M1/M2 counts in right 
OT 
 M1 increased*  M1 increased* 
M2 equal 
 SMM-189 significantly increased the number 
of M2 microglia compared to 50V 
           
 EYFP bulbs in the right 
OT 
 Increased*         -  50SMM and 0V not significantly 
different from one another 
   
           
 
*Denotes statistical significance ≤ p=0.05. 
- means no change. 
Italics indicate an evident trend.
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CHAPTER 6.    DISCUSSION 
 
 
 In Chapter 2, we proposed a set of experiments to investigate visual dysfunction 
in our mouse model of overpressure blast-induced TBI, and to test the hypothesis that a 
major pathway of the disease is immune-mediated secondary injury.  While previous 
studies had demonstrated significant immune involvement after injury, specifically in 
areas important to the visual system in the brain, little information existed about the 
pathology within the eye itself.  The histopathologic studies in this dissertation have 
revealed much about the underlying damage to the eye in this model, and these will now 
be discussed in more detail. 
 
 
The Elucidated Histopathology of mTBI-Associated Visual Dysfunction 
 
 
The retina 
 
 In our previous studies, the retina of blasted animals at 10 weeks after blast 
showed signs of significant damage, in the form of thinning in the left eye, and 
thickening in the right eye 179.  The left eye thinning was due in part to thinning within 
the INL, but this could not account for the total retinal thickness loss.  Little was 
previously known about what happened in the retina at more acute time points, and thus it 
became a pertinent focus of this dissertation work to examine the retina at earlier time 
points after blast. 
 
 Microglial inflammatory response.  Significantly, it was found that within 3 
days of blast exposure, the left retinas of blasted animals already showed signs of a 
substantial microglial response.  Quantification in the left retina demonstrated that blast 
animals had an increase in microglial density that was nearly triple that of controls.  
Counts from the nasal and temporal side of the same eye at the level of the optic nerve 
head were statistically equivalent, indicating a seemingly uniform increase in microglial 
presence across the middle retina.  The morphology of the microglia in left eyes after 
blast was more robust, with darker staining and thicker, less complex processes. 
 
 Retinal microglia have a somewhat different morphology than that of brain-
resident microglia.  At physiological conditions, retinal microglia are found 
predominantly in the inner retinal layers 221 and have thinner, longer, and more complex 
processes 222,223.  Under pathological conditions, even very early in disease pathogenesis, 
subtle morphologic changes can occur in retinal microglia that indicate a reaction to 
inflammatory stimuli 223,224.  Processes shorten, as in brain microglia, but rarely to the 
point of being fully retracted with an amoeboid appearance.  Microglia will begin to 
migrate from their normal location in the inner retina to the outer retinal layers 221, using 
the Müller cell glia as scaffolding, and interacting with them to regulate the immune 
response 225.  This gives them a more vertical appearance (i.e. vitread to sclerad), making 
them thus relatively easy to identify compared to the normal horizontally-oriented and 
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stellate microglial cells in physiological conditions.  Microglia in the left eyes of 50V 
animals 3 days after blast appeared to penetrate further into the outer layers of the retina 
when compared to control left eyes, and their processes seemed more numerous 
throughout the whole of the retina.  Additionally, there were numerous vertically-oriented 
microglial processes in 50V left eyes, whereas controls had none (Figure 6-1A and B).  
These observations taken together suggest that microglia were reacting to an 
inflammatory micro-environment by polarizing and traversing the retinal layers in 
response to cytokine and chemokine signals 226.  Interestingly, the drug treated animals 
only showed a marginal, non-significant increase in microglial counts over that of 
controls, but their microglia still appeared to have more vertically-oriented processes 
(Figure 6-1C).  As discussed in Chapter 2, research on CB2 inverse agonists has shown 
them to decrease leukocyte recruitment 227, which may be the reason for the decrease in 
microglia numbers in drug-treated animals.  However, it cannot be ruled out that 
cessation of microglial proliferation is instead the cause of this drug benefit, since the 
mechanism of microglial increase after blast injury is not currently known.  Because 
SMM-189 is thought to selectively polarize microglia to the M2 state, their altered 
morphology indicates that perhaps they are still interacting with the Müller cell glia but in 
this case to organize a more neuroprotective immune response.  At the same time that the 
left eye showed signs of significant microglial response in 50V animals, the right eyes of 
blasted animals showed no such reactive increase, with statistically equivalent numbers 
of microglia as controls.  The morphology of microglia in the right eye also appeared 
more consistent with those of controls, with fewer processes visible, and no apparent 
vertically-oriented processes. 
 
 At 30 days out from blast, the LE microglial presence was still evident, albeit 
diminished by a little over 50% from day 3 levels.  Microglial processes at this point 
were still clearly more abundant throughout the inner retinal layers than in 0V animals, 
and similarly to the 3-day retinas, had many vertically-oriented processes (Figure 6-2C).  
In the right eye, while there were no signs of inflammation early on, at this 30-day time 
point there was a significant increase in microglial density that was only marginally 
lower than that of the left eye.  Interestingly, although the drug treated animals had a 
significant decrease in the number of microglia present in the retinas when compared 
with 50V animals, the morphologic characteristics of the microglia appeared more similar 
to the 50V animals than they did to controls (Figure 6-2A, C, and E).  Their processes 
appeared thicker overall, as in 50V animals, but they had many more vertically-oriented 
cells present, even more so than in 3 day 50V animals.  Aside from vertically-oriented 
cells, the microglia in the left eyes of 50SMM animals looked similar to that of 50V 
animals, with a lightning bolt appearance, and medium-density processes that were 
sometimes relatively long.  However, in the right eye of 50SMM animals, cells appeared 
thicker and more robust, much different than in any of the other retinas at this time point 
(Figure 6-2B, D, and F).  Control 0V animals had highly dendritic, star-shaped microglia 
present predominantly in the IPL, with thinner, more ornate processes (Figure 6-2A and 
B).  These types of cells were not seen in either eye of 50V or 50SMM animals. 
 
 The persistence of microglial activation and accumulation at this late time point 
indicates an extended disease process within the retina 228, and one that is unique when  
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Figure 6-1. Microglia in the retina at 3 days after blast. 
 
These images show Iba-+ microglia in the left retinas of 0V (A), 50V (B), and 50SMM 
(C) animals at 3 days after blast.  In 50V animals, microglia appeared to penetrate further 
into the outer layers of the retina when compared to control eyes, and their processes 
seemed more numerous throughout the whole of the retina.  Microglia visible in the 50V 
animals seemed to have thicker processes, possibly indicating a reactive morphology.  
Drug treated animals had fewer microglia and fewer processes, but still penetrated into 
the more superficial layers of the retina.  Both 50V and 50SMM animals had a large 
number of vertically oriented microglia, which appeared to reach across the retinal layers 
(white arrowheads).  These were not evident in 0V animals.  The scalebar is 50 μm. 
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Figure 6-2. Microglial morphology in the retina at 30 days after blast. 
 
These panels are from the eyes of 0V (left eye A, right eye B), 50V (left eye C, right eye 
D), and 50SMM (left eye E, right eye F) animals at 30 days after blast with Iba-1 
immunostaining to visualize microglia.  Panels 1 and 2 show two distinct cell populations 
seen during analysis.  The control retinas had distinctive stellate microglia present in the 
IPL (A-1, green arrowhead).  These were found in both the left and right eyes (A-1 and 
B-1, respectively).  A majority of the cells were horizontally- oriented and within the 
inner layers of the retina in both eyes (A-2 and B-2).  Blasted animals showed many 
vertically-oriented in both eyes (C-2, D-1, and D- 2), with some penetrating into the outer 
retinal layers (D-2).  More horizontally-oriented cells in the left eyes of 50V animals had 
a characteristic lightening bolt appearance (C-1, white arrowhead), that were unlike those 
seen in controls.  Drug treated animals had numerous vertically-oriented reaching cells in 
both eyes as well (E-1, E-2, and F-2), with fewer penetrating into the outer retinal layers 
than the 50V animals.  The horizontally- oriented cells within the inner retina of the left 
eye in 50SMM animals generally had a lightening bolt appearance similar to the 50V 
animals.  However, the right eye of 50SMM animals contained cells with thicker 
processes that did not have the characteristic lightening bolt appearance, but instead 
appeared to branch in all directions (F-1).  The scalebar is 100 μm. 
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compared to temporal patterns of microglial activation in the brain.  Previously published 
experiments using this model found significant microglial activation in the OT beginning 
at 3 days and lasting until around 7 days after blast 179.  At and beyond 2 weeks post-
blast, no evidence of microglial activation was seen in any visual area, and yet evidence 
of actively degenerating axons were still found in both the optic nerve and the optic tract.  
The time period of microglial activation in the optic tract follows the temporal 
progression of axon bulbs and, subsequently, visible axon degeneration fragments, 
indicating their probable role of phagocytosing and disposing of axon degeneration 
products.  But their quiescence at later time points when active degeneration is still 
occurring is puzzling.  This may mean that brain microglia only respond in significant 
ways to a large number of axons degenerating, while fewer, scattered degenerating axons 
don’t require microglial debris clearing.  It could also indicate that the initial axonal 
degeneration was driven by a different mechanism, i.e. that of traumatic axonal injury, 
whereas later degeneration occurs as a result of the actual RGC cell dying, with the axon 
subsequently degenerating as well.  If either of these is the case, the continued presence 
of reactive microglia in the retina at one month indicates the persistent need for 
phagocytosis and inflammatory regulation that is above and beyond what is necessary in 
response to axonal degeneration at this same time point in other areas.  This is highly 
suggestive 229 of ongoing cellular loss within the retina at this later time, which 
necessitates the continued activation of the resident microglia. 
 
 Müller glial cell response and retinal ganglion cell survival.  Müller glia are an 
important support cell in the retina, releasing trophic factors, clearing away debris, and 
acting as a structural framework for neural RGCs 230.  Under pathologic conditions, 
Müller glial cells react to stress and increase GFAP expression in their processes.  
Normally, GFAP immunostaining is found predominantly in the NFL and RGC layer of 
the retina, but during pathology GFAP immunoreactivity will extend into the outer retina 
231, with the extent of penetrance being roughly correlated with the severity of retinal 
injury 232.  GFAP immunopositivity can be evident for long periods of time in ongoing 
disease processes, and can be an early indicator of retinal injury when few other signs are 
evident 233.  In focal retinal injury, GFAP reactivity can be seen as early as 24 hours, but 
in diffuse retinal injuries GFAP reactivity can take 7 days or longer to be visible 234.  
Since there was no reason to think the retinal injury in this model was focal in nature, it 
was decided to examine GFAP immunohistochemistry at 7 days after blast, but not 
earlier.  No increase in reactivity was seen in either eye of the 50V or 50SMM animals at 
this time point when compared to controls.  However, at 30 days post-blast, 50V animals 
had a large increase in the number of GFAP processes in the LE retina compared to the 
LE of both 0V and 50SMM animals (Figure 6-3A, C, and E).  The right eye of 50V 
animals showed a moderate, but non-significant increase in staining as well, but clearly 
had a slightly thicker zone of GFAP staining in the NFL at some areas of the retina, 
whereas other areas appeared the same as control animals (Figure 6-3B, D, and F).  
Widening of the NFL GFAP band is a very early Müller glial change 235, possibly 
indicating that even earlier time points than those examined may show a similar 
activation pattern as the LE in 50V animals. 
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Figure 6-3. Müller glial morphology in the retina at 30 days after blast. 
 
GFAP immunostaining was used to visualize Müller glial cell reactivity in the retina at 30 
days after blast in 0V (left eye A, right eye B), 50V (left eye C, right eye D), and 50SMM 
(left eye E, right eye F) animals.  Panels 1 and 2 show different representative areas of 
the retina.  The control animals showed a thin band of GFAP staining in the NFL of the 
retina in both eyes (A-1, A-2, and B-2), and occasional regions with little or no staining 
at all (B-1).  50V animals had a large number of processes in the left eye that penetrated 
into the IPL and beyond (C-1 and C-2), with a variably thickened band of GFAP staining 
in the NFL (C-2, white arrowheads).  The right eye of 50V animals had much fewer 
GFAP processes that penetrated into the IPL, but still had a variable presence of NFL 
widening (D-1, white arrowhead).  The 50SMM animals looked similar to control 
animals in both eyes, with little or no penetration of Müller cell processes, and a thin, 
variably absent band of GFAP in the NFL of both eyes (E and F).  The scalebar is 40 μm. 
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 GFAP immunostaining in the LE of 50V animals was not uniform, but showed a 
patchy, sparse distribution.  Some regions would have numerous processes visible in the 
IPL and INL, whereas other areas would appear the same as control retinas.  Studies by 
others have shown that regions of reactive Müller cell glia usually correspond to focal 
areas of injury at that location 236.  Diseases that affect the whole retina, as with diabetic 
or drug-induced retinopathy, usually present with uniform and widespread GFAP 
reactivity 237, whereas age-related retinal degeneration is indicated by a patchy GFAP 
reactivity that is scattered throughout the retina 232.  The latter pattern is the most similar 
to that seen in 50V LE retinas, and is important because it may speak to the injury 
mechanism of the left eye. 
 
 As discussed in Chapter 1, axonal injury from TBI is characterized as diffuse, and 
results from random shearing of axons in white matter tracts throughout the brain, with 
subsequent axonal degeneration.  Given the orientation of the optic nerve and tract, being 
basically perpendicular to the vector of the blast wave, these structures might be 
particularly vulnerable to shear stress from the blast wave, resulting in diffuse axonal 
injury selectively in the RGC axons coursing through these white matter tracts.  It has 
long been known that RGC axonal injury, even in the absence of direct somal injury, may 
lead to RGC cell body damage and possible degeneration 238.  If the underlying pathology 
in the LE is indeed due to this mechanism, diffuse RGC axonal degeneration with 
subsequent injury in the RGC cell bodies themselves, then reactive GFAP processes may 
indicate areas with damaged or dying RGCs whose axons have undergone degeneration.  
This would explain the patchy, somewhat atypical GFAP staining pattern, as axons 
experiencing damage from the blast would theoretically be randomly scattered 
throughout the affected structures.  With that being said, the logical question is whether 
RGCs are, in fact, lost in the LE.  An antibody to Brn3a was used to quantify this, and the 
LE of 50V animals did show a nearly significant decrease in number of RGCs.  The right 
eye showed a very minimal decrease in RGC number as well, but was not significant. 
 
 To further consider the possible relationship between RGC loss and reactive 
Müller glia, a Pearson correlation was run on RGC counts and GFAP counts.  This 
identified a small negative association between the two factors that was not significant.  
This correlation hints that these GFAP processes may be present to a greater extent in 
retinas with greater RGC loss, although more investigations would need to be done to say 
this with any certainty.  Importantly, drug treated animals also had a very nearly 
significant decrease in the LE RGC count compared to controls, a fact that initially seems 
to rebut the possible Müller glia-RGC inverse correlation, since these retinas were not 
found to have an increase in GFAP reactivity.  One possible explanation for this is that 
the initial RGC loss at 30 days is due solely to the direct axonal damage of the initial 
injury, and this RGC loss is irreversible even in drug-treated animals.  In this scenario, 
drug-treated animals may have an increase in anti-inflammatory microglia that may act to 
promote a cessation of the continued immune response, in which case reactive Müller 
cells in 50V animals may represent areas where a second wave of RGC loss is occurring 
due to the degenerative environment of the first wave of cell loss, a phenomenon that has 
been observed experimentally 238.  The time course over which retinal ganglion cells 
degenerate after their axons are lost is heavily dependent upon the mechanism of injury 
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239, and further studies will need to be undertaken to investigate RGC loss at time points 
further out from blast.  It may be the case that this hypothesized second wave of RGC 
loss will be much more significant in 50V animals, and that at later time points a drug 
benefit would then be evident. 
 
 Optical coherence tomography.  Various measurements of retinal thickness 
were collected by OCT both prior to blast, and then again at 30 days after blast.  In this 
way, changes within the same animal could be tracked.  No pre-blast/post-blast 
differences were observed in any treatment group for the right eye.  In the left eye, there 
was a significant thinning in the outer retina of the 50V animals, compared to their pre-
blast measurements.  The outer retinal measurement corresponded to both the outer 
nuclear layer and the photoreceptor inner and outer segments, and its significant 
diminution in blasted animals indicates the loss of and/or injury to photoreceptors in the 
LE.  This finding is significant since it is the first evidence for outer retinal damage in 
this model.  Photoreceptor alterations are common in the traumatic retinal injury known 
as Commotio Retinae 240, and have been seen in motor vehicle accidents without any 
head injury 241.  This indicates the possibility that photoreceptor changes early after 
trauma can occur due to head acceleration, and possibly blunt ocular trauma 242.  Previous 
studies in our model have thoroughly documented that limited head accelerations occur 
after 60-psi blasts, which are classified as sub-concussive according to various injury 
criterion scales 243.  These same studies with our model imaged the blast administration at 
high speed and found no direct blunt ocular trauma.  However, it may be the case that the 
blast wave causes a ripple effect through the retina that yields similar mechanical 
disruption to that of high speed head acceleration, and thus at early time points manifests 
as photoreceptor alterations.  As will be discussed later, there are additional implications 
for the presence of photoreceptor pathology, having to do with the ERG findings.  These 
will be considered in the section on functional vision tests. 
 
 It is necessary to discuss the potential conflict these findings display when 
compared to previous data.  As discussed in Chapter 2, this mouse model has been shown 
to result in a significant thinning in retina of the left eye at 10 weeks after blast, while the 
right eye showed significant thickening.  The thinning in the LE was traced to decreases 
specifically within the INL and the photoreceptor layer.  However, in our pre-blast post-
blast OCT measurements at slightly over 4 weeks, there was no significant thinning in the 
total retina, nor in the inner retina, but there was thinning of the outer retina.  This 
discrepancy can reasonably be attributed to one of two things: either the majority of the 
INL degeneration occurs at time points later than one month, or edematous fluid causes 
an artificial increase in the apparent thickness of the entire retina at 4 weeks post-blast.  It 
seems possible that either or even both of these explanations may give rise to the OCT 
findings at 30 days.  The fact that edema would leave outer retina thickness 
measurements still significantly decreased might indicate that photoreceptor degeneration 
occurs on a more escalated time scale than that of the INL.  Right eyes at 30 days showed 
no signs of thickening in any layer, which seems to indicate that the right eye thickening 
in animals at 10 weeks after blast must occur after the 30 day time point.  It is still 
possible that the thickening seen in the right eye at 10 weeks is due to either edema or 
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sclerosis, since neither option can be definitively ruled out on the basis of the OCT 
findings. 
 
 
The optic nerve 
 
 Quantitative assessments:  Axon counts.  Optic nerve cross sections were 
examined at 11 weeks after blast and found to be significantly atrophic in the LE of 50V 
animals.  Random counts throughout the 4 quadrants of the optic nerve also revealed a 
significant decrease in the axon density and total axon count in the LE of 50V animals 
when compared with controls (Figure 6-4).  This shows that after blast, axonal damage 
observed acutely ultimately results in axonal degeneration of those fibers.  Drug 
treatment did not save the LE atrophy or total axon counts, but it did increase the axon 
density toward normal.  From these data, it seems that the 50V animals have atrophic, 
less densely packed LE ONs than 0V animals, while drug treatment somewhat rescues 
the axon density, but leaves a significant number of axons still terminally injured.  In the 
right eye, no atrophy of the ON was seen, but there was still a significant decrease in the 
axon density of 50V animals when compared to controls.  Drug treatment rescued the 
axon density in the right eye, making them indistinguishable from the control nerves.  
These right eye changes, however, yielded no significant changes in total axon number 
for any group. 
 
 Interestingly, when examining the relationship of the axon density and the ON 
area in the left and right eyes, additional insights can be gained for between-group 
differences.  Axon density gives an idea of what a specific field of view within the optic 
nerve looks like at any given area when compared with other ONs.  In ONs with lower 
axon densities, each field of view contains fewer axons and more non-axonal space.  
Non-axonal space is usually composed of glial processes and/or glial cell bodies, and 
generally increases in disease or pathology, corresponding to a concurrent decrease in 
axonal density 244.  In the left eyes of control animals, there is a negative association 
between axon density and the ON area (Figure 6-5).  Since one would expect control 
animals all to have a similar number of axons in the optic nerve, our observed inverse 
correlation of axon density and the ON area is as expected.  It is a simple matter of space 
efficiency in that, if axons are more densely packed with less non-axonal space, the optic 
nerve does not need to be as large to accommodate a normal number of axons, whereas if 
axons are less densely packed, the nerve area will be larger to accommodate those same 
axons.  In 50V animals, however, this trend is almost completely ablated, and there is 
instead almost no correlation between the axon density and the ON area (almost flat 
regression line).  In 50SMM LEs, the trend is completely reversed from 0V animals, with 
a relatively positive correlation between the axon density and ON area.  Essentially, optic 
nerves that have a greater concentration of axons are also larger, whereas those with 
fewer axons are smaller in 50SMM LEs.  This may be indicative of the presence of 
reactive gliosis, since optic nerves seem to have to increase in size to accommodate even 
densely packed axons.  The right eyes of all groups show negative association trends 
similar to those of the 0V LE group, indicating that there is a different pathological 
mechanism underlying the damage in the right eye of blasted animals.  The main  
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Figure 6-4. High power cross sections through the optic nerve to visualize and 
quantify axons at 11 weeks after blast. 
 
This figure shows high power light micrographs through the optic nerves of 0V (left eye 
A, right eye B), 50V (left eye C, right eye D), and 50SMM (left eye E, right eye F) 
animals. Even at this high magnification, no gross pathology is evident in either eye of 
50V animals (C and D), when compared to control animals (A and B).  For this reason, 
manual axon counts were performed to investigate possible loss of axons. The scalebar is 
20 μm. 
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Figure 6-5. Scatterplot of optic nerve axon density versus optic nerve cross 
sectional area at 11 weeks after blast. 
 
This figure shows a scatterplot to aid in visualizing the relationship between the ON axon 
density and the cross sectional area of these animals.  A trend line is present for each 
group.  In their left eye, control animals show a clear negative association between the 
axon density and the ON size.  This makes sense, because more densely packed axons 
would not need as much ON size to accommodate them.  The same trends hold true for 
the right eye of control animals.  However, 50V animals show a near ablation of the trend 
in the left eye, indicating that the axons are being lost and possibly replaced by glial scar 
of varying thicknesses, making the axon density now independent of the ON size.  The 
drug treated animals have a reversal of the left eye trend seen in the 0V animals, possibly 
also speaking to a reactive gliosis that is instead protective in nature.  The right eyes of all 
groups show negative associations between the axon density and ON size measurements, 
showing that the pathology and presumably pathogenic process in this eye is different 
than that of the left eye. 
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difference between groups for the right eye seems to be predominantly in the amplitude 
of the association, with 50V animals showing a much lower range of axon densities than 
the 0V group.  The 50SMM group is increased toward normal, falling directly between 
the 0V and 50V groups. 
 
 Qualitative assessments from IHC.  Analysis of the optic nerve using 
immunohistochemistry was difficult since so few ideal sections were captured through 
the optic nerve longitudinally in any one case.  For this reason, the numbers of nerves 
available for examination were too small to use for quantification purposes.  Nonetheless, 
some of the nerves offered important insight into the injury of 50V animals that was not 
previously known, and for that reason it is important to discuss these specifics from a 
qualitative standpoint.  The first significant finding was in one 50V LE optic nerve at 3 
days after blast.  This EYFP reporter mouse had numerous large axon bulbs clearly 
visible in the optic nerve just centimeters from the optic nerve head (Figure 6-6).  Double 
labeling with Iba-1 showed these bulbs to be associated with a population of large 
reactive microglia, appearing more amoeboid than in any other areas of the brain or 
visual system.  Previously, it was not known whether axonal injury was localized to any 
specific area along the axons running from the eye to the optic tract in the brain.  Given 
the abnormally large number and size of the bulbs found in this case, especially when 
compared to the axon bulbs found in the optic tract of this same animal, it is hypothesized 
that the injury in the optic axons originates from an injury more proximal to the eye, 
possibly at a point of torsion where the optic nerve runs through the bony optic nerve 
canal in the skull, yielding a significant point of stress 245,246(Figure 6-7). 
 
 GFAP immunostaining also gave an interesting case study in LE ONs at 30 days 
after blast.  The astroglia form a structural support mosaic in the ON distal to the eye, and 
are highly ordered in the myelinated regions of the optic nerve 247.  Like in the retina, this 
meshwork can give insights into reactive changes occurring during pathology.  In crush 
injuries of the optic nerve, GFAP meshwork forms gliotic scarring that is clearly visible 
localized to the site of injury 248.  Likewise, examining the left ON of a 50V animal 
immunostained for GFAP, we were able to identify an obvious increase in the GFAP 
network along one side of the optic nerve that seems to localize around two blood vessels 
(Figure 6-8).  In this case, it is obvious that the GFAP meshwork has an altered 
orientation from a uniform cross-hatch pattern, to a more radial and clearly asymmetric 
pattern of orientation.  Again, these data could not be quantitatively analyzed, but give 
interesting insight into the injury in this model.  Also, it is important to note that no 
50SMM animal displayed this type of asymmetric astroglial change within an individual 
optic nerve, indicating that the drug improved, or at least decreased this injury response.   
 
 
The optic tract 
 
 The optic tract is the posterior continuation of the axons originating from the 
RGCs in the retina.  As they leave the eye in the optic nerve, the fibers decussate at the 
optic chiasm, where in the mouse a large majority of fibers from the left eye cross over 
and continue on the contralateral side 249.  Our previous work had shown indications of  
 93 
 
 
Figure 6-6. Histologic evidence for a focal optic nerve injury in a 3 day post-blast 
animal. 
 
This figure shows a longitudinal section through the proximal left optic nerve of a 50V 
animal 3 days after blast.  Double labeling for EYFP and Iba-1 allows visualization of 
both axons (green) and microglia (red) in the same section.  Within the white circle, an 
intense concentration of large diameter axon bulbs (blue arrowheads) is present, 
surrounded by intensely-stained, amoeboid microglia, some of which are seen engulfing 
axon bulbs (white arrowheads).  This focalized area of injury may indicate a point of 
torsional stress on the left ON during blast, as it is held stationary passing through the 
bony canal of the skull to leave the orbit, while both the brain and eye remain relatively 
mobile.  The scalebar is 100 μm. 
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Figure 6-7. Hypothesized left eye injury mechanics in the moments directly after 
blast. 
 
This schematic shows a top-down view of the mouse’s head and visual system, along 
with hypothesized mechanics that may occur in the left eye moments after blast.  The 
blast wave, coming in from the left, causes movement of the head (and brain) toward the 
right.  The eye, having more degrees of freedom, would move left relative to the head, 
due to momentum.  In this way, the canal of the optic nerve would serve as a point of 
torsion, where the optic nerve head, the optic nerve on either side of the bony canal, and 
possibly the optic tract as it enters the brain, would feel shear stress leading to mechanical 
injury.  This type of movement would also cause normal stress in the axons of the left 
optic nerve, leading to an axonal stretch injury.  As discussed in the text, the right eye 
injury may stem from a combination of central visual damage and sympathetic 
ophthalmia from the LE inflammatory response. 
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Figure 6-8. Alterations in the glial meshwork of the left optic nerve at 30 days 
after blast. 
 
This figure shows the glial meshwork of the left optic nerve at 30 days after blast in 
longitudinal sections immunostained with GFAP.  The 0V animal (A) shows a somewhat 
random appearing meshwork with no apparent densely stained or ordered areas, 
consistent with the normal structural framework of the ON.  In the 50V animal (B), there 
is an obvious confluence of glial processes on the leftmost border of the optic nerve, 
appearing to encircle what may be small blood vessels.  This localized organization of 
glial processes indicates a focalized injury with subsequent glial scarring, such as may 
occur at a point of torsional stress to the optic nerve as it courses through its bony canal 
to leave the orbit.  The drug treated animal (C) shows no such ordering of glial processes.  
The scalebar is 100 μm. 
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axonal disruption in the right optic tract (ROT), and to a much less extent in the LOT, in 
the form of axon bulbs.  It was not known in this model whether the axonal injury 
occurred as a result of the primary mechanical insult, or instead as a secondary injury 
caused by immune and glial over-activation, preventing even minimally harmed axons 
from regenerating 250.  Because of the high lateralization of the axon injury, it was 
decided to selectively investigate the ROT in these experiments.  The animals were 
examined at 3, 5, and 7 days after blast.  Additionally, drug treated animals were 
examined at 3 days for comparison with 50V animals at this acute time point. 
 
 Axonal injury.  At 3 days after blast, bulbs in 50V animals were large, and 
scattered randomly throughout the optic tract, exhibiting a heterogenous size distribution 
from 6.5-25.6 µm (Figure 6-9).  At 5 days after blast, the majority of bulbs in 50V 
animals began to shrink in size, and take on a more granular appearance.  Finally, by 7 
days, very few large bulbs were evident, but there were numerous dotted and granular 
bulbs visible throughout the whole ROT.  This pattern is highly consistent with the 
morphology of degenerating axons undergoing Wallerian degeneration secondary to 
traumatic axonal transport disruption 251.  As discussed in Chapter 2, disruption of axonal 
transport occurs secondary to microtubule disruption, causing axolemmal varicosities 
where cellular transport products build up.  This can be due to traumatic mechanical 
insult, or other pathologic processes, and can result in axonal degeneration 252.  In vivo 
investigations of axon lesions have shown that, proximal to the site of injury, axon bulbs 
can be sometimes seen within hours, while the portion of the axon distal to the injury 
may not show signs of morphologic change until as long as 36 hours afterward 253.  
Following this temporary delay, the distal axon undergoes a rapid axolemmal 
segmentation often known as blebbing, which aids in subsequent cleanup by phagocytic 
cells 254.  Occasionally, portions of the axon proximal to the site of injury can also 
undergo blebbing, which can variably affect the soma of the cell depending on its 
proximity to the injury 253.  This time course and morphologic transition indicates that the 
bulbs initially seen in these animals at 3 days after blast probably represent a distinctly 
different phenomenon than those seen at 5 and 7 days after blast.  For this reason, the size 
of the bulbs included in the quantification were restricted to only those larger than 6.5 
µm, since bulbs smaller than this became difficult to distinguish from axons diving in and 
out of the section, as well as small axon blebs.  Bulb counts in 0V animals at 3, 5 and 7 
days found few, if any bulbs present.  In 50V animals, there were significantly more 
found at all time points, with a peak number seen at 3 days and tapering off until 7 days.  
In our previous studies, no bulbs were found in the OT at any time point examined later 
than 7 days.  Drug-treated animals examined at 3 days after blast had a near-significant 
decrease in the number of bulbs compared to their 50V counterparts, and were 
statistically equivalent with 0V animals.  These results indicate that much of the axonal 
degeneration seen at 3 days in this model can be rescued by abating immune-mediated 
secondary injury.   
 
 The M1/M2 microglia story.  Our evidence suggests that an integral part of the 
SMM-189 benefit in this model was the role of differentially polarized microglia, and 
their regulation of immune function after trauma.  Previous studies have indicated that 
SMM-189 may work by altering the polarization of activated microglia from a pro-  
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Figure 6-9. Axon bulbs in the right optic tract at 3 days post-blast. 
 
This figure shows longitudinal sections through the right optic tract of EYFP reporter 
mice at 3 days after blast.  In 0V animals (A), the axons can be seen diving in and out of 
the section, are all relatively uniform in size, and contain no obvious regions of 
axolemmal disruption.  The 50V animals (B), however, show a large number of EYFP 
accumulations, and frank axon bulbs (white arrowheads), indicative of areas of traumatic 
axonal transport disruption.  Drug treated animals (C) have significantly fewer, but still 
evident bulbs (white arrowhead) at this time point.  The scalebar is 50 μm. 
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inflammatory M1 state to a neuroprotective M2 state.  These different microglial states 
are commonly identified by distinct cell surface markers CD16/CD32 (M1), and CD206 
(M2) 131.  CD16 and 32 are low affinity Fc receptors, which bind to the Fc portion of 
antibodies and assist phagocytes in ingesting opsonized cells or bacteria 255.  CD206 is 
known as the mannose receptor, and is present on cells to also assist with phagocytosis, 
but also seems to have important intracellular functions for cytokine expression 256 and 
clearing lysosomal hydrolases during inflammation 257.  In order to determine whether 
SMM-189 was functioning in this model by way of microglial polarization shifts, IHC for 
these two markers was done in the ROT of animals at 3 days after blast.  Unexpectedly, 
the two markers were expressed in nearly every Iba-1 positive cell in the OT of all 
groups, making a clear M1/M2 distinction impossible based on qualitative assessment 
alone (Figure 6-10).  For this reason, it became necessary to classify microglia instead 
based on the marker that showed predominance on a cell-by-cell basis.  We found that 
M1-predominant microglia comprised the majority of microglia in all groups, but to a 
much greater extent in the 50V animals.  Control animals had the highest number of 
microglia without a predominant marker, as would be expected for resting microglia.  
The M2-predominant cells were present in very low numbers in 50V animals, and drug 
treatment increased the presence to a level almost equivalent to control animals.  
Examining the changes of each type of microglia across the three groups gives insight 
into how microglia alter their polarization in each microenvironment (Figure 6-11).  
When comparing 50V animals to 0V animals, it becomes apparent that there is an almost 
complete conversion of M0 and M2-predominant microglia into M1 microglia, increasing 
the M1 count by almost 40%.  This makes sense, as one would expect the 
microenvironment during trauma to selectively polarize microglia into the M1 state in 
response to inflammatory signals.  With drug treatment, there is a 20% decrease in the 
number of M1 reactive microglia, with almost 100% of these converted into M2 
microglia when compared to 50V animals.  This change was significant across all groups, 
supporting the view that the drug does act on at least part of the microglial population to 
polarize them into a more protective phenotype.  Importantly, there is also a negative 
correlation between the number of axon bulbs and the number of M2-predominant 
microglia in the same section of ROT in SMM-treated animals, although this correlation 
did not reach significance (Figure 6-12).  This hints that this increased presence of M2 
microglia may be protective against bulb formation. 
 
 The classical view of microglia as having distinct polarization states has long 
been understood to be an oversimplification, but its usefulness in providing a simple 
nomenclature to fit with their role as being either pro- or anti-inflammatory in action has 
perpetuated its existence 258.  It was not until recently, with an increase in research 
focused on ways to target the immune system in neuropathology, that the 
oversimplification has posed a significant barrier for in vivo investigations 259.  The 
classical view defines specific cell surface markers as being selective for an M1 or M2 
polarization state, however this was clearly not the case in our experiments.  Almost all 
cells, even those with significantly greater staining for the M2 mannose receptor, had a 
level of CD16/32 expression higher than that of background, indicating at least a low 
level of co-expression for both markers.  Other recent studies have also found a large 
number of cells co-expressing surface markers that are classically defined as being M1  
 99 
 
 
Figure 6-10. Microglial morphology and polarization markers in the right optic 
tract. 
 
This figure shows double labeled cross sections through the right optic tract.  Panels A, 
B, and C show EYFP+ axons (green), and Iba-1+ microglia (red).  Control microglia are 
delicate and highly arborized, indicative of resting microglia (A).  The axons are ordered 
and uniform in size.  In 50V animals (B), microglia have retracted their processes, and 
are highly reactive in their morphology (pink arrows).  Reactive microglia can be seen in 
close association with bright green axon bulbs (white arrowheads).  Drug treated animals 
(C) show significantly fewer axon bulbs (white arrowhead), with some reactive (pink 
arrows), but also some resting microglia.  Panels D-J show sections stained for either 
CD16/32 or CD206 (D, E, and F) or Iba-1 (H, I, and J).  Iba-1 panels adjacent to 
CD16/32 or CD206 panels are the same field of view, where blue/pink arrowheads 
indicate the same cell in each panel.  In the control animal, very little CD16/32 or CD206 
staining is evident (D), although it is clearly staining microglial cells (H).  In 50V 
animals, much greater staining is evident overall, with more CD16/32 present (E).  
50SMM animals also have a high level of staining (F) compared to controls.  From 
sections E and F it is apparent that M1 and M2 markers are highly colocalized, although 
varying in intensity in each cell.  Panel E demonstrates a cell that clearly stains more 
predominantly for CD16/32 (blue arrowhead), where an adjacent cell stains more 
predominantly for CD206 (pink arrowhead).  The scalebar is 50 μm.  
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Figure 6-11. Microglial polarization comparison chart. 
 
This comparison chart allows visualization of how microglial polarization is altered from 
one group to another.  When comparing 50V to control animals, it is clear that there is a 
conversion of both M0 and M2 microglia into M1 reactive microglia.  50SMM animals 
are more similar to 0V in their microglial polarization profile than 50V animals.  When 
comparing 50SMM to 50V animals at the bottom of the chart, it is clear that there is 
almost a direct conversion of M1 reactive microglia into M2 microglia, lending support 
to the hypothesis that SMM-189 acts by altering microglial polarization. 
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Figure 6-12. Scatterplot of axon bulbs versus number of M2-biased microglia. 
 
This scatterplot shows the relatively strong negative correlation between the number of 
axon bulbs in the right OT and the number of M2-biased microglia.  This correlation 
indicates a protective role for M2-biased microglia in helping to prevent axon bulb 
formation. 
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and M2-specific.  The expression levels in these experiments differed significantly and 
seemed to be dependent upon both disease progression and pathogenic mechanism at 
work 260,261.  Most experiments done defining microglial polarization have used cytokine 
and receptor expression profiles from cells stimulated with one or two specific cytokines 
124.  It is clear that in vivo, such unadulterated cytokine stimulation is probably never 
encountered, and instead many conflicting M1 or M2 signals may all exist concurrently.  
This line of reasoning has prompted many researchers to re-define the thinking on 
microglial polarization, instead positing that microglial polarization is a continuum, of 
which M1 and M2 represent extreme ends of this spectrum, and must be treated as such 
258. 
 
 In our study, it was somewhat surprising to find that control animals also had a 
large number of cells expressing both M1 and M2 markers.  Many cells contained equal 
amounts of both markers, while a majority of cells expressed predominantly CD16/32, an 
M1 marker.  One possible explanation for this is that these mice were not actually pure 
untouched controls, in that they were injected with a vehicle solution on the same regime 
as drug-treated animals.  While the vehicle solution itself may not have had immune-
initiating actions, it is possible that a low-level systemic inflammation was initiated by ip 
injections in these animals.  Systemic inflammation is known to play a critical role in 
CNS immune system activation 262, and could have caused a brain-wide subclinical 
priming of microglia, subtly altering their surface receptor expression.  Another 
explanation is that, as has been suggested by recent literature, even these “resting” 
microglia may still exhibit receptor expression levels normally attributed to an activated 
phenotype, in the absence of apparent reactive stimuli.  One paper suggests that resting 
microglia might more closely resemble M2, neuroprotective microglia, phenotypically 
since they perform many of the same functions for normal tissue maintenance and 
immune system regulation 263.  Either way, it is clear that assuming the existence of a 
simple M1/M2 dichotomy might not be practical in this model, or any in vivo model 
hoping to deeply probe these questions.  Future studies of the in vivo action of SMM-189 
must address this issue in a more complete way, using numerous M1/M2 markers in 
combination to fully represent the full spectrum of microglia states present in any 
microenvironment. 
 
 
Functional Visual Tests and Their Relevance to Histologic Findings 
 
 
The ERG B wave increase:  Discussions of a Seemingly Paradoxical Finding 
 
 In 50V animals, the left eye showed a significant increase in the ERG B wave 
peak amplitude 30 days after blast, both compared to their pre-blast measurements, and 
when compared to control animals.  The right eye showed a similar trend, but did not 
reach significance.  The A-waves of both eyes showed a corresponding trend toward 
being higher in amplitude than the control animals, while also failing to achieve 
significance.  There was no change in the latency time for any of the ERG components 
measured in any group.  Drug treatment remedied this ERG defect, bringing both the A- 
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and B-waves of both eyes back toward control levels.  Under pathologic conditions, the 
ERG waves are almost universally expected to show a decrease in the peak amplitude of 
one or more components 264.  This makes sense, because the ERG wave is composed of 
summed voltage originating from retinal cellular activity.  If retinal cells are damaged, it 
would be assumed that the electrical activity from these cells would decrease.  Because of 
this, ERG wave increases due to pathology are rarely reported, rendering the ERG 
findings in these experiments to be somewhat paradoxical.  Importantly, at least one other 
group has seen ERG wave augmentation in a blast overpressure-induced TBI model 265, 
while clinicians working with human cases of TBI visual disturbance have also identified 
such anomalies 266.  Despite this, it seems that ERG wave augmentation remains poorly 
understood.  Theoretically, under specific conditions, the ERG wave response might be 
altered by both intra- and extra-retinal changes, one or many of which may be at play in 
animals exposed to blast overpressure.  In order to discuss these possibilities, it is 
necessary to first understand the components of the ERG wave, and what contributes to 
them. 
 
 Contributors to the ERG waveform:  Evidence from the literature.  Scotopic 
ERG readings acquired from the corneal surface represent a summation of radially-
directed currents emanating from the retina which pass through the vitreous and anterior 
portions of the eye, to finally pass through the cornea and sclera, and circle back around 
215.  The cells contributing to the A-wave component are the photoreceptors, where the 
negative A-wave corresponds to the hyperpolarizing current occurring when light 
interacts with a photoreceptor.  For this reason, the A-wave is said to be a pre-synaptic 
response.  The B-wave component is generally thought to be dependent upon Müller glia 
and bipolar cells, although this seems to be debated in the literature for reasons that will 
be discussed.  Generally speaking, the B-wave represents the post-synaptic transmission 
of signal from the photoreceptors to second-order cells in the ONL.  The C-wave is the 
final major component of the ERG, and is derived from RPE activity. 
 
 The specific cellular contributions to the B-wave component of the ERG are 
complex, and countless experiments have been done aimed at clarifying this information.  
One major hypothesis is that the B-wave originates solely from Müller glia, which 
generate a large current from selective uptake of light-evoked extracellular K+ 267.  Light-
evoked K+ can come from ON-bipolar cells in the OPL and amacrine cells and RGCs in 
the IPL, and thus in this scenario B-wave currents are also indirectly dependent upon 
generation of those light-evoked [K+] increases 267.  However, experiments with results 
that negate this hypothesis have demonstrated the potential complications of this 
conclusion, and have high relevance to the seemingly anomalous B-wave augmentation 
seen in our 50V animals.  Lei and Perlman used specific K+ channel blockers to 
investigate the ERG B-wave dependence on K+ currents, and it was discovered that 
barium and cesium ions injected intra-vitreally significantly augmented the B-wave, 
without affecting the A-wave component 268.  Since Müller cells are highly dependent on 
K+ channels for uptake, blocking them should have extinguished the K+ current if it were 
responsible for the B-wave generation, but instead it had the opposite effect.  This led the 
researchers to conclude that the simple Müller cell/K+ hypothesis of B-wave generation 
was demonstrably incorrect - a subject that is still debated to this day - but also gave 
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important insight on what possible mechanisms underlie a selective B-wave 
augmentation.  They concluded that one of three scenarios must be involved: an increase 
in photoreceptor input to bipolar cells; a direct action on the cells responsible for B-wave 
generation; or a reduction of cellular components acting to suppress action of cells 
responsible for B-wave generation.  In addition to these, a fourth possibility must also be 
considered, and that is a potential decrease in resistivity of the tissue through which these 
electrical currents flow. 
 
 An increase in photoreceptor sensitivity.  Photoreceptors are unlike many other 
conducting cells of the body in that their resting membrane potential is slightly 
depolarized, or more positive, during the absence of stimulus.  Where normal neurons 
have a resting potential of around -70 mV, a photoreceptor rests around -40 mV 269.  This 
means that under dark conditions, a persistent electrical current known as the “dark” 
current is generated by the cell’s high Na+ permeability.  Upon photo-stimulation, the cell 
becomes hyperpolarized through a complex series of actions that ultimately lead to the 
closing of Na+ channels.  This hyperpolarization is what drives the A-wave negative 
current during light stimulation- the dark current reversal is recorded as a negative spike 
in the ERG curve 270.  In order for photoreceptors to be more sensitive to light, 
theoretically this would require the resting membrane potential to decrease, toward that 
of a normal neuron.  Under these circumstances, it would be easier to elicit a response 
from that photoreceptor cell, rendering it hypersensitive.  Practically speaking, this is 
something that occurs every day, since dark adaptation- or a purposeful increase in 
photoreceptor sensitivity- allows us to see more clearly in the dark.  Without this 
important mechanism, humans would walk around with night blindness and an inability 
to see low intensity light levels.  Abnormal photoreceptor sensitivity, which can occur 
under photopic conditions, is a phenomenon that is also observed with phosphodiesterase 
inhibitors, such as IBMX and theophylline, where ERG data has shown a clear B-wave 
augmentation and photoreceptor hypersensitivity after administration 271.  The 
mechanisms behind this effect are not fully understood, but probably lie in the heavy 
reliance of phototransduction biochemistry on levels of cGMP within the cell.  
Alternatively, a significant body of knowledge points to calcium as an important 
feedback molecule in rod photoreceptors, possibly acting through modulation of cGMP 
levels 272.  Intracellular calcium levels have been shown to affect photoreceptor 
sensitivity, with moderate levels enhancing phototransduction, and high levels having an 
opposite effect 273.  The mechanism of calcium-assisted photoreceptor sensitization is 
more well established, since calcium levels have long been known to play a role in light 
adaptation 274. 
 
 For discussion in the context of mTBI-associated visual dysfunction, the 
inflammatory micro-environment that exists within the retina after blast, as evidenced in 
the histological data, may cause changes in intra- and extra-cellular ion concentrations 
that yield a similar effect as these pharmacologically-induced cases of photoreceptor 
sensitivity.  From a clinical standpoint, calcium plays an important role in diseases 
involving long-term inflammation.  Often seen clinically, gross, ectopic deposits of 
calcium can signal the first signs of pathology in a number of human diseases 275,276.  
Calcium receptor investigations have shown that it plays an important role as a signaling 
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molecule in inflammatory conditions, and its high levels in serous exudate probably act to 
recruit macrophages to sites of damage 277.  Studies in contusive spinal cord injury have 
identified abnormally low levels of extracellular calcium 3 hours after injury, owing to 
cellular uptake of local calcium stores around the site of injury 278.  As discussed in 
Chapter 1, calcium also plays a role in the primary injury of TBI, with damaged cells 
often having difficulty with intracellular calcium regulation due to the mechanical insult 
of the primary injury 98.  It may be the case that alterations of calcium homeostasis after 
blast initiates a biochemical change in photoreceptors of 50V mice that renders them 
hypersensitive to light, even under photopic conditions.  Significantly, our structural 
studies have found a thinning in the LE photoreceptor layer at 30 days (on OCT), as well 
as histologically at 10 weeks after blast 179, indicating proof of photoreceptor damage that 
may be accompanied by this hypersensitivity.  While B-wave augmentation in our 
experimental animals may not definitively, or even exclusively, be tied to photoreceptor 
sensitivity, it is important to note that photoallodynia is a commonly encountered 
symptom of TBI-associated visual dysfunction.  Increased critical flicker fusion 
frequency in individuals with mTBI are directly related to self-reported problems with 
light and motion sensitivity, hinting that electrophysiological changes in retinal function 
may give rise to subjective visual hypersensitivity 279.  These facts, paired with the 
histological evidence of outer retinal thinning, and a B-wave defect in the ERG of these 
animals, suggest that photoreceptor alterations may play a critical role in the pathology of 
mTBI-associated vision problems. 
 
 Rod-driven on-bipolar cells and loss of lateral inhibition.  Photoreceptors seem 
superficially to be the most important cell in the retina, since they are the major cells 
involved in photo-transduction.  However, the simple on-off dichotomy of photoreceptor 
activation could never convey the intricate images sensed by the mammalian visual 
system in all of their rich detail.  This requires a complex network of cells acting in 
concert to organize pertinent visual information, pass this information on to the neurons 
of the retina, and subsequently the visual centers of the brain.  A huge number of 
interneurons- called horizontal cells, and amacrine cells- provide refinement of the on-off 
signal from photoreceptors through feedback, feedforward, negative, and positive 
regulation at synaptic connections to bipolar cells 280.  In passing of information from the 
photoreceptors to the bipolar cells, horizontal cells in the outer retina and amacrine cells 
in the inner retina provide lateral feedback to improve the signal before passage to the 
RGCs.  Lateral feedback is largely responsible for temporal and spatial refinement of 
photoreceptor signals 281, and may play an important role in conveying directional 
selectivity to RGCs 282. 
 
 An important potential cause for the ERG B-wave augmentation in blasted 
animals is the selective loss of one or many of these regulatory interneurons, specifically 
those interneurons with negative feedback on bipolar signaling.  As discussed previously, 
the ERG B-wave gives information about activation of cells specifically within the INL, 
most pertinently to this topic, the bipolar cells.  If a negative regulatory subpopulation of 
horizontal cells were selectively lost due to blast injury, it would cause a loss of negative 
feedback at the level of the OPL.  Functionally, this would yield a decrease in the 
inhibition of signals passing from the photoreceptors to the bipolar cells, and might 
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theoretically be visible as an increase in the B-wave due to increased bipolar cell activity.  
Loss of negative feedback from amacrine cells in the IPL is more complicated to explain.  
If an amacrine cell is regulating the synapse between the bipolar cell and the RGC, one 
might not expect the loss of negative input to have an effect on the B-wave, since bipolar 
cells would be functioning normally, but their signals to RGCs would be amplified.  In 
reality, amacrine cells synapse with bipolar cells all along the cell body, as well as 
dendrites and axons 283, which leaves the possibility for an increase in bipolar cell firing 
with a loss of inhibitory input at the level of the IPL.  Other studies have indicated that a 
loss of OFF-bipolar cells could cause B-wave increases, since their input seemed to shape 
and suppress the B-wave under physiological conditions 284.  While it is difficult to 
understand a mechanism by which only inhibitory interneurons or hyperpolarizing 
bipolar cells would be lost in TBI, one important piece of evidence does speak to this 
possibility.  As discussed in Chapter 2, retinal histology in this model found a significant 
decrease in the thickness of the INL, indicating a loss of one or more cell types within 
this layer.  This could include any of the regulatory interneurons, as well as the bipolar 
cells themselves.  So although this seems to be a less likely scenario, it is important to 
identify it as a possibility nonetheless. 
 
 Alterations in tissue resistivity.  The electrical circuit recorded in the ERG wave 
is similar to any non-biological electric circuit in that it can be described by the 
relationship that voltage is directly proportional to the product of current and resistivity, a 
relationship commonly known as Ohm’s law 285.  If one assumes that no cellular changes 
in function have caused the ERG B-wave augmentation, a final possibility still exists for 
why this seemingly paradoxical finding occurs.  That is, the voltage change is not caused 
by a change in the current, but instead by a decrease in the resistivity of the retinal circuit 
through which the current flows.  In biological terms, tissue resistivity is dependent upon 
a number of factors, including water, ion, air (in the case of the lungs), and mineral 
content 286.  Of the body tissues, blood has one of the lowest resistances, at 100 Ω cm, 
while normal cell-dense tissues may be closer to 1000 Ω cm 287.  With reference to ocular 
resistivity and its effect on ERG readings, this has been long recognized as a potential 
complicating factor in ERG result interpretation, especially when recording from the 
cornea 288.  With corneal-surface ERG readings, electrical current flows through a 
number of higher resistivity areas in the outer retina, toward the vitreous humor, the so-
called low-resistivity shunt, before circling back toward the originating cells in the retina 
to complete the circuit 215,289.  An important possibility to consider with the ERG findings 
in our experiments is the potential decrease in resistance of the retina as a result of the 
inflammatory microenvironment. 
 
 Examples of physiologically-induced changes in tissue resistivity are surprisingly 
well documented in the literature.  Both temperature and hematocrit have been shown to 
alter resistivity of human blood 290, while necrosis and edema produced significant 
decreases in muscle tissue resistivity after traumatic electrical burns 291.  Fluid movement 
in the form of edematous extracellular fluid accumulation is a common finding in both 
brain and retinal trauma 176,292, and its high electrolyte and protein content explain why it 
would cause a decrease in the resistivity of any affected tissue 293.  There is no overt 
evidence of edema in the retinas of our 50V animals after blast, but previous experiments 
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have found about a 0.08% increase in the fluid content of the brain at 1 day after blast 179.  
Edematous expansion could account for the lack of total retinal and INL thinning in the 
LE of 50V animals at 30 days after blast on OCT, even though histology of these same 
eyes at 3 months shows signs of significant retinal thinning.  The OCT in vitro method 
would preserve this artificial water content and make the retina appear to be thicker even 
in the presence of significant cellular losses.  One important consideration to weighing 
the possibility of this explaining the ERG findings is that a decrease in the resistivity of 
the retinal tissue should theoretically yield an increase in the peak amplitude of the entire 
current across the ERG function.  This means one would expect the A-wave to have an 
increase in peak amplitude as well, since the decreased resistance would make both the 
negative and positive voltage travel with greater ease through the circuit.  Although it 
was far from significant, the ERG in the left and right eyes did show a trend toward 
having a higher peak amplitude than the control eyes.  It is difficult to say whether this 
trend should be considered as part of this story, but it certainly raises the probability of 
tissue resistivity being at least partially responsible for the ERG findings in blasted mice.  
Given the possibilities discussed, it seems most reasonable to conclude that the ERG 
changes are probably due to more than one factor, but nonetheless indicate a significant 
functional change in the eyes of blasted animals, that is improved by treatment with 
SMM-189. 
 
 
Optokinetics 
 
 Optokinetic nystagmus (OKN) refers to the eye movement involved in reflexively 
tracking a large scale displacement of the visual field.  It serves to stabilize the visual 
field on the retina when the visual field is being moved 294.  OKN is a visual function that 
can easily be elicited in both humans and animals by horizontally moving vertical stripes 
that cover a large part of the visual field.  The OKN reflex is mediated by a collection of 
visual nuclei and circuits in the brain known collectively as the accessory optic system 
(AOS) 295.  The optokinetic (OKT) testing device used in our experiments allows free 
movement of the experimental subject, and thus OKN is gauged by the observation of an 
animal tracking (head movement) the moving pattern.  Tracking behavior, usually called 
optomotor tracking, is generally accepted to be a good indicator of the OKN reflex, and 
has been reliably used to assess visual function in mice 183.  Using the OKT device, 
vertical stimulus bars can be changed to test a subject’s visual acuity and contrast 
sensitivity thresholds, since the OKN reflex is only present when a stimulus is at or above 
the perceptible level for that subject. 
 
 The OKT response is known to be mediated almost exclusively by sub-cortical 
visual areas in the brain, and is not altered even with full cortical ablation 183.  While the 
neurobiological underpinning of the OKN reflex is relatively well understood, the 
pathway underlying the initiation and execution of the optomotor reflex observed in the 
OKT response is much less so 183.  Optokinetic nystagmus, visual orienting, and motor 
movements involved in the execution of tracking must ultimately rely on an intact 
retinofugal system 295, including the tectospinal (colliculospinal) tract 65 and accessory 
optic system 295.  Cranial nerves driving extraocular muscles as well as cervical motor 
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circuits, must be intact to coordinate head, neck and eye movements.  Finally, the 
perception of spatial or contrast information is, of course, reliant upon the intact function 
of photoreceptors, ganglion cells, and directionally-selective cells within the retina 296.  
Put together, these features allow OKT to serve as a sensitive and comprehensive test of 
the visual system.  However, this heavy reliance on the function of so many disparate 
pathways can be a double-edged sword.  With the involvement of the entire sub-cortical 
visual pathway, it is difficult to localize lesioned areas responsible for a complex 
pathology such as that seen in our model.  The OKT results in these experiments 
highlight this weakness clearly, since some of the results seem contradictory, and have 
conflict with our own previously published data.  To fully understand and scrutinize the 
VA and CS data found in these and previous experiments, it is first necessary to briefly 
discuss the complicated pathway involved in eliciting the OKT response. 
 
 The pathways involved in the OKN and optomotor response.  The axons 
leaving the eye and projecting to brain regions involved in visual processing compose the 
so-called retinofugal pathway.  These fibers contain all sensory information from the 
retina projecting to systems involved in both OKT and cortical vision.  With relevance to 
the OKN response, stimuli moving rapidly across the visual field will initiate signals sent 
from RGCs in the retina to the pretectal nucleus of the optic tract (NOT) and other 
terminal nuclei of the AOS also located in the midbrain 294.  The NOT, as well as the 
dorsal terminal nucleus (DTI), contains directionally selective neurons that are known to 
play a critical role in the initiation of OKN to horizontally moving stimuli 294.  Retinal 
ganglion cell axons leaving the retina also project directly to the superior colliculus 65.  
The superior colliculus (SC) is a layered structure divided into superficial and deep 
layers, whose cells serve differential functions in relaying visual signals received from 
RGCs in the retina.  The cells in the upper layers of the superior colliculus project to the 
thalamus for relay to visual association areas that assist in perception and coordinating 
eye movements 297, while the deep layers of the superior colliculus project through the 
contralateral tectospinal tract to coordinate head movements for visual orienting 298.  
Previously in our TBI model, the superior colliculus was found to contain a population of 
highly reactive microglia, indicating a possible role for SC-coordinated dysfunction in 
yielding functional vision defects.  Coordination of eye and head movements are integral 
for normal visual function, and dysfunction in this coordination is a commonly 
encountered sign in human cases of mTBI-associated visual dysfunction 53.  Since axons 
throughout the left optic nerve are lost, it is possible that signal loss to any of these 
important visual nuclei could yield OKN defects observed in this model. 
 
 Visual acuity.  Visual acuity testing in animals 30 days after blast found no 
difference between any group, in either eye, in the present study.  This is in contrast to 
previously published data in this model, where both the left and right eyes of blasted 
animals had significant deficits at 3 weeks post blast, with the right eye deficit being 
more severe 181.  The reason for this disparity most likely stems from the different 
experimenter administering the tests in these studies versus that of the previous studies.  
The optokinetic test can be confounded by human variation, since it is a subjective 
judgment by the observer to determine if the mouse has moved its head or not in response 
to a given stimulus.  Thus, if a viewer only detects robust head movements as tracking 
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movements, and if a treatment makes movements less robust, that viewer might detect no 
movement, while another viewer might detect movement.  The former viewer would then 
report a deficit and the latter not.  As the viewer is always blinded to treatment and 
stimulus, detection of a deficit in a treated group is objective and unbiased.  Nonetheless, 
a different observer might not detect the same change due to their greater ability to detect 
an OKT tracking movement.  Thus, the prior data indicate that TBI does yield an OKT 
defect on the VA task, but paradoxically that defect will be more difficult to detect by an 
observer who more readily detects OKT tracking.  Consistent with this, the CS defect 
detected here is less than in our prior study at around the same time point. 
 
 Notably, 4x multi-blasted animals tested by this same experimenter showed 
significant defects in visual acuity at a year post-blast.  In these animals, the injury and 
defect are likely much more severe, and accordingly were evident even to a more 
sensitive observer.  At this point in time, there still appears to be some debate on whether 
concussive and sub-concussive events can accumulate over time to yield long-term 
deficits in the brain 157.  This is despite the high profile finding of CTE in football players 
and other athletes, even those with no history of concussive injury 21.  Experimental 
verification that long-term injuries can result from multiple sub-concussive events holds 
great importance in the field of mTBI research, specifically as it relates to high-impact 
sports and military applications. 
 
 Contrast sensitivity.  Contrast sensitivity is the ability to distinguish between 
different intensities of light and dark.  This is what conveys the crispness to vision, and is 
important in night vision and other instances where gradients between light and dark are 
minimal.  Contrast and gain detection seem to be an intrinsic property of cells both within 
the retina and in the retinofugal projection nuclei, the LGN and SC 299.  Additionally, the 
primary visual cortex may also play a role in contrast detection in more challenging 
situations that require integration of higher order processes for perception 300.  In 50V 
animals, contrast sensitivity thresholds measured at 6 different spatial frequencies 30 
days after blast demonstrated a severe deficit when compared to control animals.  Both 
eyes were affected, with the right eye showing a more substantial deficit than the left.  
Drug treatment remedied this deficit, bringing the CS functions of 50SMM animals back 
toward control levels in both eyes.  Since the LE at this time point shows thinning of the 
photoreceptor layer and a loss of RGC axons running through the optic nerve and tract, it 
is logical to conclude that these must be at least partially responsible for the functional 
CS deficits in the LE of these animals.  Additional evidence for this hypothesis is that 
drug treated animals show significant improvements on both of these histopathological 
readouts, indicating they may be linked to the functional improvements seen with drug 
treatment as well. 
 
 Oddly, the right eye at this time displays no such histopathology, and as was seen 
in previous VA testing at 3 weeks from blast, displays a paradoxically more severe deficit 
than the left eye.  This gives strong indication that the right eye deficit is not only 
different in pathophysiological mechanism that that of the left eye, but may actually be 
linked to damage in more distal visual processing nuclei, which correspond to the left 
side of the brain.  The axon projections from the right eye, in both the optic nerve and 
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tract, show very few signs of damage compared to the left eye, at both acute and extended 
time points, and by a number of different markers of pathology.  This speaks to the 
potential for some, if not all, of the visual acuity deficit in the RE to be traced back to 
more central visual system causes.  Damage to the retinofugal pathway could be mediated 
by loss of connectivity in visual nuclei projections, or even loss of second-order neurons 
within those nuclei.  Recent investigations in the mouse lateral geniculate nucleus have 
identified cells with high specificity for single-directional movement 301, meaning their 
loss on the left side of the brain due to blast might mediate a significant defect in the RE 
visual response.  Visual deficits in this eye could also be due to a defect in the initiation 
of saccadic response, or coordinated head movements, due to loss of cells in the superior 
colliculus who are integral to these functions.  An experiment in cats validated that 
unilateral ablation of the superior colliculus causes a loss of the OKN reflex in the eye 
contralateral to the lesion 302.  Denervation of the superior colliculus from RGC axon 
degeneration could result in eventual SC neuronal degeneration, a phenomenon that has 
been demonstrated experimentally in rats 303, or direct effect of the blast injury might 
injure SC neurons on the left side of the brain, giving rise to at least part of the RE visual 
deficit. 
 
 Multi-blast animals displayed significant deficits in CS at a year out from blast, 
but interestingly had an apparent reversal of which eye was more severely impacted.  In 
these animals, 50-psi yielded more significant deficits in the LE than the RE.  However, 
if one compares the CS threshold at only 0.272 c/d in 50V animals at 30 days post-blast, 
it is clear that the LE threshold is actually increased compared with the RE at this spatial 
frequency.  It may be the case that the entire CS function in long-term multi-blast animals 
more closely resembles the function of 50V animals, but further studies will be needed to 
determine this.  Also of note, where the LE threshold of 50V animals 30 days post-blast 
is around 48% for detecting 0.272 c/d, the long-term multi-blast animals required nearly 
60% to see this spatial frequency.  Interestingly, when comparing the RE of 30 day 50V 
animals to 50-psi multi-blast animals a year out, the CS threshold is almost unchanged, 
speaking yet again to the different mechanism that must exist between the two eyes.  
Since the multi-blast animals would presumably have a more severe injury than single-
blast animals, it is difficult to make direct comparisons between the two.  Specifically, it 
is impossible to conclude whether the more severe LE deficit in multi-blast animals 
comes from long-term injury, multiple blasts, or both. 
 
 Future research strategies.  Contrast sensitivity and visual acuity are highly 
sensitive, but non-specific tests in identifying retinal and visual system disease 182.  It is 
evident that by these two metrics, mice have subtle, but evident, visual system changes 
that would contribute to significant difficulties in the activity of daily life.  Further 
studies should be done to investigate changes in both pre-blast and post-blast VA/CS 
measurements at many more time points after blast, including a critical period from the 
first weeks to the first months after blast.  The data in this dissertation conflicts with that 
of previous studies in this model, and should be confirmed over multiple time points to 
clarify the true nature of the functional visual defects.  OKN should optimally be 
combined with corresponding ERG/pERG, and OCT measurements.  Additionally, 
stereological counts of the LGN, SC, and visual cortices should be undertaken, to 
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determine whether a diffuse loss of cells from one or more visual brain regions may 
contribute to the complex pathology of mTBI-associated visual dysfunction in this model. 
 
 
A Discussion of Injury Mechanisms and Inconsistencies 
 
 
Axonal shearing and stretching due to head, eye, and brain movement 
 
 One purpose of these experiments was to further investigate the mechanism of 
injury in mTBI-associated visual dysfunction.  The histological and functional data have 
indicated that at least one part of the injury must undoubtedly come from the axonal 
shearing, but the secondary question then becomes when and where does this shearing 
occur, and what makes the visual system so particularly vulnerable to this?  In previous 
experiments, animals at one day after blast showed no changes in the optic tract.  Many 
studies have shown that, in axons directly harmed by primary injury, axon bulbs often 
become visible within hours, and can take as long as 24 hours 251.  The fact that the OT 
seems relatively normal at this time point indicates that points of axonal breakage are 
probably located more proximal to the eye.  As discussed previously, at 3 days after blast, 
there was found to be a localization of bulbs in the left ON that were much larger and 
more numerous than those in the OT at the same time, indicating that a significant point 
of stress may be in the bony canal of the skull that serves as the passageway for the ON 
to leave the orbit of the eye and enter the brain case.  The eye and brain have a significant 
amount of freedom to move within their bony enclosures 304, with the eye having an 
additional opening through which more extensive movement is clearly possible.  
Complex biomechanical analysis using computer simulations have demonstrated that 
shock waves incident upon the head may transmit energy in the form of compression, 
tension, and shear stress waves 305.  Together with the measured head movement, these 
forces may cause the brain and eyes to move in opposing directions during the 
milliseconds after shock wave incident.  Since the ON is held fixed by its bony canal, this 
may act as an axis of torque, about which mechanical breakage of axons would inevitably 
occur.  Shock waves can also act directly on the skull, causing a very small but 
measurable compression, which can then act to raise intracranial pressure 306.  
Interestingly, increases in intracranial pressure are now being identified as potential 
causes for biomechanical stress injury at the optic nerve head245, another area where our 
previous studies have found axon bulbs at 3 days after blast 179. 
 
 If a focal injury of the proximal visual tracts lies at the heart of the primary injury 
in our model, downstream axonal damage (in the OT and distal) may be axons 
undergoing Wallerian degeneration due to upstream breakages.  Unlike in humans and 
some other mammals, the RGC axons of mice do not maintain a retinotopic organization 
once they leave the retina, and instead exhibit a highly random arrangement in the optic 
chiasm and optic tract 307.  This may explain the seemingly random arrangement of 
damaged axon fibers, uniformly spread throughout the OT and in no identifiable pattern.  
However, it is important to note that SMM-189 treatment did significantly decrease the 
number of axon bulbs in the OT at 3 days.  Since drug treatment, and immune 
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modulation, may not be able to salvage the axons damaged in the primary injury, it may 
be the case that a majority of the damaged axons seen in 50V right OT at 3 days are due 
to some secondary injury.  The absence of significant axon rescue in SMM-189 treated 
left ONs at 11 weeks hints that perhaps some initial wave of axonal damage is occurring 
more proximal to the eye at time points prior to 3 days, and that the axons seen in the OT 
at 3 days and beyond are due to secondary inflammatory damage.  However, there is at 
least some evidence that even axons damaged by primary injury may have a critical 
period during which they might be saved, if acted upon by the correct regenerative 
mechanisms 308.  SMM-189 may polarize microglia in such a way that they release 
trophic factors needed for this regenerative pathway to dominate in many axons.  A 
schematic overview of this hypothesis can be seen in Figure 6-7. 
 
 
The problem of the left eye-right eye difference 
 
 A persistent difference between the left and right eye permeates the structural and 
functional vision end points, hinting at a different injury mechanism at work in each eye.  
Potential injury mechanisms of the left eye were discussed in the previous section, with a 
hypothesized stress locus at the ON at the point of the bony canal and the ON head, with 
subsequent secondary injury.  Functionally, the right eye shows both short-term (in these 
experiments), and longer term (previous studies) deficits in VA and CS by measure of the 
OKN reflex.  As recounted earlier in that section, these RE deficits can almost entirely be 
explained by direct injury to the visual nuclei on the left side of the brain (blast side).  
With that being said, there still exist some histological evidence of RE injury that must be 
relevant in any explanation for the RE deficit, and vice versa.  In previous experiments, 
the right retina was found to be significantly thickened at 10 weeks from blast, and in our 
current studies, the RE had a significant microglial presence at 30 days after blast.  
Initially, this seemed like there may be direct injury to the RE, potentially from the eye 
being compressed into the foam during blast administration.  However, at this same time 
point, GFAP reactivity was not seen, where it was seen in the LE.  Furthermore, in the 
left OT, very few damaged axons were seen at early time points after blast, and the small 
number present can reasonably be attributed to the 1-10% percent of axons whose fibers 
remain uncrossed from the left eye.  These contradictory findings leave a puzzle as to 
why there is any damage to the RE at all, and why this pathology seems to differ from 
that of the LE so significantly. 
 
 An important possibility to consider for the findings in the right eye is that the 
inflammatory response from the LE may give rise to inflammation in the RE, even in the 
absence of any direct damage.  This inflammatory response might then cause direct 
damage to the retina or RGC axons of the RE, leading to functional deficits in that eye 
and long-term axon loss in the optic nerve.  Significant precedent exists for this as a 
mechanism in many diseases affecting the visual system 309.  It is a well-known 
phenomenon that infections can spread from one eye to another, a condition termed 
Sympathetic ophthalmia, sometimes leading to disastrous results in the contralateral eye 
310.  Indeed, this may have been the reason for Louis Braille’s complete vision loss as a 
child 311.  Studies of direct ocular globe penetration reveal significant monocyte and 
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lymphocyte invasion into the non-injured eye 312.  Relevantly, direct injury to the RGC 
axons in the ON has also been shown to cause microglial reactivity in the contralateral 
uninjured eye 313-315.  One paper postulated that the injury signals from uncrossed fibers 
in the damaged optic nerve may be contributing to damage in the nuclei of the unaffected 
eye by releasing local inflammatory mediators 315.  Interestingly, two studies found the 
contralateral eye to have evident GFAP reactivity, albeit less than in the ipsilateral eye, 
that was found predominantly in astrocytes in the NFL 314,316.  This is similar to what was 
found in our animals at 30 days after blast, since the right eye qualitatively seemed to 
have more GFAP in the NFL, but did not have the large number of processes penetrating 
into the IPL as the LE. 
 
 
SMM-189 Benefit and Implications Going Forward 
 
 These experiments validated the use of SMM-189 in a mouse model of mTBI, 
with many functional and histologic measures of benefit over vehicle-treated animals.  
SMM-189 was hypothesized to act through alterations in microglial polarization, 
potentially shifting the polarization state from an M1 to an M2 phenotype.  Our 
experiments have partially confirmed this hypothesis, since many readouts of immune 
system activation are altered in drug-treated animals, and these alterations are 
accompanied by functional and structural benefit on disease pathology.  Furthermore, 
M2-like microglia were increased significantly in damaged OTs of animals receiving 
drug.  However, these experiments have also highlighted the complex nature of in vivo 
microglial polarization, posing more questions about precisely how the drug is affecting 
microglia in the multifaceted environment created after trauma. 
 
 
The complicated issue of microglial polarization 
 
 Traditionally, macrophages have been forcibly categorized into two dichotomous 
states, being either classically or alternatively activated.  New research on macrophages 
has amended this belief to recognize the variety of activation states, including extensive 
overlap, according to the actions and central role of the macrophage in specific states of 
disease or physiologic condition 258.  It is documented that microglia can take on mixed 
M1/M2 phenotypes due to conflicting pro and anti-inflammatory cytokine release, and 
for this reason it becomes important to observe the balance of phenotypic markers 
relative to one another, rather than in isolation 317.  According to the literature, at least 4 
distinct macrophage polarization phenotypes have been traditionally lumped into the M2 
“alternative” activation group: M2a, M2b, M2c, and Mox 116,318.  M2a microglia are more 
close to the typical understanding of M2 polarization in that they are primarily anti-
inflammatory in effect, promote tissue repair, and release anti-inflammatory cytokines 
IL-1 and IL-10, while M2c (often found with M2a) are more consistent with the resting 
immunosuppressive “M0” state 319.  The M2b activation state is a mixed-phenotype, 
involved in regulatory T cell recruitment and immune modulation 320.  Despite the 
extensive literature identifying these M2 class subtypes, little research has been done on 
the role of M2b microglia in specific disease pathologies, and how they may help to alter 
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the immune response in a favorable way.  It is probably most beneficial to view their 
actions as primarily regulatory, meaning their presence can be positive or negative, 
depending on the pathology and its return to homeostasis. 
 
 In vitro cytokine assays on human microglia have demonstrated SMM-189’s 
ability to alter a variety of pro and anti-inflammatory cytokines and chemokines released 
after LPS stimulation 181.  The expression levels of LPS-stimulated microglia after SMM-
189 treatment mimics almost identically those seen in type M2b microglia in a recent 
study investigating different microglial activation states 321.  In M2b microglia, as 
opposed to M2a and M2c types, levels of TNF-alpha, IL-6, IL-10, and IL-12 are still 
significantly elevated, although less so than M1 microglia.  This speaks to the somewhat 
mixed picture of M2b microglia, since they are still actively involved in recruiting 
peripheral T cells and acting as APCs 322.  In our IHC studies there was a significant level 
of CD206 in individual microglia of the ROT in all groups, and interestingly, M2b 
microglia are not known to express CD206.  Taken together, these indicate there should 
be a mixed M2 phenotype being expressed by drug-treated animals, with a selective 
polarization to an M2a/M2b phenotype.  Given the immensely complex nature of 
microglial polarization, it is probably not possible to determine a microglial phenotype 
based on a single cell surface receptor.  Investigating the specific M1 and M2 
categorization of microglia in drug-treated animals should be planned for the future, 
giving a more complex understanding of not only what, but why these different 
microglial phenotypes might prove more or less beneficial in mTBI pathology. 
 
 
Cannabinoids as immune modulators:  Issues, benefits, complicating factors 
 
 CB2 receptor tissue distribution.  Many studies have demonstrated the use of 
cannabinoids acting on both CB1 and CB2 receptors in regulating the immune response 
198,323.  What continues to be problematic is identifying the ways and locations in which 
these molecules exert their effects.  Aside from their known presence on immune cells, 
including microglia, the cellular and tissue distribution of CB2 receptors on non-immune 
cells continues to be a hotly debated topic 324,325.  While much research has indicated an 
absence of CB2 receptors on non-immune cells in the CNS, an equally significant body 
of evidence demonstrates their presence on many different neural and non-neural cells 
(see Atwood and Mackie 2010 for an excellent review325).  Studies have identified CB2 
receptors on neurons within the cerebellum and brain stem 326, in the hippocampus, 
striatum, cerebral cortex 327, and even in the retina 328.  One study postulated the existence 
of CB2 receptors on neurons in virtually every major area throughout the brain, 
strengthening their IHC evidence with neuropsychobiological correlates corroborating 
this tissue distribution 329.  Recent studies have hypothesized a potential role for 
endocannabinoids in regulating cerebral blood flow, with particular importance on CB2 
receptor activation 330.  A study in humans found CB2 receptors were present on vascular 
endothelium, but not nearby astroglia, indicating their potential role in blood flow 
regulation 331.  Other studies have confirmed this finding 332, and as a result cannabinoids 
are now being investigated for their use in ischemia/reperfusion injuries in the heart and 
liver 330,333. 
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 The studies undertaken in this dissertation show that SMM-189 acts on microglial 
cells in the brain, altering polarization in at least a subset of cells near sites of known 
injury.  It is also clear that the drug decreases a number of pathologic findings present 
after mTBI in our model.  The possibility of some additional benefit occurring due to 
SMM-189’s action at other cellular locations cannot be ruled out.  For example, if SMM-
189 acted even partially at the neurovascular endothelium, to heal a leaky BBB, this 
could convey a significant benefit to the long term outcome in mTBI.  Direct action at 
neurons in the brain, or RGCs in the retina, could also temper programmed cell death 
pathways to yield the long-term benefits seen in our model.  Determining if CB2 
receptors are actually present centrally on non-immune cells, and whether some of the 
beneficial effects of cannabinoids in a number of disease processes are indeed due to non-
immune cell effects, remain critical questions in understanding and using cannabinoid 
pharmacotherapy going forward, and may provide additional mechanisms of action for 
how SMM-189 is exerting its beneficial effects in our model. 
 
 Cannabinoids and their receptors:  Beyond CB1 and CB2.  There is a 
significant body of evidence that indicates the presence of additional receptors to which 
cannabinoids may act as ligands 186.  One heavily researched non-psychotropic phyto-
cannabinoid, cannabidiol (CBD), has been proposed to exert its action through a variety 
of receptors and modulatory targets, including glycine, opioid, TRPV, and 5-HT1A 
receptors, amongst others 334.  In addition, new evidence also poses the possibility that 
endogenous molecules released during times of inflammation may act to allosterically 
regulate CB receptor function, further modifying action of both endogenous and 
exogenously administered cannabinoids in vivo 335.  Many of the anti-inflammatory 
phyto-cannabinoid activities are now known to be mediated through non-CB1/CB2 
receptor activity 336, raising the possibility that the drug used in our studies, SMM-189, 
may be acting via an additional receptor to convey its healing effects in mTBI.  Extensive 
pharmacology studies on SMM-189 in CBR-transfected human embryonic kidney cells 
have shown intracellular cAMP levels to be definitively linked to the drug’s action at 
CB2 receptors 218.  These studies have also confirmed that SMM-189 exerts no functional 
activity at CB1 receptors 218,337.  Assays used in previous studies of SMM-189 could only 
account for CB1- or CB2-mediated changes in cAMP, so there is a possibility that the 
drug may act on other receptors giving rise to off-target effects.  Future studies should be 
aimed at investigating this to more thoroughly understand both the mechanism of the 
drug’s action, and potential off-target effects. 
 
 Natural and synthetic cannabinoids present an exciting future in 
pharmacotherapeutics, with their ability to potently and selectively act on the body’s 
immune system to suppress undesirable activation.  It is, however, important to recognize 
that immune system modulation is not a desirable target in all diseases, and in the case of 
cancer can even prove devastating 338.  As the notorious psychedelic scholar and self-
proclaimed “altered-statesman” Terence McKenna once said to a doctor, when remarking 
on the potential for phyto-cannabinoids to cure cancer 334 after his own devastating 
diagnosis of glioblastoma multiforme (GBM), “Listen, if cannabis shrinks tumors, we 
would not be having this conversation,” 339.  While cannabis and phyto-cannabinoids 
alike, will probably not represent the magic key to curing all immune-mediated diseases, 
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their potential to offer molecules for therapeutic investigation - particularly within the 
realm of neurotherapeutics - is undeniable and important to recognize.  Indeed, this 
dissertation has demonstrated the vast improvements a purposefully-designed 
cannabinoid can convey in an immune-mediated pathology with few currently available 
treatment options.  The complex pharmacology and receptor interactions of cannabinoids, 
paired with their proven efficacy in providing novel therapeutics, make experimental 
investigations of their mechanisms and myriad of effects an important and worthwhile 
pursuit.  It is our hope that these studies can help de-stigmatize the idea of cannabinoid-
based therapeutics, and pave the way for future studies into these fascinating molecules. 
 
 
Study Limitations 
 
 As with all research, certain limitations existed within our studies.  Male mice 
were used exclusively within our experiments, since this model was previously 
characterized using only male mice.  Because of this, it is unknown what effect both blast 
exposure and SMM-189 treatment would have on female mice.  Furthermore, as with all 
animal models it is not known how SMM-189 would improve outcomes in human cases 
of TBI.  With regard to the drug SMM-189, in vivo dose-response studies were not done 
to determine if the dose we used in these experiments was the optimal dose, so it may be 
the case that this dose was above or below the ideal therapeutic level.  As discussed 
previously, SMM-189’s mechanism of action is not fully understood, which presents a 
limitation in interpreting the improvement after drug administration.  Another limitation 
that has been touched on previously exists in interpreting the M1 and M2 polarization 
information from the ROT.  Having used only two immunomarkers to distinguish 
activation states, we were not able to fully identify microglia as being M1 or M2 
polarized, and instead could only say definitively which of the two markers was 
expressed to a greater extent in a specific cell.  Finally, the acute time points had sample 
sizes that were very small, significantly limiting our ability to achieve statistical 
significance, and to detect subtle changes.  Other limitations have been previously 
identified and discussed throughout the text, some of which will be addressed in the 
proposal of future studies. 
 
 
Future Research Strategies 
 
 Going forward, many avenues for investigation remain of great interest, and there 
are many possible experiments that could shed light on some of the more complex 
discoveries of this dissertation work.  Longitudinal behavioral and histologic studies on 
single-blasted animals treated with SMM-189 should be undertaken to determine long-
term benefits in this model.  These investigations should include OKN and ERG testing, 
as well as OCT.  Ideally, tests should be administered prior to blast, and then at acute and 
long-term time points after blast, in order to track changes over time within the same 
animal.  Many changes seemed to occur in this model between 30 days and 2+ months 
after blast.  For this reason, it would be particularly important to gather data consistently 
over the first few weeks and months after blast, and then decrease the testing interval 
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after 2 months for longitudinal studies.  Another functional test that may give insight into 
the mTBI blast injury is pattern ERG (pERG), an electrophysiological readout highly 
sensitive for RGC function 340.  Pattern ERG changes have been seen prior to the onset of 
visual function changes, and may serve as an early indicator of RGC dysfunction or loss 
in these animals.  Since a common finding in human cases of mTBI-visual dysfunction is 
extrocular muscle defects, testing of extraocular muscle function using high speed video-
oculography 341 would be an important functional test to add to the repertoire of visual 
system description in this model. 
 
 Future studies should ideally seek to clarify the complex effect of blast injury on 
the extra-retinal visual system.  In addition to obvious damage to the retina and optic 
nerve, many of the signs and symptoms seen in mTBI-associated visual dysfunction can 
be reasonably traced back to disruption of retinofugal projection regions.  To visualize 
retinal projections, and investigate their potential loss after blast, intraocular injection of 
Cholera toxin B conjugated to fluorescent dye should be used in combination with IHC to 
image both excitatory and inhibitory input to the SC and LGN, or other visual accessory 
nuclei 342,343.  Some of the data in our experiments hinted that at least part of the RE 
function deficits may in fact be linked to loss of left brain visual nuclei inputs or neurons.  
If synapses are decreased in any or all of these areas, it would yield a potential 
pathophysiological correlate for this disease and associated visual dysfunction.  
Additionally, stereological counts of NeuN+ cells in the specific visual nuclei would aid 
in achieving this end. 
 
 Importantly, further investigation of the SMM-189 drug benefit in this model 
should include detailed IHC studies in animals from 24 hours to 7 days after blast, 
immunostaining for a number of cellular markers associated with the diverse microglial 
phenotypes 258.  Our data found right OTs of blasted and drug-treated animals to have a 
microglial population expressing both M1 and M2-associated markers, but at differing 
ratios.  Since the literature touches very little on these mixed-phenotype microglia, and 
they seem to play a critical role in positively modulating the immune response to trauma, 
it is important to investigate phenotypic profiles of microglia in blasted animals both 
treated and non-treated with SMM-189.  More complex studies might include rtPCR of 
cytokine and chemokine expression from highly damaged areas, such as the left ON, in 
order to more completely describe the microglial polarization states in blasted animals.  
Other histologic investigations should aim at microglial polarization in the retina and 
optic nerve, during the first week after blast, to characterize the microglia in these regions 
as well.  Also in the optic nerve, more thorough axon counts should be done using EM, as 
opposed to LM, since many of the smallest axons can not be visualized on LM alone.  At 
least some evidence suggests that axon caliber may be tied to RGC type, and since a 
particular type of RGC may be selectively lost in mTBI, it is an important aspect to 
consider in the future 344. 
 
 
 
 
 118 
Closing Remarks 
 
 It is clear from the experiments in this dissertation that this mouse model of 
overpressure blast-induced mTBI with associated visual dysfunction shows a complex 
and multifaceted disease process.  Histopathology has provided significant insight into 
the underlying causes of visual function deficits, and speaks to the substantial role of 
neural immune cells in responding acutely to trauma in the eye and visual pathways of 
the brain.  SMM-189 has continued to show promise as a neurotherapeutic after mTBI, 
significantly alleviating many of the functional and histopathologic findings after blast 
administration.  Its role in altering the immune system is clear, and is likely more 
complex in vivo than previously hypothesized.  Future research should be aimed at 
investigating the extra-retinal causes of mTBI-associated visual dysfunction, with 
continued emphasis on functional-structural correlates in this model, as well as 
determining more comprehensively how SMM-189 alters microglia in a traumatically 
inflamed state.  Our hope is that these studies may add to the significant body of 
knowledge on a mild disease that is exceedingly common, and often life-altering, 
providing hope that neuroinflammatory modulation may provide the key to efficacious 
treatment in the future.  
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